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Summary 
My novel contribution to the literature is to show that the Epithelial Mesenchymal 
Transition (EMT) is associated with a poor response to neoadjuvant radiotherapy in 
patients with locally advanced rectal cancer.  
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Abstract 
Background: Non-response to neoadjuvant therapy is a significant challenge for 
clinicians managing solid cancers. This thesis aimed to determine whether Epithelial 
Mesenchymal Transition (EMT) was associated with non-response to neoadjuvant 
therapy in patients with locally advanced rectal cancer. 
Methods: Representative tissue specimens from the tumour invasive front of 
consecutive patients undergoing resection of rectal cancer from 2009-2011 were 
used. Patients with marked regression to neoadjuvant therapy were classified as 
responders with the remainder as non-responders. Markers of EMT included: 
reduced immunohistochemical expression of membranous E-cadherin, increased 
nuclear beta-catenin expression and tumour budding. In-situ-hybridisation was used 
to assess the expression of microRNA-200c (mir200c), an upstream master-
regulator of EMT. Real-time polymerase chain reaction was used to quantitate 
expression of the gene for E-cadherin. 
Results: From 103 patients undergoing resection of rectal cancer, 69 received 
neoadjuvant chemoradiotherapy; 65% of these were non-responders. Reduced 
mir200c expression was significantly associated with higher T grade. Reduced 
membranous E-cadherin, increased nuclear beta-catenin and tumour budding 
individually predicted the presence of extra-mural vascular invasion. Reduced E-
cadherin, nucleic beta-catenin, reduced mir200c and tumour budding were all 
significantly associated with non-response to neoadjuvant therapy (all p<0.001). 
Reduced E-cadherin and mir200c expression were both associated with reduced 
cancer specific survival (log-rank p-value 0.036 and 0.009 respectively). E-cadherin 
gene expression was not related to radiotherapy response or tumour budding. 
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Conclusion: Targeted biomarkers of EMT were associated with non-response to 
neoadjuvant therapy and reduced survival in advanced rectal cancer. EMT may 
provide a practical clinical biomarker and novel therapeutic target, to improve the 
proportion of patients who respond to neoadjuvant therapy. 
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1.1 Prognostic factors for advanced rectal cancers  
1.1.1 Background 
Colorectal cancer is common with an estimated 1.23 million new cases globally 
during 20081. In the United Kingdom, there are over 14,000 newly diagnosed rectal 
cancers per year, of which between 50 and 65% are locally advanced (T3/4) at 
presentation2. Complete surgical resection using total mesorectal excision is 
currently considered the best curative treatment for non-metastatic (stage I to III) 
rectal cancers3. The addition of neoadjuvant radiotherapy improves local control 
such that only between 5 and 10% of rectal cancers are expected to recur in the 
modern era4. Neoadjuvant chemotherapy for locally advanced colonic cancers is 
currently being assessed in a large randomised trial5. Total mesorectal excision has 
been established as the standard surgical technique for the treatment of rectal 
cancer. Total mesorectal excision (TME) with the addition of neoadjuvant 
radiotherapy has led to margin negative rates approaching 90% and local recurrence 
rates of between 4 and 10%2-4.  
1.1.2 Definition of the rectum 
Definitions for the rectum have been heterogeneously defined in the literature and 
between different institutions, leading to a clear requirement to standardise the exact 
definition of this term. Variability is introduced by having non-standardised definitions 
of what constitutes the rectum, which has been represented as 12, 15, or 16cms 
from the anal verge in high quality multicentre trials6-10. Further variation is 
introduced by defining the rectum into lower, middle and upper thirds. Radiation trails 
have used length of the rectum as a definition. Recent research suggests that the 
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rectum is more variable and longer than these trials would have appreciated. The 
mean distance from the anal verge to the anterior peritoneal reflection was 11.9 cm 
(men) and 10 cm (women). To the origin of the sigmoid mesentery, the 
measurements were 18.8 cm (men) and 19.1 cm (women) and to the confluence of 
the taenia coli, 20.3 cm (men) and 18.8 cm (women)11. 
In the modern era, high-resolution MRI based measurements are used to define 
tumour height more frequently than the traditionally used rigid sigmoidoscope. It is 
likely that there is anatomical variation between individual patients; collation between 
clinical and MRI assessment is likely to lead to the most accurate assessment. For 
this thesis, the rectum is defined by anatomical criteria demonstrated on MRI as 
being the portion of the large bowel below the sacral promontory that is surrounded 
by a definable mesorectum posteriorly12. 
1.1.3 Diagnosis 
The standard of diagnosis for primary rectal cancer is tissue biopsy confirmation, 
typically via a rigid or flexible endoscope. The location of the tumour should be 
recorded using the anal verge as the landmark. Early imaging to determine the 
chances of an R0 oncological margin should be established.  
Diagnosis of recurrent rectal cancer (RRC) is more challenging due to anatomical 
inaccessibility. Approximately half of patients with recurrent rectal cancer will have 
an isolated, potentially curable recurrence and warrant attempts at tissue 
confirmation13. Highly selected patients with RRC and synchronous metastatic 
disease may sometimes be appropriately offered combined resection as well, again 
necessitating tissue confirmation. Recurrences are either symptomatic or 
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asymptomatic14 15. Advanced pelvic recurrences presenting with symptoms, 
especially pain, have a worse survival as they are often associated with 
neurovascular invasion and clear resection margins may not be achievable16. Clinical 
examination to detect recurrence should include digital examination which may 
determine luminal or extraluminal recurrence and give an indication of relative 
fixation. Digital examination of the vagina can also indicate fixity not indicated by 
imaging. However, fixation does not necessarily prove malignancy and can also be 
post-radiation fibrous tissue or a desmoplastic reaction. Proctoscopy (following 
restorative surgery) is used to identify luminal recurrence. EUA/ vaginoscopy and 
cystoscopy are also used selectively to identify recurrences and assess adjacent 
organ invasion and tumour fixity. 
On-going pelvic infection or late anastomotic leakage may simulate recurrence. MRI 
may not be able to distinguish scar tissue from recurrence. FDG PET-CT may 
provide a metabolic approach to identifying such tumours, although false negative 
results can occur in small deposits or in mucinous tumours. An increase in serum 
CEA may assist in reaching a diagnosis although a spuriously high or low result can 
be misleading17. 
1.1.4 Imaging assessment of tumour, node, metastasis 
There is variation in the locoregional staging of rectal cancer. Most high volume 
centres are now using high-resolution MRI for pelvic staging18-20. MRI is superior to 
CT pelvis for imaging in lower rectal tumours, especially in assessing involvement of 
the sphincter complex and in determining depth of penetration within the mesorectal 
fascia21. However, MRI can have a lower sensitivity when assessing the pelvic 
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sidewall and female urogenital organs22. It may be improved by combining findings 
with diffusion weighted MRI or PET-CT. Mucinous adenocarcinoma has a poorer 
FDG uptake and therefore may not be visualised by PET scan23. ERUS has been 
reported to have high sensitivity and specificity for staging primary T4 disease and is 
useful for targeted biopsy24. CT pelvis and ERUS are sometimes used instead of, or 
in addition to, MRI in some centres in the UK and North America. ERUS may have 
an application for determining adjacent organ involvement in certain anatomical 
compartments, particularly the rectal/prostate interface. ERUS alone provides limited 
information on anatomical planes and is inadequate to safely assess resectability.  
Treatment strategy is dependent on achieving an R0 resection. MRI is considered 
the method of choice for the prediction of a clear, or positive, margin2. For primary 
rectal cancer beyond TME planes (PRC-bTME), this will include the mesorectal 
fascia as well as en-bloc removal of involved structures. For RRC, this may involve 
residual parts of mesorectum, but is more likely to involve assessment of extra-
anatomical R0 planes. Correlation between histopathological findings in relation to 
precise prediction of the threatened margin is being addressed by on-going trials, 
including the NIHR Portfolio Low Rectal Cancer Study (MERCURY 225).  
Identification of nodal disease is still a diagnostic problem for radiologists with nodal 
disease in the lateral pelvic sidewall an area of particular concern. MRI and FDG-
PET/CT may both help to assess the malignant potential of pelvic sidewall nodes. 
Mesorectal lymph nodes are likely to be cleared as part of TME and exenterative 
surgery for primary cancer, and extended resection for recurrence is likely to clear 
residual nodes. Thus assessment of nodal disease is less important than 
assessment of R0 resection margin.  
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High resolution CT scanning of the thorax, abdomen and pelvis is the gold standard 
for extra-pelvic staging. CT is likely to be the best modality for imaging the lung 
fields. MRI is helpful in further characterisation of suspect liver lesions identified by 
CT scan. Bone scans and brain imaging are required where symptoms indicate 
need. Positron emission tomography (PET-CT) may help detect additional occult 
extra-pelvic disease and exclude patients from futile attempts at curative disease 
resection26. Use of PET or PET/CT in patients with PRC-bTME has demonstrated 
significant changes in staging and management in these patients27. Whilst useful in 
investigating circumstances such as increasing CEA, it can provide false-positive 
and false-negative results. Some centres use PET-CT routinely on all patients likely 
to undergo multivisceral resection or with suspicion of recurrence, whereas some 
centres use it selectively.  
A standardised approach to reporting of imaging, particularly MRI, at all stages of 
management for patients with primary and RRC is recommended. Consensus on 
reporting of post-radiotherapy MRI in terms of ymrT and mrTRG is required28. These 
should be related to a single, universal classification system. This may best be 
addressed through a workshop approach for radiologists and referral to MDT where 
appropriate2. 
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Figure 1: Examples of high resolution pelvic MRI of patients locally advanced 
primary rectal cancer. 
 
 
Primary posterior compartment 
disease affecting the S2-4 sacral 
segments 
 
Anterior disease affecting the 
seminal vesicle and prostate. The 
patient requires extended extra-
levator abdominoperineal resection 
with en-bloc excision of seminal 
vesicles and prostate.  
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Figure 2: Examples of high resolution pelvic MRI of patients with recurrent rectal 
cancer. 
 
 
A central compartment anastomotic 
recurrence. The patient underwent re-
do anterior resection. 
 
Routine follow-up post-operative MRI 
detected a nodule suspicious of re-
recurrence in the same patient.  
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1.1.5 Staging 
Staging is performed through combination of contrast enhanced CT chest, abdomen 
and pelvis, high resolution MRI pelvis, endoscopic examination where suitable and 
endorectal disease where local expertise allows. Examination under an anaesthetic 
can add to the overall assessment of the patient and the tumour and is commonly 
used by teams experienced in this type of surgery. Digital rectal examination is the 
only available means of reliably assessing the level of the tumour in relation to the 
anorectal junction. The use of diagnostic laparoscopy to stage peritoneal disease 
prior to planning major exenteration requires further evidence. There are several 
staging systems that combine information to form prognostic categories.  
1.1.5.1 The American Joint Committee on Cancer Staging System 
This standardised system combines information of the tumour (T), lymph nodes (N) 
and distant spread (M). This TNM system is widely used, and shall be used in the 
present thesis when discussing staging. The TNM classification system has 
undergone several revisions in recent years. The 5th edition of TNM was released in 
1997 and is applied in slightly modified form within the UK7. The 7th and most recent 
edition released in 2010 is widely applied in North America and Australasia29. The 
categories include: 
Tumour status (T): 
• Tx: No description of the tumour's extent is possible because of incomplete 
information. 
• Tis: The cancer is in the earliest stage (in situ). It involves only the mucosa. It 
has not grown beyond the muscularis mucosa (inner muscle layer). 
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• T1: The cancer has grown through the muscularis mucosa and extends into 
the submucosa. 
• T2: The cancer has grown through the submucosa and extends into the 
muscularis propria (thick outer muscle layer). 
• T3: The cancer has grown through the muscularis propria and into the 
outermost layers of the colon or rectum but not through them. It has not 
reached any nearby organs or tissues. 
• T4a: The cancer has grown through the serosa (also known as the visceral 
peritoneum), the outermost lining of the intestines. 
• T4b: The cancer has grown through the wall of the colon or rectum and is 
attached to or invades into nearby tissues or organs. 
Nodal status (N):  
• Nx: No description of lymph node involvement is possible because of 
incomplete information. 
• N0: No cancer in nearby lymph nodes. 
o N1: Cancer cells are found in or near 1 to 3 nearby lymph nodes 
o N1a: Cancer cells are found in 1 nearby lymph node. 
o N1b: Cancer cells are found in 2 to 3 nearby lymph nodes. 
o N1c: Small deposits of cancer cells are found in areas of fat near 
lymph nodes, but not in the lymph nodes themselves. 
• N2: Cancer cells are found in 4 or more nearby lymph nodes 
o N2a: Cancer cells are found in 4 to 6 nearby lymph nodes. 
o N2b: Cancer cells are found in 7 or more nearby lymph nodes. 
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Metastatic status (M): 
• M0: No distant spread is seen. 
• M1a: The cancer has spread to 1 distant organ or set of distant lymph nodes. 
• M1b: The cancer has spread to more than 1 distant organ or set of distant 
lymph nodes, or it has spread to distant parts of the peritoneum (the lining of 
the abdominal cavity). 
Once T, N, and M categories have been determined, this information is combined to 
form a stage group (table 1). The prefix ‘p’ is used to indicate pathological staging. If 
neoadjuvant preoperative chemotherapy or radiotherapy has been given, the prefix 
‘yp’ should be used to indicate that the original p stage may have been modified by 
therapy. For example, when there has been complete regression of the tumour, the 
TNM stage is ypT0, ypN0, ypMx. 
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Table 1: Prognostic groupings of the 7th AJCC TNM Colon and Rectum Cancer 
Staging system. 
Stage TNM Description 
0 Tis, N0, M0 The cancer is in the earliest stage. It has not grown beyond the inner layer (mucosa) of the 
colon or rectum. This stage is also known as carcinoma in situ or intramucosal carcinoma. 
I T1-T2, N0, M0 The cancer has grown through the muscularis mucosa into the submucosa (T1) or it may also 
have grown into the muscularis propria (T2). It has not spread to nearby lymph nodes or 
distant sites. 
IIA T3, N0, M0 The cancer has grown into the outermost layers of the colon or rectum but has not gone 
through them (T3). It has not reached nearby organs. It has not yet spread to the nearby 
lymph nodes or distant sites. 
IIB T4a, N0, M0 The cancer has grown through the wall of the colon or rectum but has not grown into other 
nearby tissues or organs (T4a). It has not yet spread to the nearby lymph nodes or distant 
sites. 
IIC T4b, N0, M0 The cancer has grown through the wall of the colon or rectum and is attached to or has grown 
into other nearby tissues or organs (T4b). It has not yet spread to the nearby lymph nodes or 
distant sites. 
IIIA T1-T2, N1, M0 The cancer has grown through the mucosa into the submucosa (T1) and it may also have 
grown into the muscularis propria (T2). It has spread to 1 to 3 nearby lymph nodes (N1a/N1b) 
or into areas of fat near the lymph nodes but not the nodes themselves (N1c). It has not 
spread to distant sites. 
 T1, N2a, M0 The cancer has grown through the mucosa into the submucosa (T1). It has spread to 4 to 6 
nearby lymph nodes (N2a). It has not spread to distant sites. 
IIIB T3-T4a, N1, M0 The cancer has grown into the outermost layers of the colon or rectum (T3) or through the 
visceral peritoneum (T4a) but has not reached nearby organs. It has spread to 1 to 3 nearby 
lymph nodes (N1a/N1b) or into areas of fat near the lymph nodes but not the nodes 
themselves (N1c). It has not spread to distant sites. 
 T2-T3, N2a, M0 The cancer has grown into the muscularis propria (T2) or into the outermost layers of the 
colon or rectum (T3). It has spread to 4 to 6 nearby lymph nodes (N2a). It has not spread to 
distant sites. 
 T1-T2, N2b, M0 The cancer has grown through the mucosa into the submucosa (T1) or it may also have grown 
into the muscularis propria (T2). It has spread to 7 or more nearby lymph nodes (N2b). It has 
not spread to distant sites. 
IIIC T4a, N2a, M0 The cancer has grown through the wall of the colon or rectum (including the visceral 
peritoneum) but has not reached nearby organs (T4a). It has spread to 4 to 6 nearby lymph 
nodes (N2a). It has not spread to distant sites.= 
 T3-T4a, N2b, M0 The cancer has grown into the outermost layers of the colon or rectum (T3) or through the 
visceral peritoneum (T4a) but has not reached nearby organs. It has spread to 7 or more 
nearby lymph nodes (N2b). It has not spread to distant sites. 
 T4b, N1-N2, M0 The cancer has grown through the wall of the colon or rectum and is attached to or has grown 
into other nearby tissues or organs (T4b). It has spread to at least one nearby lymph node or 
into areas of fat near the lymph nodes (N1 or N2). It has not spread to distant sites. 
IVA Any T, Any N, M1a The cancer may or may not have grown through the wall of the colon or rectum, and it may or 
may not have spread to nearby lymph nodes. It has spread to 1 distant organ (such as the 
liver or lung) or set of lymph nodes (M1a). 
IVB Any T, Any N, M1b The cancer may or may not have grown through the wall of the colon or rectum, and it may or 
may not have spread to nearby lymph nodes. It has spread to more than 1 distant organ (such 
as the liver or lung) or set of lymph nodes, or it has spread to distant parts of the peritoneum 
(the lining of the abdominal cavity) (M1b). 
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Other staging systems include the modified Dukes staging system: 
• Dukes A: Tumour limited to the wall of the bowel, lymph nodes negative 
• Dukes B: Tumour spread beyond muscularis propria, lymph nodes negative 
• Dukes C1: Lymph nodes positive but apical node spared 
• Dukes C2: Apical lymph node involved 
Table 2: Comparison of TNM, Dukes and Astler-Coller staging systems. TNM is the 
most widely used system as it allows pre-operative and post-operative staging 
comparisons, with additional use of stratification by use of neoadjuvant therapy. 
AJCC/TNM Dukes Astler-Coller 
0 - - 
I A A, B1 
IIA B B2 
IIB B B2 
IIC B B3 
IIIA C C1 
IIIB C C1, C2 
IIIC C C2, C3 
IV - D 
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1.1.6 Classification  
Various pelvic classifications have been proposed to assess tumour resectability. In 
addition to assisting with decision-making as to resectability, classification adds 
information about prognosis30. Central recurrences have been shown to have 
improved results over posterior or lateral recurrences31 32.  
The Mayo clinic classified local recurrence according to site and points of tumour 
fixation33 while Yamada et al. described local recurrence by the pattern of pelvic 
fixation into localized, sacral or lateral34. The Memorial Sloan Kettering group has 
categorised local recurrence based on the anatomical site of invasion by the 
tumour35. In a recent prospective study by The Royal Marsden Hospital that 
examines the relationship between site of recurrence and survival after resection, a 
new classification is described based on the extent of tumour invasion in each of 
seven intra-pelvic compartments as seen on the preoperative pelvic MRI. These 
correspond to the fascial boundaries and planes of dissection between the pelvic 
organs and are described as (central (C), posterior (P), inferior (I), anterior above 
(AA) and below (AB) the peritoneal reflection, lateral (L) and peritoneal reflection 
(PR)32. 
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Table 3: Pelvic classifications systems in use for locally recurrent rectal cancer. 
 
Study group Classification Definitions  Outcomes 
Mayo Clinic Symptoms S0 Asymptomatic Pain free patients had better 
survival S1 Symptomatic without pain 
S2 Symptomatic with pain 
Degree and site 
of fixation 
F0 No fixation More points of fixation resulted in 
more complications and worse 
survival 
F1 Fixation to one point 
F2 Fixation to two points 
F3 Fixation to >2 points 
Yamada Pattern of pelvic 
fixation 
Localised Invasion to the adjacent pelvic organs or tissue 5-year survival of 38% 
Sacral 
invasive 
Invasion to lower sacrum (S3, S4, S5), coccyx, 
periosteum 
5-year survival of 10% 
Lateral 
invasive 
Invasion to sciatic nerve, greater sciatic foramen, 
lateral pelvic wall, upper sacrum (S1, S2) 
 
5-year survival of 0% 
Wanebo Five stages TR1 Limited invasion of the muscularis  
TR2 Full thickness penetration of the muscularis propria  
TR3 Anastomotic recurrences with full thickness 
penetration beyond the bowel wall and in to the 
perirectal soft tissue 
 
TR4 Invasion in to adjacent organs without fixation  
TR5 Invasion of the bony ligamentous pelvic including 
sacrum, pelvic/side walls, or sacrotuberous/ ischial 
ligaments 
 
Memorial-
Sloan-
Kettering 
Anatomical 
region involved 
Axial Anastomotic, mesorectal, perirectal soft tissue, 
perineum (APER) 
Axial only recurrence has 90% 
likelihood of R0; Lateral 
recurrence is associates with 36% 
likelihood of R0 
Anterior Genitourinary tract 
Posterior Sacrum and presacral fascia 
Lateral Soft tissues of the pelvic sidewall and the lateral 
bony pelvis 
Leeds Anatomical 
region involved 
Central  Tumour confined to pelvic organs or connective 
tissue without contact onto or invasion into bone 
 
Sacral  Tumour present in the presacral space and abuts 
onto or invades into the sacrum 
 
Sidewall Tumour involving the structures on the lateral 
pelvic sidewall, including the greater sciatic 
foramen and 
sciatic nerve through to piriformis and the gluteal 
region 
 
Composite Sacral and sidewall recurrence combined  
Royal 
Marsden 
Hospital  
MRI; Planes of 
dissection 
Central Rectum or neo-rectum, intra-luminal recurrence, 
perirectal fat or mesorectum, extra-luminal 
recurrence 
MRI diagnosis of tumour invasion 
within the lateral, posterior or in 
more than two compartments was 
associated with reduced disease 
free survival 
PR Recto-vesical pouch or recto-uterine pouch of 
Douglas 
AA PR Ureters and iliac vessels above the peritoneal 
reflection, sigmoid colon, small bowel and lateral 
side wall fascia 
AB PR Genitourinary system 
Lateral Ureters, external and internal iliac vessels, lateral 
pelvic lymph nodes, sciatic nerve, sciatic notch, S1 
and S2 nerve roots, piriformis or obturator internus 
muscle 
Posterior Coccyx, pre-sacral fascia, retro-sacral space, 
sacrum up to the upper level of S1 
Inferior Levator ani muscles, external sphincter complex, 
perineal scar (APER), ischio-anal fossa 
 
PR = peritoneal reflection; AA = anterior above; AB = anterior below
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1.1.7 Neoadjuvant therapy 
Surgery remains the mainstay of curative treatment, with the total mesorectal 
excision (TME) being established as the standard surgical technique36. 
Subsequently, improvements in imaging techniques have led to accurate staging and 
delivery of multi-modality therapy. Of these multimodality therapies, it has been 
pelvic radiation that has presented the most significant improvements in reducing 
local recurrence and improving survival. 
1.1.7.1 Indications  
The evidence base from randomised trials of radiotherapy for rectal cancer has 
provided conflicting results which have led to controversy. The widespread 
introduction of pelvic irradiation during the 1990s provided significant improvements 
in local recurrence and survival rates. The Swedish Rectal Cancer Trial and the 
Dutch TME Trial both showed the advantages of neoadjuvant radiotherapy over 
resection alone. The Stockholm III trial will provide evidence of the benefits of short 
versus long-course pre-operative radiotherapy 
The benefit of neoadjuvant radiotherapy with doses over 30Gy versus surgery alone 
has been shown by meta-analysis of randomised trials, in terms of both local 
recurrence and overall survival37. Neoadjuvant versus adjuvant chemoradiotherapy 
has been shown to reduce local recurrence but without an effect on overall 5-year 
survival; it may however reduce complications9 38. The benefits of short versus long-
course pre-operative radiotherapy, including the optimum time delay to surgery, are 
yet to be confirmed and are being further assessed in a randomised trial39-41  
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Surveillance, Epidemiology, and End Results data has been used to show survival 
differences in colorectal cancer comparing tumour location, tumour details and 
treatment details42 43. The timing, nature and indications of pelvic radiotherapy for 
rectal cancer remain controversial. Introduced in the 1980s, adjuvant radiotherapy 
was found to improve local control rates, but with little effect on overall survival44 45. 
Subsequent experimentation with neoadjuvant radiotherapy led to the development 
of short and long course techniques. The Swedish Rectal Cancer Trial and the Dutch 
TME Trial both showed the advantages of neoadjuvant short course radiotherapy 
over resection alone4 46. Long-term follow-up of the Dutch TME trial has shown the 
benefits of short course pre-operative radiotherapy over surgery alone for rectal 
cancers4. The risk of local recurrence at 10 years was reduced by 50% (5% versus 
11%, p<0.001). Although there was no overall survival difference, patients with stage 
III resection margin negative cancers treated with neoadjuvant radiotherapy had a 
significantly improved survival (50% versus 40% surgery alone, p=0.032). These 
findings were confirmed by a meta-analysis of 22 randomised studies by the 
Colorectal Cancer Collaborative Group, which found the strongest benefit when pre-
operative doses were above 30Gy37.  
The next controversy debated was the timing of radiotherapy, comparing 
neoadjuvant to adjuvant regimes. The German Rectal Cancer Group randomised 
patients to neoadjuvant or adjuvant long-course chemoradiotherapy9. Although there 
was no difference in 5-year survival (76% neoadjuvant and 74% adjuvant, p=0.8), 
they found significantly lower rates of local recurrence (6% versus 13%, p=0.006) 
and lower rates of acute and chronic toxicity in the neoadjuvant arm. Sauer et al., 
showed that preoperative chemoradiotherapy, as compared with postoperative 
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chemoradiotherapy, improved local control and was associated with reduced toxicity 
but did not improve overall survival9. The MRC-CR07 and NCIC-CTG C016 trial 
further showed that pre-operative radiotherapy was superior to selective post-
operative radiotherapy in terms of local control and disease free survival, but with no 
effect on overall survival38. To add further to this debate, single centre reports of 
standardised surgery without radiotherapy have shown local recurrence rates of 
equivalence to those from radiotherapy trials, emphasising the importance of high 
quality surgery47. The German Rectal Cancer Study Group showed that the adjuvant 
arm had higher acute (27% versus 40%, p=0.001) and long-term (14% versus 24%, 
p=0.01) toxicity rates than the neoadjuvant arm. Neoadjuvant radiotherapy may be 
associated with fewer complications and thus improved treatment compliance37. 
If neoadjuvant radiotherapy is accepted as the optimum strategy, the benefits of 
short-course over long-course are uncertain. The Polish Colorectal Study Group 
randomised 312 patients to either neoadjuvant short course radiotherapy or 
neoadjuvant long-course radiotherapy40. They found higher toxicity in the long-
course arm with no survival differences between short or long-course therapies. The 
Stockholm III trial will add to this debate by comparing the outcome of short versus 
long-course neoadjuvant radiotherapy, including the optimum time delay to 
surgery41. 
1.1.7.2 Guideline indications for pre-operative radiotherapy 
There is variation in whether pre-operative therapy is applied or not, partly due to 
heterogeneity of current evidence. Guidelines are provided for clinicians by the 
National Institute for Health and Clinical Evidence (NICE) in the United Kingdom and 
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the National Comprehensive Cancer Network (NCCN) in the United States of 
America. NICE guidelines risk-stratify patients into risk groups based on staging MRI 
predictions (NICE clinical guideline 131, November 2011: 
http://guidance.nice.org.uk/cg131).  
Table 4: Risk stratification of local recurrence for rectal tumours as predicted by MRI. 
Risk of local recurrence Characteristics of rectal tumours predicted by MRI 
High • A threatened (<1mm) breached resection margin or 
• Low tumours encroaching onto the inter-sphincteric plane of with 
levator involvement  
Medium • Any clinical T3b or greater, in which the potential surgical margin 
is not threatened or 
• Any suspicious lymph node not threatening the surgical 
resection margin or 
• The presence of extramural vascular invasion 
Low • Clinical T1 or T2 or T3 and 
• No lymph node involvement  
 
Pre-operative treatment is not recommended for low risk lesions. For moderate and 
high-risk patients, neoadjuvant therapy with either short course pre-operative 
radiotherapy (SCPRT) or long-course chemoradiotherapy is recommended. Long-
course chemoradiotherapy should be followed by an interval before surgery to allow 
tumour response and shrinkage, compared to the immediate surgery offered after 
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SCPRT. The precise interval for this delay is uncertain and is subject to current trials, 
although 6-8 weeks is currently recommended. 
 NCCN guidelines base the decision for pre-operative treatment on pre-treatment 
stage. Chemoradiotherapy is recommended for stage II (T3-4 N0 M0) or stage III 
(Tany, N1-2) disease48. Metastatic disease (T-any, N-any, M1) is still subject to pre-
operative therapy, although the evidence base and treatments offered are different 
and are not the focus of this thesis. 
Gastro-intestinal toxicities are the most clinically significant side effects associated 
with pelvic radiotherapy9 49 50. The reported serious toxicities in these studies 
occurred in approximately 35-45% of patients undergoing RT with concomitant 
fluoropyrimidines. The data regarding late bowel toxicity is less readily available but 
long terms complication of approximately 10-20% are reported9.  
1.1.7.3 Intensity modulated radiotherapy (IMRT) 
Technical advances such as IMRT allow greater precision and can reduce dose to 
normal surrounding structures such as small bowel compared to conventional 2D or 
3D planning. Such precision may allow improved compliance to standard treatments, 
or hopefully facilitate dose-escalation without increasing late morbidity. In a recent 
comparative analysis from the Mayo clinic, 29% and 3% of patients receiving IMRT 
for rectal cancer experienced grade II and grade III acute GI toxicity respectively51. 
Yet there was no difference as regards late toxicity for any of the four arms in the 
European Organisation for Research & Treatment of Cancer (EORTC) 22921 study 
trial. 522 patients retained their sphincters and of these, only 1.4% required surgery 
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for small bowel complications52. This low level of late morbidity is acceptable, and 
therefore questions the enthusiasm to deliver IMRT more widely in rectal cancer with 
the aim of reducing small bowel toxicity unless an advantage for dose-escalation is 
proved. 
However the evidence for IMRT is currently limited and there are associated risks of 
toxicity. The phase II trial of pre-operative chemoradiotherapy utilizing IMRT for 
locally advanced rectal cancer led by Radiation Therapy Oncology Group 
(RTOG0822) demonstrated the feasibility of inverse planned IMRT in a multicentre 
setting. Of the 79 accrued patients 68 were analysable and in terms of toxicity 22% 
had grade 3 and 1% grade 453. The pathological CR rate of 15% (10/68) suggests 
that tumour coverage is not compromised by the use of highly conformal 
radiotherapy. IMRT show promise for safe dose escalation with possible benefits in 
terms of local control and reduced toxicity54.   
1.1.7.4 High Dose Rate Brachytherapy 
High dose rate intraluminal brachytherapy (HDR-ILBT) has the advantage of high 
conformity (i.e. a rapid fall-off of radiation dose), which allows the delivery of a high 
dose to the tumour while sparing normal surrounding structures such as the adjacent 
normal rectal mucosa, bladder and small bowel55. There are limited data available 
evaluating the advantages of HDR-ILBT with external beam radiotherapy (EBRT) as 
compared to EBRT alone. HDR-ILBT for advanced or inoperable tumours of the 
rectum has been used as a boost alongside external chemo-radiation to dose 
escalate for curative treatment and also in the palliative setting 56. 
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1.1.7.5 Intra-operative radiotherapy (IORT) 
IORT is a specialised method of delivering a radiation boost (i.e. higher doses) to the 
tumour bed, where there is concern about tumour margins, without compromising 
the surrounding organs at risk. IORT is delivered under anaesthetic at the time of 
surgery using electrons, or high dose rate (HDR) brachytherapy to specifically 
selected high-risk areas for close or positive margins.  
Prospective and long-term data from international centres of excellence 
incorporating IORT containing regimes is compelling. However, the IORT literature 
includes a large spectrum of tumours as the selection criteria varied from one centre 
to another, making the definite evidence of benefits difficult to ascertain. The low rate 
of tumour recurrence in IORT fields, and a convergence of survival curves for R0 
and R1/2 resections seen in studies with long-term data support the concept that 
IORT in selected cases may offer an oncological advantage.  
In a historical series from the Mayo Clinic, IORT (plus EBRT) reduced the incidence 
of local failure (40% versus 93% at 3 years) and improved OS (19% versus 7% at 5 
years; p = 0.0006)57. Others have found a significant survival benefit in patients who 
received IORT compared with patients who did not (3-year survival rate of 43% 
versus 5%; p = 0.0007)58. A recent European multi-national study evaluated 
multimodality treatment of locally advanced rectal cancer in four major treatment 
centres with particular expertise in IORT. This pooled analysis of 605 patients 
demonstrated exceptionally good oncological outcomes59.  
The limitations of these analyses are the inclusion of patients treated during a 
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relatively long period, the variety of sites of recurrence, the heterogeneity of EBRT 
and surgery, and variations in subsequent adjuvant chemotherapy.  Hence, the 
precise contribution and effectiveness of IORT as a local boost is difficult to 
accurately assess. The logic of additional focused radiotherapy to a margin at 
potential high risk of involvement, most commonly a lateral margin, is intuitive but 
attainment of high quality evidence from randomised trials is challenging. 
Randomised trials will prove difficult to design, partly due to limited multi-centre 
capacity. Another part of the problem is that even when the preoperative decision by 
the MDT has been to utilise IORT, it is not always felt necessary at the time of 
surgery. There is extremely limited capability to perform IORT in the UK. Globally 
however, there are selected centres in Europe, the USA, and Australia that can 
provide this treatment modality.  
1.1.7.6 Recurrent rectal cancer – Radiotherapy and Re-irradiation  
When local recurrence occurs where radiotherapy has not previously been 
administered, radiotherapy or chemoradiation can sterilise microscopic disease 
within the pelvic cavity and facilitate resectability. Complete responses are rarely 
achieved even with high radical doses in the region of 60 Gy60. A recent study has 
reported on patients with unresectable or locally recurrent rectal cancer treated using 
three-dimensional planning and prolonged venous infusion of 5FU to a dose of 
45Gy. There was no difference between unresectable locally advanced cancers and 
recurrent cancers as regards outcome61. IORT has also been advocated in these 
circumstances.  
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Further re-irradiation of locally recurrent cancer remains controversial62 63. Single-
institution studies and a phase II multi-institutional trial have evaluated the use of 
hyperfractionated (twice-daily) radiotherapy for reirradiation. Hyperfractionated 
reirradiation appears to be well-tolerated and may enhance local control64 65. High-
dose Rate Endorectal Brachytherapy is a very simple but effective treatment option 
that is presently offered widely in Quebec for this patient population especially when 
the recurrence is central. No centre has access to all of these modalities, and so the 
specialist MDT, via national referral pathways, should develop the ability to cross-
refer where appropriate. 
1.1.7.7 Chemotherapy 
There is a high risk of metastatic disease in PRC-bTME and a potentially higher risk 
in RRC. Intensification of chemotherapy regimens is emerging as a potential strategy 
in PRC-bTME patients to address this problem. The induction or preoperative, 
concurrent, consolidation (after chemoradiation and before surgery) and 
postoperative adjuvant chemotherapy settings offer potential improvements in 
outcome, along with the addition of different cytotoxic agents and the integration of 
biological agents. 5FU-based chemoradiation is effective at downstaging patients 
with rectal cancer, and 10–15% of patients can achieve a pathological complete 
response (pCR)49 50 66 67. Equally, on histopathological grounds, one-third of patients 
have tumours that are radiotherapy and 5FU resistant40 68 69.  
For advanced unresectable cases, when the preoperative MRI shows a threatened 
or breached CRM (when even technically optimised surgery is unlikely to achieve a 
curative resection), or for positive nodal disease at the CRM, 5FU-based 
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chemoradiation has a statistically significant effect on resectability and disease free 
survival70 71. In the more recent Scandinavian study considering all stages, local 
control was significantly better (82% versus 67% at 5 years (p=0.03), with a trend to 
improved overall survival (66% versus 53% at 5 years, p=0.09). 
1.1.7.8 Additional Cytotoxic drugs 
The additional integration of oxaliplatin and irinotecan to 5FU based chemotherapy 
has been explored within a CRT schedule in numerous phase II studies in order to 
increase tumour shrinkage prior to surgery and potentially mirror the success of 
oxaliplatin in dealing with distant micro-metastases in the adjuvant setting for colon 
cancer72.  
Radiation oncologists have attempted to increase response in the primary by 
focussing on the integration of oxaliplatin as a radiosensitizer (but at sub-systemic 
doses) in 5 phase III trials (ACCORD 12/0405-Prodige 2, STAR-01, NSABP R-04, 
CAO/ARO/AIO-04, and PETACC 6). Chemoradiation with oxaliplatin increased 
grade III/IV toxicity in all 4 trials with available data73-75  but only the German 
CAO/ARO/AIO-04 trial had a significantly higher rate of pathological complete 
response9. 
These randomised trials in rectal cancer selected patients with easily resectable 
tumours, but where examined, some schedules appear to have reduced the positive 
CRM rate73 74. None of these trials have results which are sufficiently mature to show 
late outcomes in terms of DFS or OS or late toxicity.  
Preliminary results of CRT trials with cetuximab have provided disappointing 
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results76. The use of bevacizumab in chemoradiation has considerable preclinical 
rationale, and the combination with CRT appears potentially deliverable with 
acceptable toxicity although some reports have highlighted excess postoperative 
wound infections. The strategy to incorporate these agents into chemoradiation in 
rectal cancer schedules may have emerged before full understanding of their 
mechanisms of action or the knowledge of the ideal sequence of chemotherapy, 
biological agents and radiotherapy has been learnt77. 
1.1.7.9 Positioning Chemotherapy  
Several broad strategies to improve outcome have been investigated in rectal 
cancer: surgery alone followed by adjuvant chemotherapy/chemoradiation; SCPRT 
followed by immediate surgery followed by adjuvant chemotherapy; CRT followed 
after 6-8 weeks by surgery followed by adjuvant chemotherapy; SCPRT followed 
after 6-8 weeks by surgery followed by adjuvant chemotherapy; induction 
chemotherapy followed by CRT followed after 6-8 weeks by surgery followed by 
adjuvant chemotherapy78 79; induction chemotherapy followed by SCPRT followed by 
immediate surgery followed by adjuvant chemotherapy; CRT followed by 
consolidation systemic chemotherapy followed by surgery followed by more adjuvant 
chemotherapy; induction chemotherapy alone followed by surgery followed by more 
adjuvant chemotherapy; integration of biological agents into one of the above. 
1.1.7.10 Response to neoadjuvant therapy 
Resistance to neoadjuvant therapy is a serious clinical problem for clinicians treating 
a variety of solid cancers, including oesophagogastric, colorectal, breast, pancreatic 
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and lung. Rectal cancers downstaged by neoadjuvant therapy are likely to carry an 
improved prognosis43. Between 5 and 20% of patients undergo a complete 
pathological response (no residual tumour following pathological examination of the 
resection specimen), which may improve survival further and in fact represent a 
future non-surgical cure80. However, radiotherapy also carries risks of short-term 
toxicity and long-term complications including radiation damage to adjacent 
structures. Between 40 to 60% of patients do not respond to neoadjuvant therapy81 
82, with some in fact progressing whilst awaiting surgery43 83. The reasons for non-
response whilst on treatment are incompletely understood and require urgent 
research84. 
Up to 40% of patients with rectal cancer will experience a significant response to 
neoadjuvant radiotherapy, with between two and 15% experiencing a complete 
pathological response. Downstaging has been associated with an improved survival 
compared to those who do not respond to neoadjuvant therapy and remain with an 
advanced pathological stage. There has been recent interest in the survival benefits 
of a significant response to neoadjuvant radiotherapy, which includes controversy 
over complete pathological response85. Castaldo et al., showed from SEER data that 
rectal cancers downstaged by neoadjuvant radiotherapy (on the assumption that 
those with final pathology stage 0 or I were downstaged) had an improved survival 
over those that remained at final stage II or III (which deemed termed poor-
responders)43.  
The Brazilian group pioneering this area have published long-term results of non-
operative treatment following downstaging through neoadjuvant long-course 
 55	  
chemoradiotherapy. Seventy consecutive patients with T2-4N0-2M0 distal rectal 
cancer were treated with 54 Gy radiotherapy and 5FU based chemotherapy86. Forty-
seven (68%) of patients had initial complete clinical response, with a failure rate of 
eight patients in the first 12 months. Thirty-nine maintained complete clinical 
response at a median follow-up of 56 months. To date, four additional patients have 
developed late local recurrences, and 50% of patients remain un-operated. Due to a 
lack of international validation and the relatively small numbers in current 
publications, these approaches are only recommended as part of carefully controlled 
prospective trials with active follow-up. 
Conversely, non-response exposes patients to the risks of toxicity whilst delaying 
surgery with no benefit. In an era of personalised medicine and ‘super-staging,’ 
biomarkers to predict significant response are being sought including: oncogenes, 
tumour suppressor genes and markers of apoptotic pathways. Currently, KRAS is 
the only biomarker used in the routine clinical management of colorectal cancer. 
KRAS mutations are present in approximately 40% of patients with metastatic 
colorectal cancers87. They are predictive of a poor response to the biological agent 
Cetuximab (an anti-epidermal growth factor receptor), which can significantly 
improve survival in KRAS wild-type tumours77. Further biomarkers are urgently 
needed to allow for individualised treatment of patients with cancer. KRAS acts as a 
proof of principle that biomarker research and subsequent clinical application can 
lead to significant patient benefits. Biomarkers predictive of non-response are lacking 
and are urgently needed. They would allow current neoadjuvant therapies to either 
be targeted or avoided, and also allow development of novel therapeutic targets to 
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improve the response.  
Improvements in neoadjuvant radiotherapy techniques for rectal cancer have led to a 
high rate of downstaging and clinical complete response, with excitement over the 
potential for subsequent local excision or non-operative management in place of 
standard proctectomy88. The SEER (Surveillance, Epidemiology, and End Results) 
programme collects data on incidence, prevalence and survival from specific 
geographical regions representing approximately 28% of the USA population. An 
analysis of SEER showed that in patients with downstaged rectal cancer undergoing 
neoadjuvant radiotherapy (n=1335), local excision, compared to major resection, 
was associated with oncological equivalence for T1 cancer (cancer specific survival 
[CSS] adjusted HR 1.21, 95% CI 0.27-5.51, p=0.802) and T2 cancer (adjusted HR 
1.23, 95% CI 0.44-3.45, p=0.701). This is compared to the oncological outcome of 
local excision from patients not undergoing radiotherapy: an oncological equivalence 
with T1 cancer (CSS adjusted HR 1.18, 95% CI 0.91-1.54, p=0.220) and oncological 
disadvantage with T2 cancer (CSS adjusted HR 1.83, 95% CI 1.32-2.54, p<0.001).  
These results suggests that local excision for downstaged rectal cancer may be an 
oncologically safe treatment. In selected patients undergoing neoadjuvant 
chemoradiotherapy and local excision, early randomised data showed that local 
excision leads to similar local recurrence rates and disease free survival (n=100)89. 
However, since modern non-randomised data has showed early recurrence rates of 
15% following local excision of tumours downstaged to T0-2N0, further trial data is 
required before recommending this routinely90. Future patients should be assessed 
as part of carefully controlled prospective trials.  
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There is much debate surrounding the optimum modality to accurately re-staging 
following completion of longcourse neoadjuvant therapy, and definition of tumour 
response81. The role of clinical examination, endoscopic confirmation and imaging all 
remain controversial86. However, MRI remains the mainstay of assessment. If time 
elapsed from the last MRI to the proposed date of surgery is longer than 6 weeks, re-
staging is recommended to ensure an accurate and up to date assessment.  
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Figure 3: High-resolution MRI 6 weeks after neoadjuvant therapy, showing a 
recurrent rectal cancer in the lateral compartment. It is infiltrating into the left sciatic 
nerve, indicating irresectability. Since the size of the tumour has not shrunk, it was 
deeded radiologically not to have responded to neoadjuvant therapy. 
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1.1.9 Surgery 
1.1.9.1 Total mesorectal excision 
Historical recurrence rates following surgery were high, in the order of 15 to 45%91 92. 
During the 1980s and 1990s, the concept of total mesorectal excision 9TME) for 
rectal cancer was established, proposed primarily by Professor RH Heald at the 
North Hampshire Hospital, Basingstoke93. This technique involves sharp dissection 
between the parietal and visceral peritoneum, ensuring that the rectum and 
mesorectum are removed en bloc. Removal of the mesorectum means clearance of 
the embryologically derived perirectal fat, blood vessels, nerves and lymphatics. 
Since rectal cancer spread is primarily through regional lymph nodes and blood 
vessels in the mesorectum, complete excision theoretically leads to reduce local 
recurrence and increased survival. In Heald’s initial series of 7.5 years duration, the 
low rate of abdominoperineal resection (11%) and the subsequent 10 year local 
recurrence rate of 4% confirmed this technique’s superior survival3 93.  
1.1.9.2 The role of local excision of rectal cancer 
The modern management of early colorectal cancer poses a dilemma for the 
colorectal surgeon and multidisciplinary team. With the advent of population level 
colorectal cancer screening programmes, the rate of these patients requiring curative 
treatment is expected to further increase94. The high quality oncological clearance 
obtained by major surgical resection must be balanced against the risk of post-
operative morbidity and mortality95. This surgery includes colectomy, anterior 
resection and abdominoperineal resection of rectum, with the subsequent risk of 
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anastomotic leak and/or poor functional outcome95-97. Technological advances have 
enabled endoscopic and local excision techniques to be applied in the treatment of 
early colorectal cancer in preference to radical resectional surgery98-101. Initially used 
as a means to treat frail patients, these have gained popularity and are now used as 
a first line curative options. An analysis of SEER data has shed light on the subject. 
The study included 7378 (18.0%) local excisions and 36 116 (83.0%) major 
resections for 30 232 colon and 13 262 patients with rectal cancer. There were 3553 
(8.2%) patients with carcinoma-in-situ and 39 941 (91.8%) with a clinical stage I 
cancer (20,480 with T1 and 19,461 with T2 cancer). 
After adjusting for confounding factors, local tumour excision (compared to major 
resection) for carcinoma-in-situ was associated with HRs for 5-year cancer specific 
survival (CSS) of 1.06 (p=0.814) and 0.78 (p=0.494) for colon and rectum lesions 
respectively. There were also no overall survival differences for carcinoma-in-situ 
(colon OS HR: 1.04, p=0.688 and rectum OS HR 1.05, p=0.777). Local excision of 
T1 and T2 colon cancer were associated with reduced CSS (HR 1.31, p=0.020 and 
HR 2.89, p<0.001 respectively) and reduced OS (HR 1.56, p<0.001 and HR 2.41, 
p<0.001). Local excision of T1 rectal cancer did not affect CSS (HR 1.16, p=0.236) 
but was associated with reduced OS (HR 1.29, p<0.001). However local excision of 
T2 rectal cancer was associated with significantly reduced CSS (HR 1.71, p<0.001) 
and OS (HR 1.71, p<0.001).  
These findings allow adaptation of current indications for local excision, more 
thorough informed consent (especially for younger patients) and will inform future 
research questions. The greater difference in overall compared to cancer specific 
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survival suggests that increased patient frailty in the local excision group may have 
contributed to mortality. This type of selection bias is common in population-based 
studies, which are, by definition, not randomised. However, patients under the age of 
59 years formed 30.6%, 25.5% and 19.8% of the carcinoma-in-situ, T1 and T2 
groups respectively. Since it is unlikely that indications for local resection in these 
groups included frailty, it must be considered that these patients with T1-2 colon and 
T2 rectal cancer are at risk of reduced oncological survival.  
1.1.9.3 Exenterative surgery for advanced rectal cancer 
Although neoadjuvant therapy may downstage cancers so that conventional TME will 
allow complete surgical resection, approximately 6% of rectal cancers will still breach 
the mesorectal plane, and invade adjacent structures2 4. Potentially resectable locally 
recurrent rectal cancer offers additional technical difficulty, with current R0 resection 
rates being between 37 and 57%102 103. Distorted tissue planes, aggressive biology 
and prior irradiation leading to higher risks of margin positive resections increase the 
hazards and difficulty of salvage surgery.  
Multivisceral, exenterative surgical resection offers the best chance of cure for locally 
advanced primary and recurrent rectal cancer104 105. Primary rectal cancer beyond 
total mesorectal excision planes and locally recurrent rectal cancer (those requiring 
exenterative type surgical resection, beyond conventional total mesorectal excision 
(TME) planes) are challenging and life threatening clinical problems. There is 
increasing recognition that aggressive multi-modality approaches incorporating 
contemporary neoadjuvant therapies with radical surgery offers options for potential 
cure and long-term survival. This complex strategy is optimal and cost-effective in 
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carefully selected patients and represents a new standard of care. However, this 
must be balanced against a high rate of post-operative adverse events, a high risk of 
a margin-positive resection and varying survival rates 103. 
There are many surgical principles for treatment of patients with PRC-bTME and 
RRC cancer. Planes of dissection are often lost in RRC patients compared to those 
in PRC-bTME patients, particularly after extensive radiotherapy. Regional and 
national referral pathways may involve referral from a specialist MDT to a super-
specialised MDT (e.g. for consideration of high sacrectomy). 
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Figure 4: Surgical planes of dissection in the pelvis: (1) total mesorectal excision 
plane; (2) ureteric plane; (3) vascular plane; (4) sacrectomy plane.  
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1.1.9.4 Pre-operative assessment 
Optimising patients prior to multi-visceral resection is vital to minimise peri-operative 
morbidity and requires a multi-specialist approach19 20. These clinicians include 
anaesthetists, respiratory physicians, urologists (for assessment of the need for 
ureteric stents or nephrostomies), cardiologists and stoma nurses.  Formal cardio-
pulmonary testing is an objective test to assess fitness and diagnose cardiovascular 
and lung pathophysiology106. Areas for potential improvement can be identified, 
including ischaemic heart disease107. A management plan can then be determined 
for their perioperative care and pathway108. Admission 24 hours prior to surgery into 
a critical care setting may allow for maximal pre-operative optimisation in special 
cases. Intra-operative monitoring, such as oesophageal Doppler, in association with 
other invasive monitoring provides further information on the physiological status of 
the patient109.  
General pre-operative surgical principles include pre-operative stoma counselling/ 
marking, discretionary ureteric stenting to clearly identify the ureteric course, the 
availability of haemostatic agents during pelvic dissection and intensive post-
operative monitoring. A multi-specialist team approach is vital in achieving this, 
which may include specialists in colorectal, plastic, urology, vascular and 
orthopaedic surgery, and radiation oncology. Due to the major resectional nature of 
the surgery, routine cross-matching of blood is recommended. Clotting products and 
platelets should be available at short notice in case of severe bleeding, such as 
during sacrectomy or pelvic dissection close to iliac veins. Haemostatic materials can 
assist in sealing bleeding in raw surface areas. 
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Post-operative intensive care (at either level 1 or 2) is mandatory in cases of major 
exenteration. The major post-operative inflammatory response will require close 
physiological monitoring to maintain organ perfusion and function.  The use of 
enhanced recovery principles such as perioperative sip feeding; attention to post-
operative analgesia, nausea and vomiting, careful fluid management and proactive 
nursing pathways are all applicable to this group of patients. Prolonged post-
operative ileus is common. Consideration should be given to early postoperative 
parenteral nutrition if the likelihood of prolonged ileus is likely.  Some patients with 
end stomas undergoing certain exenterative procedures are likely to be able to orally 
feed at an early stage.  
1.1.9.5 Resectable pelvic disease 
In the case of post-irradiated local recurrence, surgical resection offers the only 
potential for cure and long-term survival105 110 111. Individualised surgery represents 
the best strategy to deliver an R0 resection to suitable patients. This involves a 
range of procedures which are dependent on the nature of the tumour. Anterior 
invasion may require prostatectomy +/- cystectomy and urinary reconstruction/ 
diversion; posterior invasion may require sacrectomy; and lateral invasion may 
require sidewall or iliac vessel dissection. By definition, an exenterative procedure 
entails a pelvic dissection beyond the fascia propria and the mesorectal envelope. It 
often involves the removal of pelvic organs, including the bladder, prostate, seminal 
vesicles, urethra, vagina and uterus and ⁄ or part of the sacrum and ⁄ or the lateral 
pelvic vasculature.  
Planned resection lines following neoadjuvant chemoradiotherapy may be altered 
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from those identified at the initial staging MRI scan. It is not yet clear whether 
surgical planning is best based around the initial or post neo-adjuvant treatment MRI 
scan and further research is needed to assess the reliability of this latter scan. 
However clear response on MRI may allow for more organ preserving surgery. 
The key to successful long-term survival is the ability to achieve an R0 resection (i.e. 
a clear resection margin)103 111. This is controversial, however, as tumour at or within 
1mm of the resection margin may not be classed as R0 but as R1 (microscopic 
residual disease at the margin)112. A 2-mm or even a 3-mm circumferential margin 
may not, therefore, be a ‘safe’ circumferential resection margin in the context of local 
failure and RRC113.  
1.1.9.6 Contraindications to Resectability 
Contradictions to resectability are based around the probability of R0 resection, the 
benefit of R1/2 resections, and the resulting quality of life from extended resections. 
Different centres have different contra-indications depending on the surgical 
expertise available, resulting in varying levels of consensus. In addition, some 
experts considered relative contra-indications to be more appropriately classed as 
absolute, and vice-versa. 
• Absolute contraindications to resectability include: 
o Poor performance status/ medically unfit patients (e.g. severe 
cardiopulmonary impairment)  
o Bilateral sciatic nerve involvement  
o Circumferential bone involvement  
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• Relative contraindications to resectability (benefit unclear) include: 
o Extension of tumour through the sciatic notch  
o Encasement of external iliac vessels – requiring en bloc resection and/ 
or reconstruction of external iliac vessels 
o High sacral involvement – resection above the S2/3 junction can be 
performed with suitable surgical expertise and equipment in super-
specialist centres 
o Irresectable distant metastases 
o Predicted R2 resection – should only be offered in rare circumstances 
with MDT agreement, where the indications should be justifiable and 
the outcomes recorded in an auditable manner 
1.1.9.7 Sacrectomy 
The main controversy is the definition of resectability in terms of height of 
sacrectomy required. The traditional cut-off has been at the S2/3 junction104 114. 
However, higher sacrectomy, including S1/2 and L5/S1 may be possible115. There 
are increased risks of bleeding and neurological damage, although prolonged 
survival is achievable in carefully selected cases19. A wider evidence base is 
needed, including the potential future role of computer aided sacrectomy116. This 
supra-radical procedure is best carried out by specialised surgeons and so clear 
referral pathways to these surgeons are needed in order to maximise the treatment 
options open to the individual highly selected patient.   
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Figure 5: High resolution pelvic MRI of recurrent rectal cancer necessitating 
sacrectomy, and illustration of planes of sacrectomy. 
 
pre-sacral recurrence following a previous R1 anterior resection, affecting the pre-sacral fascia up 
to the S3 level. The patient required abdominoperineal resection with en-bloc S2/3 sacrectomy and 
periosteal lift of the S2 segment to achieve R0 resection. 
 
planes of dissection for sacrectomy (top to bottom): high sacrectomy with oblique incision and 
periosteal lift; oblique osteotomy; transverse osteotomy; coccygectomy with periosteal lift 
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1.1.9.8 Pelvic sidewall disease 
In cases of bony involvement or threatened resection margins, intra-operative 
radiotherapy (either as IORT or HDR brachytherapy) may improve outcomes in 
those who have non-R0 resections and certain close R0 resections110 117 118. There 
is no clear evidence of benefit in offering surgery to patients with tumour invasion of 
the pelvic side wall (sciatic nerve, obturator fossa, piriformis muscle). 
1.1.9.9 Anterior compartment/ urogenital disease 
Involvement of the urogenital organs may occur with both PRC-bTME and RRC. 
Radiotherapy may decrease the extent of spread. In highly selected cases without 
involvement of the sidewall or sacrum, involvement of the prostate may be amenable 
to bladder sparing prostatectomy, although morbidity is increased. 
The role of bladder reconstruction rather than cystectomy and ileal conduit is also 
unresolved. If the urethra and its sphincters can be preserved, an intestinal neo-
bladder can be formed. However, the risk of fistulation is very high especially if a low 
rectal anastomosis is performed at the same time. Over a 4-year period, Koda et al 
performed five such operations while 38 others had only an ileal conduit; two of five 
developed fistulae. However, three of the five eventually returned to work while only 
two of the 38 did so. This was taken to justify the risks of the reconstructions. As only 
11% of possible patients had the urinary reconstruction, there must have been 
substantial case selection119. 
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1.1.9.10 Distant metastases 
Optimum preoperative staging of patients to determine the extent of local disease 
and the presence or absence of distant metastases is vital when considering surgery 
for patients with PRC-bTME and RRC. There is controversy over whether resectable 
synchronous lung or liver disease is a contraindication to attempted removal of local 
recurrence. In these circumstances preoperative chemotherapy may be useful in 
evaluating tumour responsiveness. If local and distant tumour response is achieved, 
resectional surgery may be considered, although the long-term outcome of such 
borderline cases is yet to be published in large series. The role of synchronous 
pelvic and hepatic resection is also questionable and may be reserved only for the 
young fit patient with PRC-bTME cancer. 
1.1.9.11 Unresectable local disease and palliative resection 
The key objectives of palliative resections act as a guide to whom this type of 
surgery may be appropriate for. Many patients with low volume metastatic disease 
will live a considerable period with modern chemotherapy and the role of surgery in 
facilitating this is important. 
The possible benefits of debulking in the presence of grossly unresectable disease 
require clarification. R1 resection is likely to worsen quality of life outcomes 
compared to R0 resection, especially following exenteration120. Resection with an R1 
margin (microscopic residual disease) may lead to longer survival than resection with 
an R2 margin. However an R2 resection may not improve quality of life if pain is 
present pre-operatively. The best methods for palliation, which may include 
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radiotherapy, chemotherapy and/or palliative surgery require careful selection. The 
role for isolated pelvic chemoperfusion in a select group of patients with 
unresectable pelvic-contained cancer needs further investigation121. 
More information is needed to assess surgery and chemotherapy in terms of QoL 
compared with long term chemoradiotherapy. Audit of current management 
outcomes are needed to determine the role of radical surgery to provide palliation in 
both PRC-bTME and RRC. 
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Figure 6: High resolution pelvic MRI showing examples of irresectable disease. 
 
 
High-resolution MRI showing a 
recurrent rectal cancer infiltrating the 
pre-sacral fascia in front of S1/2. 
The patient would require at least an 
L5/S1 sacrectomy with a high risk of 
a positive margin, and so this was 
considered irresectable. 
 
Rectal cancer starting at the S1 
level, which is considered 
irresectable. The patient will be 
treated with neoadjuvant 
chemoradiotherapy in an attempt to 
shank the tumour. 
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1.1.9.13 Perineal Reconstruction 
A variety of methods for wound reconstruction, including biological implants and 
flaps, are available and should be encouraged122 123. Any attempt to reconstruct the 
perineal defect with plastic surgery techniques should be performed by surgeons 
who are experienced in the use of rotational or free flap transfers in order to achieve 
the best possible results.  
The perineal defect after exenteration may be significant, particularly after 
sacrectomy, and reconstruction is advantageous to decrease the time frame for 
wound healing. Techniques used include the myocutaneous oblique or vertical 
rectus abdominis muscle flap, gracilis muscle flap, gluteal rotation flap, inferior 
gluteal artery perforator (IGAP) flap or free-flap124-126. Each has its advantages and 
disadvantages and because there are no comparative studies each centre has 
adopted its preferred technique(s). Nevertheless they significantly add to the 
duration of the procedure and all carry the risk of longer bed-rest, flap related 
complications, and donor-site morbidity127 128. Biologic grafts combined with 
omentoplasty may also be used for repair of large perineal wounds without the 
addition of a flap procedure even in irradiated patients129-131. Future comparative 
studies should consider evaluation of the optimal method of perineal reconstruction 
and include short and long-term outcomes as well as quality of life. Important 
complications of flaps include wound breakdown and perineal hernias, which can 
both be challenging to treat and may impact on QoL. 
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Figure 7: Post-operative high-resolution pelvic MRI of a patient who underwent 
sacrectomy at S3 with flap reconstruction of the perineum. 
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1.1.12 Pathology and Prognostic Markers 
Close collaboration between the surgeon, radiologist and pathologist is of particular 
importance, especially in complicated specimens, to ensure that the pathologist 
knows which margins are most likely to be involved so that he/she can sample it 
adequately. The pathologist can improve clinical management by working as part of 
the multidisciplinary team. He/she is vital for informing prognosis and evaluating and 
auditing quality through accurate reporting of resection margins and other prognostic 
pathological features. Direct collaborative review of the resected specimen by both 
the surgeon and pathologist is encouraged. 
Guidelines published by the Royal College of Pathologists in the United Kingdom 
have gained widespread acceptance as the minimum standard for reporting 
colorectal cancer132 as well as College of American Pathologists (CAP) guidelines in 
the USA133. Further assessment of the multi-visceral and extended resection 
specimen is also required. There should be national, or preferably international, 
guidelines for dissection and reporting to help ensure uniformly high standards by 
pathologists working in a wide range of clinical setting. 
1.1.12.1 Pathological assessment 
The histopathology report must include:  
1. Gross description: This includes: which part of the large bowel has been 
resected, the length of the surgical specimen, if part of the bowel is extra-
peritoneal (and if so, how much)  the site of tumour (and its relationship, if any to 
the peritoneal reflection), the tumour size (3 dimensions), the distance from 
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proximal or distal margin, depth of invasion, perforation and other lesions not 
related to the tumour (adenoma, ulcerative colitis, Crohn’s disease).  Evidence of 
previous surgery should be noted. Especially in advanced and recurrent cancer, 
the presence of other organs and the relationship of these organs to the tumour 
needs to be assessed and documented. Ideally, these specimens should be 
received unfixed. This will facilitate examination of the specimen and allow tissue 
to be taken for tissue banking. Photography of the specimen is extremely 
valuable as is discussing the case with the surgeon before cutting it up.  
2. Microscopic description: histological type, histological grade, the response to 
preoperative therapy (if relevant) depth of invasion, the presence of a pushing or 
an infiltrating margin, the presence or absence of a marked lymphocytic infiltrate 
at the tumour margin, positive lymph nodes  / total number of lymph nodes 
examined, involvement of the apical node or specific groups of lymph nodes 
identified by the surgeon (e.g. paraaortic nodes), extracapsular spread of tumour, 
perineural invasion, vascular invasion (specify if there is extramural venous 
invasion), tumour infiltrating lymphocytes, (y)pTNM classification, extension of 
tumour through the bowel wall and into adjacent structures and, if relevant, 
involvement of other organs, involvement  of proximal, distal and radial margins. 
For adequate staging, current evidence shows that at least 12 nodes must be 
removed and identified to prevent under-staging of positive nodal disease. This is 
particularly important for stage II patients to reduce the risk for understaging, 
although this may be more difficult in patients who have received neo-adjuvant 
therapy134 135. A minimal dataset for adapted for use in PRC-bTME and/or RCC 
would be valuable. 
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1.1.12.2 Pathological examination after exenterative surgery 
The most common problems during these multi-visceral resections include invasion 
into adjacent structures, lateral tumour clearance and peri-rectal invasion. Accurately 
assessing the resection margin status of the complete en-bloc specimen is vital to 
guiding future therapies. R0 resection is likely to be the most important factor in 
predicting prognosis103 136 19 103 137. During sacrectomy, R1 resection rates may be as 
high as 50% which may reduce survival by at least 50% at 5 years104.  The presence 
of signet ring cells, perineural or extramural vascular invasion increases the 
likelihood of local recurrence after salvage surgery. For RRC, obtaining the original 
resection specimen can confirm the original diagnosis and confirm the original 
resection margin status if doubt exists, although this is unlikely to be routinely 
required and should not delay management. Abnormal anatomy is likely due to 
previous resection, and cut-up with a member of the surgical team present is 
recommended. Adverse pathological features, including foci of tumour away from the 
main recurrent mass, may be present in patients with RRC. 
1.1.12.3 Biomarkers 
With the exception of KRAS mutation which excludes patients unlikely to respond to 
treatment with anti-EGFR antibodies no further prognostic/predictive molecular 
marker is relevant for routine first line treatment decision out of clinical trials77. A 
range of biomarkers have been investigated in terms of prognosis. Further studies 
have concentrated on predicting which tumours will respond to chemoradiation, to 
improve patient selection. More research into novel biomarkers is needed138. 
Biomarker correlation with features from high resolution imaging may improve the 
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predictive responses from chemoradiation. Further profiling may help in determining 
response to chemoradiotherapy and prognosis139. For patients undergoing surgery 
for both PRC-bTME and RRC, CEA is likely to be of some prognostic value. For 
those with RRC, pre-operative carcinoembryonic antigen (CEA) >10 has the ability to 
predict significantly lower 5 year disease free survival (10%) compared with CEA<10 
(34%), p = 0.0513.  
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1.1.13 Follow-up Regimes 
Follow-up regimes after rectal cancer surgery aim to detect recurrence at an early 
stage to allow for successful excision. Further aims of follow-up include detecting 
second primaries, patient reassurance, audit and research. Follow up after resection 
depends on stage, type of surgery, perioperative treatment and amenability for 
resection of recurrent disease. 
A meta-analysis of the available randomized trials showed a modest but significant 
benefit for intensive follow-up regimes140. Whilst follow-up for non-advanced primary 
rectal cancer typically includes two CT thorax/ abdomen/ pelvis (TAP) in the first 3 
years and 6 monthly CEA checks for 3 years, PRC-bTME cancer may need closer 
monitoring141. An annual MRI of the pelvis for local recurrence and CT TAP for 
distant recurrence are recommended.  
For recurrent rectal cancer, an annual MRI of the pelvis for local recurrence and CT 
TAP for distant recurrence are recommended. A third resection for re-recurrent 
cancer is uncommon and the benefit of intensive follow-up regimes is questioned.  
The role of CEA in follow-up of patients undergoing surgery for primary or recurrent 
disease requires clarification, as a normal CEA does not rule out recurrence/ re-
recurrence, but a rising CEA may indicate the need for further investigation142. Until 
further evidence emerges regarding the sensitivity, specificity and cost-effectiveness 
of 18-FDG-PET in differentiation between scar tissue and post-operative 
infection/inflammation from malignant change, its routine use cannot be 
recommended143. 
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1.1.14 Quality of Life 
Traditionally, assessment of cancer treatment outcomes relied heavily on survival 
although more recent interest is being paid to quality of life (QoL). Survival without 
curative intent surgery is <5% at 5 years with a median of approximately 12 
months144 145. This has to be balanced against the considerable surgical morbidity 
and mortality and the need for prolonged rehabilitation in a substantial proportion of 
patients. Palliative surgery can be effective in carefully selected symptomatic 
patients, and this benefit needs to be quantified. Risk factors associated with poorer 
QoL are also not clearly defined, although are likely to include gender, age, bony 
resection, double stoma, pain post surgery. 
Some patients with disease amendable to pelvic exenteration may opt not to 
proceed for personal reasons. Their QoL has been poorly studied and may provide 
further information necessary in the pre-operative counselling of potential surgical 
candidates. In a recent systematic review of QoL measures used in rectal cancer, 
the EORTC C30 and/ or CR38 QoL measures were the most widely used (49%), 
with the remaining 51% comprising of a variety of QoL measures. A substantial 
proportion of studies also used non-validated investigator designed QoL measures.  
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1.2  Epithelial mesenchymal transition in colorectal cancer 
Epithelial mesenchymal transition (EMT) is the process by which epithelial cells are 
transformed into mesenchymal cells. There are three distinct functional types, 
ranging from type I found in normal embryological development to type III found in 
cancer development (table 5)146. In type III, the resultant abnormal mesenchymal 
cells are no longer under the influence of cellular control mechanisms and are highly 
motile. This leads to an aggressive and invasive phenotype, forming the initial steps 
of micro-metastases.  
Transforming growth factor β (TGFβ-1) signalling pathways are the major driving 
force of EMT. There is increasing evidence from breast, pancreatic and lung cancers 
that EMT may be responsible for an aggressive cellular phenotype leading to 
micrometastases. There is limited evidence, from non-colorectal cancer cell lines, 
that EMT may also be a cause of neoadjuvant treatment resistance146-148. As an 
EMT master-regulator, the microRNA-200 family may represent potential therapeutic 
targets across a range of cancers. More evidence proving its presence, significance 
and relation with response to neoadjuvant therapy in patients with rectal cancer is 
required before developing novel therapeutic options.  
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Table 5: Classification of epithelial mesenchymal transition. 
 
  
Class Setting Example Consequence  
Type 1 Embryological 
development 
Conversion of primitive epithelial cells 
into mobile mesenchymal cells during 
embryological development 
Normal 
development 
Type 2  Inflammation 
and fibrosis in 
adult tissue 
Wound healing, tissue regeneration 
and organ fibrosis (e.g. renal fibrosis) 
Fibrosis 
Type 3 Epithelial 
cancers 
Tumour budding at invasive fronts of 
breast, lung, pancreatic and colorectal 
cancers 
Increased cancer 
invasiveness and 
risk metastases 
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Figure 8: Epithelial Mesenchymal Transition. (1) Stable, well-ordered epithelial cells  
are transformed into mesenchymal cells, which are motile and aggressive. (2) This 
takes place at the deepest, most rapidly growing part of the tumour, which is under 
the least physiological control, and can give rise to tumour budding. (3) Motile 
mesenchymal cancerous stem cells are thought to be responsible for 
micrometastases, through migration into blood and lymph vessels. 
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Table 6: Definitions of relevant biomarkers and terminology (alphabetical). 
 
 
 
Apoptosis Programmed cell death 
Epithelial (E-) 
cadherin 
A membranous protein which maintains cell-to-cell adhesion  
β-catenin A protein that is bound to membranous E-cadherin and provides support 
to the cytoskeleton. When in cytoplasm, it is normally rapidly degraded. 
Increased cytoplasmic levels leads to protogene expression (e.g. c-myc) 
Epithelium Epithelial cells line surfaces and body cavities, often forming glands. They 
are tightly bound to adjacent cells each by E-cadherin and have many cell 
junctions.  
Invasive front The advancing edge of the tumour, where the most aggressive and 
invasive behaviour is typically found. This is often at the deepest margin 
of colorectal cancers. 
microRNAs MicroRNAs are short non-coding RNA molecules involved in regulation of 
gene expression through post-transcriptional processing 
Mesenchyme A form of undifferentiated loose connective tissue which can migrate 
easily. They contain vimentin and do not have E-cadherin in their walls. 
SMAD4 One of the SMAD family, which are intracellular proteins that transduce 
extracellular signals, particularly from the TGF-β pathways. 
Snail/ Slug  RNA transcription factors that is inhibited by SMAD4 but when present, 
suppresses E-cadherin  
Tumour budding The presence of single cells or small clusters of cells at the invasive front. 
TGF-β Transforming growth factor beta is a protein which controls proliferation 
and differentiation across many cells types, via TGF-B receptors on the 
cell membrane 
Vimentin An intermediate filament protein which forms part of the cytoskeleton in 
mesenchymal cells 
Wnt pathway Activation of extra-cellular wnt signalling pathways, via frizzled receptors, 
are heavily implicated in cancer stem cell promotion 
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1.2.1 Signal induction of EMT 
The signalling pathways controlling EMT are complex and include significant cross-
talk between several cancer related feedback-loops. These include upstream TGF-β 
and wnt/ β-catenin control pathways. They express their function through intra-
cellular mediators including the multiprotein complex consisting of axin, glycogen 
synthase kinase 3-β (GSK3β) and the tumour-suppressor protein adenomatous 
polyposis coli (APC)149. TGF-β has in fact been implicated as a key mediator of the 
EMT process. Whereas in early stages of cancer progression it is protective by 
controlling cell proliferation and differentiation, in later stages, TGF-β pathways are 
harmful as they can inhibit cell death.  
Further mediators include SMAD4 and activation of Snail, Slug and Twist 
transcription factors150 151 152 . Subsequent increased nucleic β-catenin leads to 
activation of TCF/LEF transcription factors with increased production of the EMT 
target genes, including c-myc and cyclin D1153. SMAD4 is an intracellular protein that 
transduces a variety of extracellular signals, encoded for by the SMAD4 tumour 
suppressor gene on chromosome 18q21154. Normally, activated SMAD4 protein 
complexes move to the nucleus and inhibit the main transcription factors implicated 
in the activation of the EMT pathway: Snail (SNAI1), Slug (SNAI2), Twist and ZEB1 
(Zinc finger E-box-binding homeobox 1). Figure 9 shows a schematic summary of 
key upstream pathways implicated in EMT development in human epithelial cancers. 
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Figure 9: Signal induction of EMT shows the interaction of complex upstream 
membranous pathways and cross-signalling of other cancer induction systems. 
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1.2.2 Loss of E-cadherin as a hallmark of EMT 
Loss of epithelial (E) cadherin at the cell membrane surface is a key hallmark of 
EMT154-156. Cadherins form the key complexes that maintain cell-to-cell adhesion. 
Down-regulation of membranous E-cadherin results in loss of intercellular epithelial 
junctional complexes. Loss of cellular integrity promotes motility and migration of 
cells, accompanied by the development of mesenchymal phenotypes. 
Characteristics of the mesenchymal phenotype include the expression of: vimentin, 
smooth-muscle actin, and neural (N) cadherin. Subsequent escape from growth 
factor control combined with uncontrolled proliferation, are EMT related events 
implicated in many human cancers154. These altered rapidly proliferating, motile cells 
may promote the development of micrometastases. Immunohistochemical studies 
show loss of E-cadherin in colorectal tumour masses and, especially at the invasive 
front, is an effective method to identify EMT in human colorectal cancer 
specimens157 158. 
  
 88	  
1.3.1 The role of the invasive front and tumour budding 
Tumour budding is the presence of single cells or small cell clusters at the invasive 
front of tumour growth158. These represent mobile cells that have broken off from the 
main tumour mass and proliferate under the control of cytokines in potentially 
hypoxic environments. There is strong evidence that tumour budding at this 
undifferentiated invasive front is associated with EMT157-159. E-cadherin is frequently 
absent from tumour buds and invasive fronts, even though it may still be expressed 
in the main tumour mass157 158. This loss of cell integrity would enable the properties 
needed for tumour budding. Tumour budding has been associated with lymph node 
metastasis, distant metastasis, local recurrence and a worse prognosis158  159-161.  
Investigators looking for the presence and properties of EMT should thus sample 
from the colorectal cancer invasive front, which is likely to be at its deep margins; it 
can be missed on endoscopic biopsy. The methods used for determination and 
definitions of EMT require further research and agreement; there is currently no 
universally agreed histopathological definition of EMT. At present a variety of 
methods and scoring systems are used. These mostly involve immunohistochemical 
staining for loss of E-cadherin, but also include a panel of other markers, polymerase 
chain reaction detection of alterations in DNA sequences and tests of cell migration 
and motility.  
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Figure 10: Selection of representative samples of the tumour invasive front.  
 
An formalin fixed, paraffin embedded 
rectal cancer resection specimen. The 
yellow arrow is the resection margin 
(inked green), the red arrow is the 
deepest invasive front of the tumour, and 
the red lines the superficial bowel edge.   
 
This complete slice slide shows the 
bowel lumen, tumour and excised 
mesorectum. The black arrows points to 
the deepest part of the tumour, where 
growth will be at its most aggressive and 
uncontrolled. This is the invasive front, 
where EMT is most likely to occur. It is 
less likely to occur at the superficial 
bowel lumen edge, so biopsies were not 
used 
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1.3.2 EMT and colorectal cancer progression 
In one of the largest studies on human tissue samples, Lugli et al., showed that in 
1197 mismatch repair proficient colorectal cancers, increased nuclear β-catenin 
expression and loss of membranous E-cadherin expression were independently 
associated with higher N stage, vascular invasion and worse survival. There was an 
association between loss of membranous E-cadherin and higher T stage, higher N-
stage, and worse survival162. Other studies have associated loss of E-cadherin to 
alteration in upstream markers and worsening survival163. 
SMAD4 expression has been shown to be lost in between 10 to 70% of colorectal 
cancers, with increasing losses shown in higher staged tumours164-168. A large 
analysis of 479 cases of human colorectal cancer showed that SMAD4 expression 
was lost in 52% of cases169. In 1994, Jen et al., showed that in 145 stage II or III 
colorectal cancers, chromosome 18q mutations were associated with significantly 
worse 5 year survival170. An analysis of 86 human Duke’s C colorectal cancers 
showed that all of those with low SMAD4 levels had allelic imbalance in 18q21, but 
that not all patients with 18q21 imbalances had SMAD4 repression171. In 189 stage 
III colorectal cancers, Smad4-negative tumours had a shorter time to recurrence 
than Smad4-positive tumours (20 versus 35 months, p=0.035)167. In 429 colorectal 
cancer samples, increased SMAD4 expression was related to improved survival from 
colonic cancers, although correlation to rectal cancers could not be shown167. 
Although SMAD4 is an important upstream marker, it lacks specificity for EMT alone 
as it has a range of other downstream cancer propagating effects.  
 91	  
1.3.3 The role of microRNAs in EMT  
MicroRNAs (miR) are short non-coding RNA sequences involved in regulation of 
gene expression through post-transcriptional processing172. They are important in 
the normal regulation of cell growth, proliferation and apoptosis. Their recent 
discovery has led to an improved understanding of the modulation of EMT 
pathways173. Altered microRNA expression has been linked to colorectal cancer 
development and progression, leading to recent interest in them as potential 
biomarkers as they can act as both tumour suppressor genes and oncogenes173. 
Over 1500 human microRNAs have been identified to date174. miR-9 is the main 
regulator of E-cadherin expression, with the more complex miR-200 family control 
the regulatory feedback loops of E-cadherin including miR-200a (β-catenin) and miR-
200c related suppression by ZEB175 . The strong implication of microRNA modulation 
of EMT identifies them as potential future novel therapeutic targets. With the first 
microRNA targeted drugs entering phase II trials, these agents have great 
translational promise. 
1.3.4 EMT and the response to neoadjuvant therapy 
With the increasing use of multi-modality treatment, resistance to neoadjuvant 
chemoradiotherapy has become a major challenge to clinicians treating many solid 
cancers, including colorectal cancer. The search for accurate biomarkers to predict 
good response to neoadjuvant therapy in rectal cancers has been an area of 
increasing research in the past few years84. EMT may be an important source of 
resistance to neoadjuvant therapy leading to poor tumour regression, although only 
 92	  
preliminary evidence of this association exists.  
In 30 human colorectal cancer samples, Snail was expressed in peripheral, budding 
portions of the tumour. The same study showed that Snail activation in colorectal 
cancer cell lines led to increased motility and invasiveness, with increased resistance 
to 5-flurouracil chemotherapy176. Parageorgis et al., showed that treatment of 
SMAD4 positive colorectal cancer cell lines with 5-flurouracil resulted in a profound 
induction of apoptosis, whereas SMAD4 negative cell lines exhibited almost 
undetectable levels of apoptosis 177. Yang et al., showed that in colorectal cancer cell 
lines made resistant to oxaliplatin, cellular changes were consistent with EMT, 
including spindle-cell shape, loss of polarity, and intercellular separation. There was 
accompanying loss of membranous E-cadherin with β-catenin accumulation in the 
nucleus, which they attribute to induction of EMT178. Kawamoto et al., showed that in 
26 rectal cancer specimens undergoing neoadjuvant therapy and two cell lines, 
irradiation enhanced cell migration and invasiveness, and led to molecular changes 
of EMT179. In addition, a further body of evidence now links EMT to chemoresistance 
in other cancer types, including ovarian cell lines180, pancreatic cell lines181, breast 
cancer cell lines182 183 and human lung cancer resections148.  
Evidence of these interactions from human patients with rectal cancer is lacking184. 
Similar work is needed in human colorectal specimens with associated pre-treatment 
biopsies in order to fully clarify the role of EMT, although the risk of missing deep-
seated EMT in superficial biopsies is significant. The exact role of EMT as an 
independent biomarker in the presence of both response and non-response to 
neoadjuvant therapy also requires further analysis.  
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1.4 Thesis aims 
1.4.1 Thesis hypothesis  
Epithelial Mesenchymal Transition is a route to resistance to neoadjuvant therapy in 
rectal cancer. 
1.4.2 Thesis aim 
The aim of this thesis was to determine whether EMT is associated with non-
response to neoadjuvant chemoradiotherapy in patients with advanced rectal cancer. 
1.4.3 Thesis objectives 
1. To determine the association between EMT adhesional molecules E-cadherin 
and beta-catenin with response to neoadjuvant therapy. 
2. To determine the association of the upstream EMT regulator microRNA-200c 
with response to neoadjuvant therapy. 
3. To test the association between E-cadherin biomarkers and tumour budding. 
4. To determine the association between tumour budding and response with 
neoadjuvant therapy. 
5. To determine if EMT biomarkers are associated with advanced tumour 
pathological stage.  
6. To determine the genetic changes in expression of the gene for E-cadherin in 
association with non-response to neoadjuvant therapy. 
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2 Methods 
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2.2 Patients 
2.2.1 Ethical approval  
Ethical approval for this study was granted from Northwest London Research and 
Ethics Committee (12/LO/0943, Appendix 1).  
2.2.2 Patient selection 
The Royal Marsden Hospital Colorectal Unit is a national and international referral 
centre for patients with locally advanced primary and recurrent rectal cancer. It also 
offers a full range of surgery for colorectal cancer, including: 
• Local excision for early rectal cancer: transanal resection, transanal 
endoscopic microsurgery. 
• Total mesorectal excision surgery: high anterior resection, low anterior 
resection, ultralow anterior resection with coloanal pull-through. 
• Abdominoperineal excision of rectum (APER): intersphincteric, cyclindrical, 
extralevator APER.  
• Beyond TME surgery: a full range of exenterative surgery is offered by a 
specialist colorectal team, with support from surgical oncology, spinal 
orthopedic, urological, gynecological and plastic surgeons on a case-by-case 
basis.  
For the histopathological study, patients undergoing resection of rectal cancer from 
2009 to 2011 were identified from a prospectively maintained clinical database at the 
Royal Marsden Hospital, London. The starting date was chosen due to availability 
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of specimens and the finishing date to allow for adequate minimum clinical follow-up 
of patients. Patients were included only if surgery was performed with curative intent 
and formalin fixed paraffin embedded (FFPE) rectal cancer specimens were 
available. Those undergoing operations for non-colorectal, solid tumours or benign 
retrorectal tumours were excluded.  
2.2.3 Staging and treatment decisions 
Treatment decisions were made by a specialist colorectal multidisciplinary team, 
which manages patients with non-advanced primary, locally advanced primary and 
recurrent rectal cancer. All patients were staged with: (i) complete clinical 
examination and colonoscopy; (ii) high resolution magnetic resonance (MRI) scan of 
the pelvis; (iii) high resolution computed tomography (CT) scan of the thorax, 
abdomen and pelvis; (iv) whole body positron emission tomography CT. Staging was 
performed according to the 6th Edition of the AJCC TNM system. 
The height of rectal cancer was measured from the anal verge and was based on 
endoscopy and/or digital rectal examination. Low rectal cancer was defined as those 
<5cm from the verge, and middle/high rectal cancer as those ≥5cm. 
Radiotherapy naïve patients received long-course neoadjuvant chemoradiotherapy 
(neoCRT), administered as long-course fractionated radiotherapy to a maximum 
dose of 54 Gy, with concurrent chemotherapy (either fluorouracil or capecitabine 
based regimes). Patients were fully restaged 6-8 weeks following completion of 
neoCRT. Intraoperative radiotherapy and brachytherapy are not offered at the Royal 
Marsden Hospital.   
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2.2.4 Indications for surgery 
Surgery was performed no later than 6 weeks after the last set of complete 
radiological staging. Following re-staging, decisions on indications and contra-
indications were made as according to criteria defined by the Beyond TME 
consensus statement12: 
• Absolute contraindications to resectability include: 
o Poor performance status/ medically unfit patients (e.g. severe 
cardiopulmonary impairment)  
o Bilateral sciatic nerve involvement 
o Circumferential bone involvement  
• Relative contraindications to resectability (benefit unclear) include: 
o Extension of tumour through the sciatic notch  
o Encasement of external iliac vessels – requiring en bloc resection and/ 
or reconstruction of external iliac vessels 
o High sacral involvement – resection above the S2/3 junction can be 
performed with suitable surgical expertise and equipment in super-
specialist centres 
o Irresectable distant metastases 
o Predicted R2 resection – should only be offered in rare circumstances 
with MDT agreement, where the indications should be justifiable and 
the outcomes recorded in an auditable manner. 
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2.2.5 Total Mesorectal excision 
All major resections were performed by a single surgeon using a standardised total 
mesorectal excision (TME) technique, either laparoscopically or via midline incision, 
based on decisions made with the patient taking into account their specific 
characteristics. Procedures were performed in the modified Lloyd-Davies position, 
splenic flexure mobilisation to produce a tension free anastomosis or stoma, high tie 
of inferior mesenteric vessels, and a TME using combination sharp dissection and 
electrocautery. Procedures were classified according to restoration of continuity of 
bowel anatomy, being either restorative or non-restorative. For restorative 
procedures, anastomosis was created using either a stapled or handsewn technique, 
and included anterior resection, low anterior resection, coloanal anastomosis and 
ileoanal pouch formation in the presence of subtotal colectomy. For non-restorative 
procedures, an end colostomy was fashioned. 
2.2.6 Exenterative surgery 
All operations were performed by a specialist exenterative colorectal surgeon, with 
support from spinal orthopaedic, surgical oncology, gynaecological, urological and 
plastic surgeons on a case-by-case basis. Patients underwent urethral 
catheterisation and were placed in the Lloyd-Davies position. Ureteric stenting was 
performed by a specialist urological surgeon when the bladder was free of disease.  
Using an abdominal and perineal approach, the pelvic structures were mobilised 
anteriorly and laterally, leaving the posterior and potentially involved pelvic sidewall 
structures to be dissected last. If cystectomy was planned based on pre-operative 
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MRI, an extra-peritoneal approach was used with early control of the dorsal venous 
complex, followed by division of the endopelvic fascia and urethra. If decision for 
cystectomy was made intra-operatively due to tumour fixity or pelvic sidewall fibrosis, 
the anterior compartment was tackled after mobilisation of the posterior, central or 
pelvic sidewall.  
Bilateral high ligation of the internal iliac arteries was performed in all patients who 
underwent cystectomy and in the last five patients who underwent bladder 
preservation. In the remaining patients, selective ligation of the internal iliacs was 
performed distal to the origin of the superior vesical artery. The internal iliac veins 
were ligated from above in 4 out of 5 high sacrectomies (at S1 or S2 levels). In one 
case this was not possible due to tumour fibrosis and intra-operative bleeding; 
control of the veins was achieved after division of the sacrum by the perineal 
approach. 
Perineal excision was performed in the supine position, using an extra-levator 
dissection of the sphincter complex by a combination of sharp dissection, diathermy 
and bipolar sealing device (Ligasure, Covidien). To complete the cystoprostectomy, 
anterior dissection with Ligasure was continued to the level of the previously 
controlled urethra. En-bloc resection of the vagina, ovaries, pelvic sidewall, internal 
iliac vessels and small bowel was performed as required. En-bloc lateral pelvic 
sidewall resection was performed where indicated by the pre-operative MRI, with 
procedures including extended lymphadenectomy, resection of internal iliac vessels 
or piriformis resection. With the patient in the supine position and the legs lowered, 
an ileal conduit was constructed as necessary, myocutaneous tissue flaps harvested 
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and temporarily placed at the pelvic inlet, a colostomy was raised, the abdominal 
incision was closed and the stomas opened to the skin. 
For sacrectomy at S3 or above, the patient was turned in the prone position. To 
confirm the correct height of the osteotomy, a K-wire was drilled one centimetre 
above the tumour through the anterior and posterior sacral plates and into the 
subcutaneous tissues, before turning the patient. The position of the K-wire was 
confirmed using fluoroscopic guidance, A vertical incision directly over the midline of 
the sacrum was performed followed by lateral dissection reflecting the gluteus 
muscles laterally. The sacrotuberous ligaments, sacrospinous ligaments and the 
piriformis muscle divided for sacrectomies at or proximal to the S3 level. The sciatic 
nerve was identified and slinged for all high sacrectomies and preserved. For 
division above S2, the S1 and S2 nerve roots were identified and preserved. The 
dural sac were tied off and divided distal to the origin of the S2 nerve root.  The 
sacrum was disarticulated using osteotomes, a Gigli or power saw. A periosteal lift 
was performed on the anterior surface of the sacrum to the sacral segment above 
the osteotomy to maximise tumour clearance. For low sacrectomy (at S4/5) and if 
exposure was adequate, sacral division was performed in the supine position 
through the perineal incision using serial oblique osteotomies.  
Thorough haemostasis of the pelvis and perineum was achieved through a 
combination of diathermy, suture, packing and a topical haemostatic agent (Tachosil, 
Nycomed) for raw pelvic surfaces. Post-operatively, patients were routinely admitted 
to the critical care unit, intravenous antibiotics given for at least three days and total 
parenteral nutrition started in anticipation of a ten-day post-operative ileus. 
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2.2.7 Reconstruction 
Perineal reconstruction were based upon the size of the residual defect whilst being 
tailored to the individual patient and their wishes. For large defects (for example 
following sacrectomy or total pelvic exenteration), patients were prepared for 
myocutaneous flap reconstruction. This included pre-operative assessment by 
plastic reconstructive surgeons, computed tomography angiography to assess the 
location and patency of the inferior epigastric arteries, and pre-operative marking of 
incisions and stoma sites. For small perineal defects, primary closure was 
performed, with omentoplasty if a large pelvic inlet defect was predicted. The final 
decision was made intra-operatively alongside plastic reconstructive surgery 
colleagues. Patients underwent urethral catheterisation and were placed in the 
Lloyd-Davies position. Ureteric stenting was performed by a specialist urological 
surgeon when the bladder was free of disease. The urological options for bladder 
reconstruction following cytoprostatectomy was made following discussion between 
the patient and specialist urologist, and included ileal conduit185, double barrelled wet 
colostomy186 or colonic conduit187. Bladder repair was performed immediately with 
urological support; vaginal reconstruction was performed by plastic and 
reconstructive surgeons. 
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2.3 Primary and Secondary Study Outcomes  
2.3.1 Primary outcome 
The primary outcome for this thesis was response to neoadjuvant therapy. Response 
to neoadjuvant therapy can be assessed using clinical, radiological and pathological 
methods. Response is a novel marker which is not yet in standardised use, although 
it may eventually prove to be more important than downstaging. In a comparison of 
119 patients with advanced rectal cancer undergoing neoadjuvant therapy, good 
pathological response was associated with improved disease free survival (p=0.007), 
whereas pre-operatively determined downstaging was not related to survival188.  
2.3.1.1 Clinical assessment 
Clinical re-assessment following neoadjuvant therapy involves digital rectal 
examination, and endoscopic examination with biopsy. The strength in this approach 
is to identify obvious clinical disease undetectable by radiological imaging. However, 
its ability to identify significant and complete response is limited, especially at a 
cellular level. A study including 220 patients undergoing pre-operative 
chemoradiotherapy compared clinical response with pathological response189. It 
showed that 19 of 31 patients with a complete pathological response had evidence 
of a residual mucosal abnormality consistent with an incomplete clinical response. 
This study showed that the majority of patients with a complete pathological 
response did not have complete clinical response. Surgeons may be detecting 
residual scar tissue, which is indistinguishable from malignancy. They may 
furthermore be cautious in the presence of such fibrous tissue. 
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World Health Organisation Response Evaluation Criteria in Solid Tumours (RECIST) 
guidelines 
This clinical system allows is designed to allow clinical assessment of many tumour 
types, and contain instructions for dealing with multiple target lesions. The original 
guidelines, publihsed in 1981, were updated in 2008 to a simplified version190:  
• Complete Response (CR): Disappearance of all target lesions. Any lymph 
nodes (whether target or non-target) must have reduction in short axis to <10 
mm. 
• Partial Response (PR): At least a 30% decrease in the sum of diameters of 
target lesions, taking as reference the baseline sum diameters. 
• Progressive Disease (PD): At least a 20% increase in the sum of diameters 
of target lesions, taking as reference the smallest sum on study (this includes 
the baseline sum if that is the smallest on study). In addition to the relative 
increase of 20%, the sum must also demonstrate an absolute increase of at 
least 5 mm. (Note: the appearance of one or more new lesions is also 
considered progression). 
• Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor 
sufficient increase to qualify for PD, taking as reference the smallest sum 
diameters while on study. 
These guidelines are infrequently used for colorectal cancer. Although some 
single centre studies support a clinical approach86, widespread validation of a 
clinical only assessment is lacking.  
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2.3.1.2 Radiological assessment 
There is increasing interest in the role of radiological detection of clinical response to 
neoadjuvant therapy. The ability to reliably and non-invasively identify significant 
response allows for accurate tailoring of future treatment for the individual patient.  
The MERCURY study assessed the accuracy of preoperative MRI staging to predict 
a pathologically clear circumferential resection margin (CRM) in 408 patients 
between January 2002 and October 20032. The overall clear circumferential 
resection margin (CRM) assessed in the study was 87% (354/408). In a subgroup 
analysis of 111 patients treated with neoadjuvant therapy, post-treatment radiological 
staging showed that MRI assessment of tumour regression grade (mrTRG) 
independently predicted overall survival (hazard ratio 4.40, 95% CI 1.65-11.7) and 
disease free survival (hazard ratio 3.28, 95% confidence interval 1.22-8.80)81. These 
sub-group analyses showed that mrTRG provided an accurate pre-operative imaging 
marker of survival that offered multidisciplinary teams the opportunity to tailor 
preoperative treatment. 
In a subsequent multicentre assessment of reimaging following neoadjuvant therapy 
from five institutions in Ireland and the USA, 285 patients with stage 2 and 3 disease 
were included. Fourteen patients were observed as complete responders and the 
remainder were operated upon. Compared to post-operative histopathological 
assessment, the ability of pre-operative MRI to predict correct T-stage (weighted 
kappa 0.212) and nodal involvement (kappa = 0.336) was low. This paper concluded 
that current MRI protocols were of limited value in choosing surgical approaches and 
could not be clinically relied upon191. Other studies contribute to the heterogeneity of 
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evidence surrounding the reliability of MRI assessment of TRG192. Because of the 
need for further research in this area before accepting this as a standard, MRI 
determined TRG was not used as the standard for determination of tumour 
regression in this thesis. 
2.3.1.3 Histopathological assessment 
Histopathological assessment of the resected specimens provides the gold standard 
of assessment of tumour regression. Several systems exist, with their use dependent 
on local practices and histopathologist preference. All systems require evaluation for 
residual tumour in as precise and objective a way as possible. No single system is 
ideal and all are subject to interobserver variability.  
Mandard Classification  
The Mandard Classification provides a standard reference of histopathological 
examination of tumour regression. Initially developed for use in oesophageal cancer, 
it is widely applied across a range of other cancers, including colorectal cancer. The 
original study by Mandard et al., studied 93 patients with oesophageal cancer treated 
with cisplatin based chemotherapy and irradiation before surgery, and was published 
in 1994193. They applied five tumour regression grades. At multivariable analysis, 
only tumour regression showed a significant factor predictive of survival. There are 
five grades, ranging from complete response (grade I) to no response (grade V). For 
this thesis, grade 1-2 indicated significant response and grade 3-5 indicated non-
response.193,132 The classifications used are: 
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• Grade 1: Complete regression; absence of histologically identifiable residual 
cancer and fibrosis extending through the different layers of the esophageal 
wall, with or without granuloma 
• Grade 2: Presence of rare residual cancer cells scattered through the fibrosis 
• Grade 3: Increase in the number of residual cancer cells, but fibrosis still 
predominated 
• Grade 4: Residual cancer outgrowing fibrosis 
• Grade 5: Absence of regressive changes 
Dworak regression grading system 
The Dworak regression grading system was developed using rectal cancer 
specimens and used similar classifications. The original paper was developed on 17 
patients treated with preoperative chemoradiation, and was published in 1997194. 
The recommended classification category grouped grade 0-2 as non-responders, 
and grade 3-4 as responders: 
• Grade 0: No regression 
• Grade 1: Dominant tumour mass with obvious fibrosis and/or vasculopathy 
• Grade 2: Dominantly fibrotic changes with few tumour cells or groups (easy to 
find) 
• Grade 3: Very few (difficult to find microscopically) tumour cells in fibrotic 
tissue with or without mucous substance 
• Grade 4: No tumour cells, only fibrotic mass (total regression or response) 
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There is no agreed consensus on which system is best used for formal 
histopathological reporting, with frequent disagreement and variation195. In daily 
practice, the Mandard and Dworak systems are most commonly used by 
gastrointestinal pathologists. 
2.3.2 Standardised histopathological assessment  
For this thesis, the original histopathology report will be used to determine tumour 
regression grade based on the Mandard Classification. There is recognised  
variabilty between histopathologists, both in reporting of prognostic variables and 
whether those factors are present or not during semi-quantative assessment. When 
considering pathology reports across multiple sites and pathologists, this can cause 
bias. The Royal Marsden Hosptial Colorectal Unit has two dedicated gastrointestinal 
pathologists. These pathologists report a standardised set of prognostic variables in 
keeping with national guidelines. The findings of these reports will be used, with no 
further re-analysis of the original specimen. Such an approach would have 
medicolegal implications beyond the scope of this study and ethical approval gained. 
However, the standarised approach used to orginal reporting minimises the risk of 
reporting bias.  
2.3.3 Secondary outcome measures 
The secondary outcome measures of this thesis were based on important prognostic 
clinical variables. Additional secondary outcomes tested biomarker correlation: 
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2.3.3.1 Secondary clinical outcomes 
• Circumferential resection margin (CRM) - a key prognostic marker used 
within multivariable analyses196, defined as112:   
o R0: microscopically clear resection margins of at least 1mm  
o R1: microscopically involved resection margin with tumour within 1mm 
of the resection margin 
o R2: macroscopically involved resection margin. 
• Extramural venous invasion (EMVI) – This is recorded when tumour is 
present within an extramural endothelium-lined space that is either 
surrounded by a rim of muscle or contains red blood cells. 
• American Joint Committee on Cancer (AJCC) stage – this was determined 
from post-operative histopathological analysis29.  
• Disease free survival (DFS): the time from the date of surgery to the date of 
pelvic recurrence and/or distant disease or death due to pelvic recurrence 
and/or distant disease.  
• Overall survival (OS): time from the date of surgery to date from any cause. 
• Local recurrence free survival (LRFS): the time from the date of surgery to 
the date of pelvic recurrence or death due to pelvic recurrence. 
2.3.3.2 Secondary biomarker outcomes 
Biomarker correlation and ability to detect tumour budding were used as secondary 
biomarker outcomes. 
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2.5 Biomarkers  
2.5.1 Tissue type selection 
Various tissue types are available for cellular and histopathological laboratory 
studies, including fresh frozen human tissue, formalin fixed paraffin embedded 
(FFPE) tissue, cell culture and animal tissue. This thesis will focus on making 
maximal use of FFPE, since it has the following key advantages over other tissue 
types: 
1. It is cheap to store at room temperature with no special conditions. 
2. Tissue is stable for periods exceeding 10 years. 
3. It allows for analysis of patient tissue, with corresponding follow-up 
information available. 
4. They are widely used and available in most hospitals, allowing for analysis of 
large patient numbers in fast time periods. 
FFPE is a standard of tissue storing and diagnosis globally. The routine formalin 
fixation process stabilises proteins via cross-linking of macromolecules which keeps 
the tissue in an excellent condition for further histopathological analysis197. Formalin 
is 37-40% formaldehyde in water, stabilised by 10% methanol, with tissues being 
routinely fixe in a phosphate buffered 10% solution of formalin. Formaldehyde reacts 
with amino groups of basic amino acids, leading to formation of highly reactive 
methylol adducts. Subsequent condensation reaction occurs through Schiff base 
formation, resulting in formation of methylene bridges, leaving inter and 
intramolecule cross-linking of proteins. The proteins and protein modifications in 
these tissues are thus preserved for years afterwards. 
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Traditionally, FFPE expression studies were linked to a limited number of proteins. In 
the modern era, the number of proteins analysable has increased greatly, widening 
the application of FFPE as a research base using immunohistochemistry. This 
means that they represent an ideal target for analysis of E-cadherin and beta-catenin 
as key biomarkers of the EMT process in FFPE rectal cancer tissue. Both markers 
are well used, with abundant quality antibody probes to allow reliable results. 
The recovery of RNA from FFPE, however, has been challenging. The fixation 
process causes cross-linkage between nucleic acids and proteins, and modifies RNA 
by the addition of monomethyl groups to the bases. Isolation of nucleic acids is also 
impaired by the presence of paraffin wax. As a result, the molecules are rigid and 
susceptible to mechanical shearing, and the cross-links may compromise the use of 
RNA as a substrate for reverse transcription. This has led to reduced quality of the 
nucleic acids obtained, which reduces the quality of molecular analysis. Recovering 
all mRNA can be difficult because some RNA will be cross-linked to other molecules 
in the FFPE sample. RNA fragmentation, common in FFPE samples, means that 
RNA isolation protocols must be able to extract all sizes of RNA. In addition, a 
heating step could be considered as a potential method of reversing formaldehyde-
induced modifications of nucleic acids. 
Subsequent techniques have been discovered to unlock the RNA potential of FFPE 
biobanks. These include in-situ hybridisation and microRNAs. Total RNA isolation 
kits optimised for FFPE, followed by high capacity RNA to cDNA conversion and 
finally real time polymerase chain reactive technology have been employed to further 
overcome these limitations for RNA extraction.   
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2.5.2 Biomarker selection 
Following a thorough literature search, biomarkers were selected based on a 
targeted approach from those shown to be relevant from a range of other cancers184. 
These were used based on the interaction of E-cadherin and beta-catenin at the cell 
membrane as integral adhesion molecules in epithelial surfaces. MicroRNA 200-c 
(mir200c) was chosen for in-situ hybridisation analysis as the upstream regulator of 
membranous E-cadherin expression and the EMT process198.  
2.5.3 Definition of the invasive front and tumour budding 
The invasive front of a tumour is the most advancing and progressively growing 
aspect of that tumour. It is often the deepest part of the tumour, which presents 
unique diagnostic and therapeutic challenges. The invasive front represents an area 
of pro- and anti-tumour activity. Pro-tumour activity includes tumour budding and 
infiltrative growth patterns, whereas anti-tumour activity includes immune responses 
and presence of inflammatory cell types.  
When anti-tumour activity predominates or balances pro-tumour growth, progression 
is limited. However when pro-tumour activity is predominant, local tumour growth is 
enhanced and micrometastatic growth is promoted. Several immunological or 
inflammatory tumour-associated antigens (including CD3, CD4, CD8, CD20, 
Granzyme B and FOXP3) have been identified as potentially prognostic in patients 
with colorectal cancer157 158.  The EMT process is highly likely to occur at this 
invasive front, leading to tumour-budding cancer migratory cancer stem cell 
phenotypes. 
 112	  
Pro-tumour activity at the invasive front leads to tumour budding, which is a key 
diagnostic target. Tumour budding is defined as isolated single cells or small clusters 
of cells scattered in the stroma at the invasive tumour margin199. These cancer stem 
cell like tumour buds are motile, aggressive and have the ability to form 
micrometastases and be radioresistant. Despite the proven prognostic impact of 
tumour budding200, there is great heterogeneity in its reporting, detection method and 
cut-off values, which current limit its clinical use. Additionally, there are no guidelines 
for histopathologists on whether to assess for tumour budding in the entire tumour, 
or just at the invasive front using haematoxylin & eosin or other stains199. 
Differentiating true tumour budding from other artefact, including active fibroblastic 
cells, may mean that its presence is underestimated. The precise method of 
assessment of tumour budding is also heterogeneous, and has included qualitative, 
semi-quantitative and quantitative methods199 201.  
A multicentre, multinational study on the diagnostic reproducibility of tumour budding 
in colorectal cancer was published in 2012199. Ten investigators evaluated five 
diagnostic methods, and resulted in highest inter-observer agreement for cytokeratin 
immunohistology compared to H&E slides, although all methods led to overall fair 
level of agreement. The need for further research in the area is clear, including 
diagnostic method and prognostic validity at the invasive front. 
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Figure 11: Example of the invasive front. The red arrows show direction of tumour 
growth, from superficial bowel edge to deep. Green arrows show tumour buds; 
individual tumour cells away from the main tumour mass. 
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2.5.5 Biomarker assessment 
2.5.5.1 Block selection 
Due to the nature of the invasive front, it is the most likely area to undergo the 
changes associated with EMT. The invasive front in colorectal cancer will be found at 
the deepest radial margin. Since most cancers start as superficial polypoid lesions, 
the bowel side of the cancer does not represent this front; the deepest advancing 
edge into muscle and stroma will be the site of most growth. 
As a consequence, the best place to test for EMT will be at this invasive front, and 
thus at the deepest margin of the tumour. Additionally, EMT is a dynamic process 
which may occur at any point across this front, and may be patchy in nature. 
Analysis of small samples of the invasive front, as provided by small cored tissue 
micro arrays, is likely to miss patchy EMT is a significant number of specimens. 
Additionally, biopsies of the lesion will represent the most superficial edge and are 
again likely to miss EMT in deeper tumour regions. Furthermore, the limited and 
selective nature of the area covered by biopsies means that they may miss EMT 
even if the depth is adequate. 
The primary aim of this thesis relates to identifying the EMT process, and relating to 
response to neoadjuvant therapy. Therefore the most reliable mechanism to detect 
EMT should be used. In this case, we judged that analysis of the entire invasive front 
was the best manner in which to identify EMT. To achieve this, FFPE tissue blocks 
were selected for each patient to represent the deepest tumour margin over the 
largest area possible, through correlation with the numbered histopathology report. 
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Where needed, multiple blocks per patient were used. If a specimen failed in the 
initial biomarker processing, it was repeated up to three times; further efforts were 
halted to preserve tissue. 
2.5.5.2 Scoring methodology 
There is no single, reliable and reproducible scoring system for assessment of slide 
based staining techniques. A balance must be struck between qualitative (e.g. 
subjective opinion) and quantitative (e.g. summary number of cells per area) 
assessment in cases where quantitative assessment is not possible. In this thesis, 
the nature of analysis means that large, heterogeneous tissue sections will need to 
be analysed. The location of this analysis is also important, which should be 
focussed towards the invasive front. A pilot of automated computerised analysis of 
slides was performed form the first slides, although this failed due to the 
heterogeneity of the slides being analysed, which included normal and cancer tissue 
as well as deep and superficial malignant fronts. Quantitative assessment can be 
aided by laser micro-dissection, but since the EMT effect may be seen at any point 
across the invasive front, this carries the risk of missing important areas. 
A semi-quantitative scoring system is a compromise between qualitative and 
quantitative methodology. It allows application of a scale, based on interpretation of 
source material by investigators. It is a widely used method in laboratory based 
science, and has been used in the application of EMT based immunohistochemistry 
and in-situ hybridisation studies previously138 199 201. In order to boost validity of this 
method, techniques such as two person independent scoring and/or second scorer 
validation are frequently used. 
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For this thesis, one author scored results according to pre-defined patterns (AB), 
which were verified by a second author (RG). This followed a training period which 
included 50 cases of rectal cancer to standardise detection of the invasive front, 
cancer cells and tumour budding. The first 10 cases from each biomarker were 
further analysed together to standardise applications of biomarker definitions. In 
cases of disagreement, discussion and re-review was undertaken until consensus 
was achieved. Authors were blinded to all clinical details (including response to 
neoCRT) during scoring, using only a numerical patient identifier for reference.  
2.5.5.3 Biomarker assessment  
In a semi-quantitate manner, biomarker expression was assessed at the tumour’s 
invasive front, compared to the tumour’s most superficial edge. Patients thus acted 
as their own control. This is important, as each patient’s baseline may be different 
from another, so a group control in this setting is likely to be inadequate. Loss of 
membranous E-cadherin, increased nuclear expression of beta-catenin and loss of 
microRNA 200c (mir200c) were used as the main biomarkers of EMT. In addition, 
the presence of tumour budding identified via beta-catenin staining was recorded, as 
tumour buds with absent E-cadherin or reduced mir200c may be undetectable. Beta-
catenin expression can be expected consistently from all cells, whether in the 
membrane, cytoplasm or nucleus.   
The following definitions were used:  
• E-cadherin loss was semi-quantitatively scored as reduction of >50% of 
intensity of membranous E-cadherin expression at the tumour’s invasive 
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edge, compared to E-cadherin expression at the tumour’s non-invasive edge 
from the same patient.  
• Nuclear beta-catenin expression was semi-quantitatively scored as positive 
staining of nuclei at the invasive edge compared to non-staining of nuclei at 
the non-invasive edge. 
• Reduced mir200c expression was semi-quantitatively scored as reduction of 
50% of intensity of membranous and/or cytoplasmic expression at the 
invasive edge, compared to the non-invasive edge.  
• Tumour budding was identified as isolated single cells or small clusters of 
cells scattered in the stroma at the invasive tumour margin199. For analysis of 
clinical histopathological outcomes, its presence identified via beta-catenin 
staining was recorded. 
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2.5.7 Immunohistochemistry (IHC) 
Immunohistochemistry (IHC) is the process of detecting protein antigens in cellular 
tissue through the principle of antibody binding to specific antigens. It is a widely 
used technique in basic science and clinical medicine, with a wide availability of 
different antibodies and applicability in a range of tissue types and formats. It is a 
cornerstone of cancer diagnostics. In order to visualise the antibody-antigen 
complex, the antibody is most frequently conjugated to an enzyme (e.g. peroxidase), 
which can catalyse a colour producing reaction.  If this reaction is tagged to a 
fluorophore, a fluorescent reaction is produced (immunofluorescence). The 
distribution of the coloured stains is then examined under microscopy. Originally, 
most antibodies were polyclonal, where they were raised by antibody reactions in 
animals including horses and rabbits. Monoclonal antibodies are now available, 
which are produced from tissue culture, and they produce one type of antibody with 
greater antigen specificity and consistency.  
Manual IHC is complex, expensive and time-consuming. For commonly used 
antibodies and antigens, it has largely been replaced by automated systems in 
National Health Service and research practice. This reduces cost and speeds 
productivity through increased capacity, whilst applying consistency across batches. 
2.5.7.1 Tissue specimens 
FFPE blocks were cooled to -15oC. The blocks were trimmed and the initial 2-3 
slices were disregarded. Following this, 3µm sections were cut and placed into a 
room-temperature water bath for unfolding. Sections were transferred to a heated 
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water bath briefly to allow tissue stretching. Sections were then mounted on 
positively charged slides from a non-contaminated package. The sections were air 
dried for 1-2 hours at 60oC. Tissue sections were cut the day before an experimental 
run.  
2.5.7.2 IHC procedure 
Automated IHC was performed using the Bond-Max system (Leica Microsystems, 
Wetziar, Germany). All steps were performed by the automated instruments 
according to the manufacturer’s instructions, following manual optimisation of times 
and concentrations (Leica Microsystems): 
1. Standard deparaffinisation of the tissue with xylene and ethanol baths 
2. Heat-induced epitope retrieval using citrate (pH 6) antigen recovery for 10 
minutes at 100oC 
3. Peroxide block placement on slides for 5 minutes at ambient room 
temperature  
4. Incubation with primary antibody, followed by incubation with post primary 
reagent for eight minutes at ambient room temperature 
5. Bond Polymer (Leica Microsystems) placement on slides for eight minutes at 
ambient temperature, followed by washing with bond wash and distilled water 
for four minutes. 
6. Colour development with DAB (3,3’-diaminobenzide tetrahydrochloride) for 10 
minutes at ambient temperature 
7. Haematoxylin counterstaining for five minutes at ambient temperature, 
followed by mounting of slides. 
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2.5.7.3 Antibodies 
Antibodies were used for E-cadherin (1:100 dilution, Dako, Cambridgeshire, UK, 
catalogue number M3612) and beta-catenin (1:300 dilution, Dako, Cambridgeshire, 
UK, catalogue number M3539). Negative controls consisted of phosphate buffered 
saline negative for the primary antibody.  
 121	  
2.5.8 microRNA 200c in-situ-hybridisation (ISH) 
MicroRNAs (miRNAs) are a group of non-coding RNAs, formed of up to 22 base 
pairs. They represent precursor RNA transcripts, with over 1000 unique types in 
existence (www.mirbase.org). They are relatively recent discoveries, with most 
information about them emerging in the last five years173. As a result, their 
development and function remains incompletely understood. A generally accepted 
pathway exists202. The miRNA primary transcripts are folded into single or tandem 
hairpin structures, which are called pri-miRNA. These are processed into single 
hairpins, which are transported into cytoplasm. The loop part of the hairpin is then 
removed, resulting in two single stranded miRNAs that form a duplex. Binding of 
miRNA to partially or fully complementary messenger RNA (mRNA) leads to 
repression of mRNA translation or mRNA degradation. 
2.5.8.1 Detection of miRNA from FFPE 
In-situ hybridisation (ISH) is a powerful technique and the most common method for 
visualising gene expression and localisation in specific tissue and cell types. The 
technique is often time consuming and difficult, requiring multiple steps of 
optimisation to achieve satisfactory and reproducible results. Although some NHS 
facilities provide automated ISH, this is not yet widely present or validated in 
research settings.  Furthermore, successful application of ISH to FFPE tissue 
samples is a relatively new process. A one-day, robust kit exists, which allows for 
rapid optimisation, fast analysis and reproducible results. The miRCURY LNA 
microRNA ISH Optimisation Kit (FFPE) is produced by Exiqon (Denmark) and is 
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likely to be suited to analysis of FFPE rectal cancer specimens202.  
2.5.8.2 Technique summary 
Following standard deparafinisation, miRNAs are demasked using Proteinase-K, 
which allows the access of double-digoxigen (DIG) labelled locked nucleic acid 
(LNA) probes to hybridise to the miRNA sequence. The digoxigenins can then be 
recognised by a specific anti-DIG antibody, which is directly conjugated with the 
enzyme Alkaline Phosphatase (AP). AP converts the solute substrates 4-nitro-blue 
tetrazolium (NBT) and 5-bromo-4-chloro-3’-indolylphosphate (BCIP) into a water and 
alcohol insoluble dark-blue NBTG-BCIP precipitate. Application of nuclear 
counterstain then allows the sections to achieve improved histological resolution. 
For in situ hybridisation, 5-6µm thick FFPE tissue sections were hybridised at 55oC, 
in an RNA free environment, with the microRNA 200c probe (LNA modified and 5’- 
and 3’-DIG-labelled oligonucleotide), followed by incubation with anti-DIG-AP 
fragments and application of nuclear red counterstain (Roche Applied, Germany). 
Positive controls (U6 small nuclear RNA, LNA modified and 5’- and 3’-DIG-labelled 
oligonucleotide) and negative controls (scrambled microRNA, LNA modified and 5’- 
and 3’-DIG-labelled oligonucleotide) were included in each hybridisation procedure.   
2.5.8.3 Tissue specimens 
Special attention was paid to limiting RNase contamination, by wearing gloves, using 
RNase depleted 0.1% diethylpyrocarbonate (DPEC) treated water, autoclaved 
glassware (8 hours at 180oC) and decontamination of all instruments and surfaces 
RNase Zap (Invitrogen). FFPE blocks were cooled to -15oC. The blocks were 
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trimmed and the initial 2-3 slices disregarded. Following this, 5-6µm sections were 
cut and placed into a room-temperature water bath for unfolding. Sections were 
transferred to a heated water bath briefly to allow tissue stretching. Sections were 
then mounted on positively charged slides from a non-contaminated package. The 
sections were air dried for 1-2 hours at room temperature. Tissue sections were cut 
the day before an experimental run and solutions prepared before or during 
experiments as per the protocol below. 
2.5.8.4 Reagents, buffers and stocks 
The following buffers and reagents were prepared according to the following 
ingredients, which were the final ones used following complete optimisation. Where 
ingredients were listed, these were prepared by hand; where commercially available, 
these are indicated. 
Reagents needed during the procedure: 
• Antibody blocking solution: Phosphate buffered solution (PBS), 0.1% Tween, 
2% sheep serum, 1% bovine serum albumin (BSA). 
• Antibody dilutant solution: PBS, 0.05% Tween, 1% sheep serum, 1% BSA 
• Sheep anti DIG AP 
• BMT/BCIP ready to use tablets 
• Levamisole – for blocking endogenous AP activity (100mM stock) 
• Nuclear Fat Red – Nuclear counter stain 
Buffers and stocks prepared and autoclaved prior to experiment day: 
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• Proteinase-K buffer – 900 ml RNase-free water, 5ml 1M Tric-HCL [pH 7.4], 
2ml 0.5M EDTA, 0.2ml 5M NaCl made to 1000ml. 
• Saline-sodium citrate (SSC) pH 7.0 – SSC was diluted with RNase-free water 
to 5x, 1x and 0.2x concentrations. 
• PBS-T (0.1%, pH 7.4) – 1ml Tween-20 diluted in 1L of PBS. 
• AP stop solution – 900ml RNase-free water, 7.9g Tris-Hcl (50mM), 8.7g NaCl 
(150mL), 0.75g KCL (10mM) made to 1000ml. 
Reagents prepared on the day of the experiment: 
• Proteinase-K reagent – 7.5 µg/ml Proteinase K stock added to 10ml 
Proteinase K buffer. 
• Hybridisation mix – 2x miRNA ISH buffer was diluted 1:1 with RNase-free 
water to form 9ml. The specific probe to mir200c probe sequence was 
TCCATCATTACCCGGCAGTATTA, and was placed in a 2ml RNase-free 
tube. The probe was denatured at 90oC for 4 minutes, spun down and 2ml 1x 
miRNA ISH buffer added to each tube. The final post-optimisation 
concentration of probe used was 80nM. 
• Antibody blocking solution and dilutant solutions – 10ml blocking and 10ml 
dilutant were made from 15ml PBS-T and 300µL sheep serum (2% final 
concentration). 5ml was removed, 5ml PBS tween added to this with 1% 
sheep serum and 330µl 30% BSA. To the remaining blocking solution, 330µl 
30% BSA was added. 
• Anti-DIG reagent – Sheep-anti-DIG-AP antibody was diluted 1:800 in antibody 
dilutant solution. 
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• AP substrate – a NBT-BCIP tablet was dissolved immediately before use in 
miRNase-free water with Levaminsol to give final concentration 0.2mM.  
2.5.8.5 Optimisation 
The following key steps were performed for optimisation: 
1. LNA U6 snRNA probe was used to optimise hybridisation temperature and 
environment, and Proteinase K treatment, until settings described as above. 
2. These optimised control parameters were used to optimise double-DIG LNA 
mir-200c probe and scrambled negative control probe. Concentrations of 
experimental probe used during optimisation were 10, 15, 20, 30, 40, 60, 80 
and 90nM using human rectal cancer tissue to be used in the main 
experiment; the final concentration used was 80nM. 
3. Adjustment of final hybridisation temperature. 
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2.5.8.7 Final one-day optimised miRNA ISH protocol 
Step 1: Deparaffinisation of slides in xylene and ethanol: using the following steps 
through slide racks and autoclaved RNA-free glass jars. 
Table 7: Deparaffinisation of slides in xylene and ethanol. 
Step  Solvent  Duration 
1  Xylene  5 minutes 
2  Xylene  5 minutes 
3  Xylene  5 minutes 
4  99.9% Ethanol  Immerse 10 times 
5  99.9% Ethanol  Immerse 10 times 
6  99.9% Ethanol  5 minutes 
7  96% Ethanol  Immerse 10 times 
8  96% Ethanol 5 minutes 
9  70% Ethanol Immerse 10 times 
10  70% Ethanol 5 minutes 
11  PBS 2-5 minutes 
 
Step 2: Incubation with Proteinase-K for 10 minutes at 37oC. Immediately before 
use, Proteinase-K was added to Proteinase-K buffer, and approximately 300 µL/slide 
was placed to fully cover the section. Slides were incubated for 10 minutes at 37oC 
for example in a hybridiser.  
Step 3: Slides were placed in PBS and washed twice. 
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Step 4: Slides were dehydrated in new ethanol solutions and air dried for 15 
minutes. 
Table 8: Slide dehydration protocol. 
Step  Solvent  Duration 
1  70% Ethanol  Immerse 10 times 
2  70% Ethanol 1 minute 
3  96% Ethanol Immerse 10 times 
4  96% Ethanol  1 minute 
5  99.9% Ethanol  Immerse 10 times 
6  99.9% Ethanol  1 minute 
 
Step 5: Application of hybridisation mix for one hour at 55oC. 25 µL of hybridisation 
mix was added to slides according to optimised concentrations. A sterile cover glass 
was placed on each section and sealed along all four edges with Fixogum (rubber 
cement). The slides were hybridised for one hour. 
Step 6: Disassembly of slide and coverglass: Fixogum was removed using tweezers 
and the cover glass carefully detached without sliding. The slides were then held in a 
slide rack placed into a glass jar containing 5x SSC at room temperature. 
Step 7: wash with SSC buffers. The following washed were performed with the glass 
jars placed in a water bath at hybridisation temperature. 
 
 128	  
 
Table 9: Saline-sodium citrate (SSC) buffer solution protocol. 
Step  Solvent  Duration Temperature 
1  5xSSC  5 minutes 55oC 
2  1xSSC 5 minutes 55oC 
3  1xSSC 5 minutes 55oC 
4  0.2xSSC  5 minutes 55oC 
5  0.2xSSC  5 minutes 55oC 
6  0.2xSSC  5 minutes Room temperature 
 
Step 8: Hydrophilic barrier applied: The slides were transferred to glass jars with 
PBS. A hydrophobic barrier was applied around tissue sections using a hydrophobic 
pen, without allowing sections to dry.  
Step 9: Slides were incubated with blocking solution for 15 minutes in a humidifying 
chamber. 
Step 10: anti-DIG: Blocking solution was removed and anti-DIG reagent applied, 
followed by incubation or 60 minutes at room temperature. 
Step 11: PBS-T wash: Slides were washed for 3x3 minutes with PBS-T. 
Step 12: Incubation with AP substrate. Freshly prepared AP substrate was applied 
and slides incubated for two hours at 30oC in a humidifying chamber away from light. 
Step 13: Incubation with KTBT: slides were incubated with KTBT buffer for 2x5 
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minutes to stop the reaction. 
Step 14: slides were washed with water for 2x1 minutes. 
Step 15: Nuclear Fast Red counterstain: 200µL Nuclear Fast Red counterstain was 
applied for 1 minute to allow counterstaining of nuclei. 
Step 16: Rinsing in tap water. Slides were washed in a container containing running 
tap water for 10 minutes.  
Step 17: Slide dehydration: slides were dehydrated according to the following 
protocol. 
Table 10: Second slide dehydration protocol. 
Step  Solvent  Duration 
1  70% Ethanol  Immerse 10 times 
2  70% Ethanol 1 minute 
3  96% Ethanol Immerse 10 times 
4  96% Ethanol  1 minute 
5  99.9% Ethanol  Immerse 10 times 
6  99.9% Ethanol  1 minute 
 
Step 18: slides were mounted with two drops of mounting solution. 
Step 19: light microscopy analysis. 
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2.5.9 Relative gene expression of E-cadherin  
The next experimental step was to determine the gene expression levels of E-
cadherin, from FFPE. As an overview, this requires RNA reverse transcription to 
cDNA, followed by quantitative real-time polymerase chain reaction (qRT-PCR). This 
process, from FFPE, is highly specialised, difficult to optimise and time consuming. A 
commercial option to expedite this process exists, which will maximise time 
efficiency and minimise waste, and was employed for this thesis. Following complete 
experimental design as part of this thesis by myself, the experiments were executed 
by Source BioScience (1 Orchard Place, Nottingham Business Park, Nottingham, 
NG8 6PZ, http://www.sourcebioscience.com/). The following steps were designed 
and performed as indicated: 
1. RNA isolation from FFPE 
Total RNA was isolated from FFPE samples using the RNeasy FFPE Kit (Qiagen, 
Valencia, CA). By isolating molecules longer than 70 nucleotides, this provides 
recovery of usable RNA fragments for downstream applications. Formaldehyde 
and time fragment and degrade RNA and leave few long chain segments, 
meaning that suitable downstream experiments must be designed. 
From each FFPE block, four 5µm were cut and placed onto uncovered, positively 
charged slides. These samples were combined into a single tube immediately 
prior to experimentation. Firstly, all paraffin is removed using a Deparaffinisation 
Solution. Samples are then incubated in an optimised lysis buffer containing 
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proteinase K, to release RNA from the sections. A short incubation at a higher 
temperature partially reverses formalin crosslinking of the released nucleic acids, 
improving RNA yield and quality. DNase treatment then eliminates all genomic 
DNA (including very small DNA fragments that are often present in FFPE 
samples after prolonged fixation/storage times). The lysate is then mixed with 
buffer, and ethanol added to provide appropriate binding conditions for RNA. The 
sample is then applied to an RNeasy MinElute spin column, where the total RNA 
binds to the membrane and contaminants are efficiently washed away. RNA is 
then eluted in RNA-free water. 
2. RNA to cDNA Conversion 
Total RNA is then subjected to reverse transcription to produce single-stranded 
cDNA. The High Capacity RNA-to-cDNA Kit is optimised to work with 
downstream gene expression systems. 
3. Real-time Polymerase Chain Reaction  
The Applied Biosystems 7900 Fast Real-Time PCR system uses fluorescence-
based PCR chemistry to determine quantitative detection of nucleic acid 
sequences using real-time analysis. It determines the change in expression of a 
nucleic acid sequence (target) in the test sample relative to the sample sequence 
in a control sample. In Real-time experiments, progress is monitored as it occurs, 
and data collected throughout the process rather than at the end. The reactions 
are characterised by the point in time during cycle when amplification of a target 
is first detected, rather than the amount of target accumulated at the end of 
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PCR203. The system software used the comparative threshold cycle method to 
calculate relative quantities of a nucleic acid sequence. Optimised TaqMan® 
assays for E-cadherin and human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) endogenous control were used. All experiments were repeated in 
triplicate. The primer gene sequences used for these experiments were: 
• GAPDH, chromosome 12, CAAGAGGAAGAGAGAGACCCTCACT 
(LifeCell, assay number: Hs03929097_g1) 
• E-cadherin, chromosome 14, CGCGTCCTGGGCAGAGTGAATTTTG 
(LifeCell, assay number: Hs01023894_m1) 
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2.7 Statistical analyses  
2.7.1 Descriptive analysis 
Continuous data were tested for distribution using visual inspection of histograms 
and the Kolmogorov-Smirnov test. Normally distributed data were presented as 
mean and 95% confidence interval (95% CI), and differences between groups were 
tested using the unpaired t-test. Non-parametric data were presented as median and 
interquartile range (25% and 75% centiles). The Chi squared test was used for 
categorical data when n>5, and Fisher’s exact test when n</=5.  
2.7.2 Correlation 
Cohen’s Kappa coefficient was used to test agreement between different biomarkers 
for the assessment of response to neoadjuvant therapy and the detection of tumour 
budding. There are various cut-offs for determining strength of agreement, although 
the following are most widely accepted and were used for this study: 
• 0.20 = poor 
• 0.21-0.4 = fair 
• 0.41-0.6 = moderate 
• 0.61-0.8 = good 
• 0.81-1.00 = very good 
2.7.3 Binary regression modelling 
Binary regression models were built for the outcomes response to neoadjuvant 
therapy. A binary positive outcome indicated significant response, and a negative 
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outcome non-response. Consequently during modelling, an odds ratio (OR) of >1 
indicated increased likelihood of an event occurring (e.g. response) for a risk variable 
(e.g. loss of E-cadherin expression) compared to a reference category from that 
variable (e.g. E-cadherin expression maintained). Factors considered for models 
were those which were judged to be clinically important and feasible. Variables 
significant at p-levels <0.1 at univariable level were entered into multivariable 
models. Variables were retained in these model if the p-value remained <0.05 during 
forward conditional stepwise processing. 
2.7.4 Survival analysis  
The following definitions of survival were used: 
§ Overall survival (OS): the time from the date of surgery to the date of death 
from any cause. 
§ Disease free survival (DFS): the time from the date of surgery to the date of 
pelvic recurrence and/or distant disease or death due to pelvic recurrence 
and/or distant disease.  
§ Cancer specific survival (CSS): the time from the date of surgery to the date 
of pelvic recurrence, distant disease or death due to any cause. 
Survival estimates were obtained using the Kaplan-Meier method, which allows 
estimation of outcome in datasets in which censored data are present at univariable 
level. Patients were censored at the last point of known contact or if they died during 
follow-up without experiencing the outcome of interest. Factors potentially related to 
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survival were assessed then using Cox proportional hazards regression models. 
These allow the effect of predictive factors on outcome to be assessed, accounting 
for censored outcome, the time of follow-up, and the interval between surgery and 
the adverse event of interest. Factors with a p-value of <0.1 on univariable analysis 
were introduced into the multifactorial Cox regression models in a stepwise manner 
were used to determine the independence of factors predicting survival and local 
recurrence. Hazard ratios (HR) and 95% confidence intervals (CI) were generated, 
relating the risk of the outcomes of interest occurring in the various categories of risk 
factors with respect to the base risk level for each factor. Variables maintaining p-
values <0.05 with 95% confidence intervals (CIs) that did not cross a hazard ratio of 
1.0 remained in the model. Life-tables are presented for Kaplan-Meier curves, which 
show the number of patients at risk that enter each time period of the analysis. 
2.7.5 Quantitation of polymerase chain reaction 
There are two methods to obtain results from RT-PCR; the standard curve method 
and the comparative threshold method. In the standard curve method, a curve is 
constructed from RNA of a known concentration. The curve is then used as a 
reference standard for comparison. The comparative method normalises an 
experimental sample to a control/reference standard, against a standard 
housekeeping gene. For this thesis, the comparative method is more suitable, 
comparing gene expression in responders to non-responders. The following 
definitions were used for calculations in this method: 
• Ct value: The Ct value is where the PCR curve crosses the threshold. 
Typically 40 cycles are run, and the higher the Ct, the less mRNA is present, 
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as more cycles are required to detect fluorescence.  
• Delta Ct: Ct[E-cadherin] – Ct[GAPDH]. This provides the Ct value for the 
sample normalised to the endogenous housekeeping gene GPADH. 
• Delta-delta Ct (ΔΔCT) = deltaCt[E-cadherin] – deltaCt[internal control].  
• RQ = Relative quantification, calculated using the formula: 2[- delta-delta Ct].  
A relative increase (i.e. RQ value) of ≥2 was taken as a significant rise and a relative 
decrease of ≤0.5 as a significant fall, compared to the control (responders). The Ct 
values of gene expression for E-cadherin in an experimental case (i.e. non-
responders) were used against a control (representative responder). The Ct values 
of both were normalised to endogenous GAPDH level for comparison. Experiments 
were repeated in triplicate and average Ct values were calculated. 
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3 Results 
  
 138	  
3.1 Clinical description of patients and survival outcomes 
Before moving to analysis of biomarkers, a thorough explanation of clinical variables 
and outcome measures for patients treated at the Royal Marsden Hospital Colorectal 
Unit is required. This has two aims. Firstly, it puts this patient cohort into context, 
which is relevant when considering generalisability to other rectal cancer patient 
populations. Secondly, biomarker assessment will be correlated to clinic-pathological 
factors (for example, extra-mural venous invasion), which should be analysed 
separately to ensure their relevance.  
3.1.1 Patients undergoing exenterative surgery 
Between 2006 and 2011 inclusively, 100 pelvic exenterations were performed. Of, 55 
were for LAP and 45 for RRC. The overall median age was 60 (25 to 85) years and 
70% of patients were male (table 1). The original operation for the 45 patients with 
recurrent cancer included 32 anterior resections, five abdominoperineal excisions of 
the rectum, three previous pelvic exenterative procedures, two local excisions, two 
sub-total colectomies and one Hartmann’s procedure. Prior pelvic irradiation was 
given in 33% (15/45) of RRC patients. 
Neoadjuvant therapy was given to 75 of the 100 patients. Seventy were offered neo-
adjuvant chemoradiotherapy and radiotherapy alone was given to an additional five. 
Three previously irradiated patients with RRC who had received total doses less 
than 54Gy received further neoadjuvant radiotherapy to an overall maximum of 
54Gy.  Neoadjuvant radiotherapy was omitted in 22% of patients from the LAP group 
(12/55) and in 29% from the RRC group (13/45). 
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Details of exenterative surgical procedures performed are shown in table 11. Most 
(49%) patients required resection of two pelvic compartments, with only one 
requiring resection of four compartments. The anterior compartment was involved in 
65% (36/55) of LAP and 33% (15/45) of RRC patients, whilst the posterior 
compartment was involved in 15% (8/55) of LAP and 53% 14/45) of RRC patients. 
These differences are explained by a higher rate of sacrectomy for RRC than LAP 
(49% versus 15 %, p<0.001, Table 12); 73% of sacrectomies were for recurrent 
disease (22/30). The inferior compartment was involved in 27 cases and required 
extra-levator abdominoperineal excision of the rectum in 19 (14 LAP and 5 RRC) 
patients with en bloc removal of the coccyx. Cystectomy was required in 40% (22/55) 
LAP and 31% (14/45) RRC patients. Bowel re-anastomosis was achieved in 32% of 
cases. Perineal reconstruction was required in 55% of cases, which involved flap 
reconstruction in 96% (53/55).  
Four associated procedures were performed for patients with an LAP cancer. These 
included three synchronous hepatectomies and one synchronous para-aortic 
lymphadenectomy. Three associated procedures were performed for RRC patients 
including one staged hepatectomy, one synchronous radiofrequency ablation to the 
liver and one staged lung lobectomy. 
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Figure 12: High resolution pelvic MRI showing a patient with locally advanced 
primary rectal cancer invading the prostate, requiring clearance of the central and 
anterior compartments, including en-bloc cystoprostatectomy. 
 
Figure 13: High resolution pelvic MRI showing a patient with recurrent rectal cancer 
breaching the pre-sacral fascia in the posterior pelvic compartment, requiring S3 
sacrectomy 
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Table 11: Demographic and early outcome characteristics of 100 consecutive 
patients undergoing pelvic exenteration for locally advanced primary (LAP) and 
recurrent rectal cancer (RRC). 
  Total LAP RRC p-value 
Number  100 55 (55) 45 (45)  
Age (mean years, 95% CI) 60.3 (39.3-80.7) 60.0 (56.2-63.8) 60.7 (57.7-63.7) 0.778 
Male gender  70 (70) 37 (67) 33 (73) 0.511 
Pre-operative chemotherapy  70 (70) 38 (69) 32 (71) 0.826 
Pre-operative radiotherapy 75 (75) 43 (78) 32 (71) 0.417 
Blood loss (mean milliliters, 95% CI) 2048 (1548-2548) 1689 (1284-2096) 2444 (1481-3406) 0.135 
Duration of surgery (mean hours, 95% CI) 8.4 (5-13) 8.1 (7.3-8.8) 8.8 (7.8-9.7) 0.243 
Number of 
adverse events* 
Intra-operative 10 3 7  
30 day/ in-hospital major 28 9 19  
 30 day/ in-hospital minor 38 19 19  
 Long-term  22 13 9  
Length of stay (mean days, 95% CI) 21 (10-59) 19.2 (16.4-21.9) 22.8 (17.2-28.3) 0.216 
Number of 
compartments 
resected 
One 30 (30) 15 (27) 15 (33)  
Two 49 (49) 29 (53) 20 (44)  
Three 20 (20) 11 (20) 9 (20)  
 Four 1 (1) 0 1 (2) 0.519 
Sacrectomy  30 (3) 8 (15) 22 (49) <0.001 
Cystectomy Complete 28 (28) 16 (29) 12 (27)  
 Partial  8 (8) 6 (11) 2 (4)  
 Not required  64 (64) 33 (60) 31 (69) 0.438 
Hysterectomy  55 (55) 34 (62) 21 (47) 0.130 
Colonic anastomosis achieved  32 (32) 21 (38) 11 (24) 0.143 
Perineal reconstruction 55 (55) 34 (62) 21 (47) 0.130 
Oblique rectus abdominis muscle flap 38 (38) 24 (44) 14 (31)  
Vertical rectus abdominis muscle flap 10 (10) 7 (13) 3 (7)  
Inferior gluteal artery perforator flap 2 (2) 0 (0) 2 (4)  
 Gracilis flap 3 (3) 3 (6) 0 (0)  
 Omentoplasty 1 (1) 0 (0) 1 (2)  
 Biological mesh 1 (1) 0 (0) 1 (2)  
Resection margin R0 78 (78) 50 (91) 28 (62)  
 R1 15 (15) 3 (5) 12 (27)  
 R2 7 (7) 2 (4) 5 (11) 0.002 
Histological type Adenocarcinoma 78 (78) 39 (71) 39 (87)  
Mucinous adenocarcinoma 16 (160 12 (22) 4 (9)  
 Signet cell cancer 3 (3) 2 (4) 1 (2)  
 Squamous cell cancer 3 (3) 2 (4) 1 (2) 0.295 
T-stage 0-2 21 (21) 13 (24) 8 (18)  
 3 27 (29) 15 (27) 12 (27)  
 4 52 (52) 27 (49) 25 (56) 0.738 
N-stage 0 67 (67) 35 (64) 32 (71)  
 1-2 33 (33) 20 (36) 13 (29) 0.429 
Extra mural vascular invasion 42 (42) 20 (36) 22 (49) 0.207 
 
CI = confidence interval; * each patient may have suffered more than one adverse event 
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Table 12: Anatomical details of resection margins positive for cancer in 22 out of 100 
consecutive patients undergoing pelvic exenteration.  
Compartment  Margin Total LAP RRC 
All Total 22 5 17 
Lateral Total 10 2 8 
 Lateral tumour   2 5 
 Sciatic notch   2 
 Internal iliac vessels   1 
Anterior below peritoneal reflection Total 5 2 3 
 Prostate  1  
 Bladder   2 
 Anterior tumour  1  
Posterior Total 4  4 
 Sacral resection    3 
 Pre-sacral fascia   1 
Anterior above peritoneal reflection Total 1  1 
 Inguinal lymph nodes   1 
Central Total 1 1  
 Proximal colonic resection  1  
Inferior Total 1  1 
 Levator complex   1 
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3.1.2.1 Short-term outcome 
There was no 30-day or in-hospital mortality. The mean blood loss was 2048 
milliliters (95% confidence interval [CI] 1548-2548, range 150-17,000). Although 
mean blood loss in LAP patients was lower than in RRC patients (1689 versus 2444 
milliliters), this did not reach statistical significance (p=0.135). The median duration 
of surgery was 8.4 hours (95% CI 5-13, range 3-17) and the mean length of stay 21 
days (95% CI 10-59, range 9-82); these were similar in LAP and RRC groups (table 
11). Sacrectomy (compared with other operations) was associated with significantly 
higher mean blood loss (2854 versus 1608 milliliters, p<0.001), longer duration of 
surgery (9.9 versus 7.6 hours, p=0.032) and longer length of stay (25 versus 19 
days, p=0.017). Cystectomy (compared with no cystectomy) was associated with 
longer duration of surgery (9.2 versus 7.9 hours, p=0.022). Perineal flap 
reconstruction (compared with primary closure or non-flap reconstruction) was 
associated with a longer mean operating time (9.5 versus 7.1 hours, p<0.001) and a 
longer mean length of stay (23 versus 18 days, p=0.042). 
3.1.2.2 Resection margin status and pathological outcome 
The overall rate of R0, R1 and R2 resection was 78%, 15% and 7% respectively. 
The margin negative rate (R0) was significantly higher in LAP (50/55, 91%) 
compared with RRC cancer (28/45, 62%, p=0.001). For LAP versus RRC, there were 
more R1 (5% versus 27%) and R2 resections (4% versus 11%, table 11). The details 
of positive margin are shown in table 12, where most of these were on the pelvic 
sidewall (n=10). All posterior positive margins were associated with sacrectomy in 
patients with RRC (n=4). Pathological complete response occurred in seven patients 
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(3 LAP and 4 RRC patients). 
Organ specific exenteration was performed for tumour infiltration based on pre-
operative MRI criteria in 63.9% of cystectomies (23/36), 73.9% of prostatectomies 
(17/23) and all sacrectomies (30/30). In other cases, resection was performed for 
surgical access or as part of concurrent procedure (e.g. cystoprostatectomy). For 
those patients with tumour infiltration, histopathological signs of tumour regression 
secondary to neoadjuvant chemoradiotherapy were seen in 30.4% of cystectomies 
(17/23), 41.2% of prostatectomies (7/17) and 26.7% (8/30) of sacrectomies. One 
patient without histopathological prostatic involvement, who did not receive 
neoadjuvant therapy, was likely to have been overstaged by MRI. 
3.1.2.3 Adverse events 
The benefits of multivisceral resection are likely to outweigh risks only when clear 
resection margins are achieved, as exenterative surgery is often associated with 
significant postoperative morbidity. From the 100 exenterations, 53 (53%) patients 
suffered at least one adverse event, with a similar rate between LAP and RRC 
groups (27/55 (49%) versus 26/45 (58%), p=0.378). There were 98 separate adverse 
events including 10 intra-operative, 28 in-hospital/ 30-day major, 38 in-hospital/ 30-
day minor and 21 long-term. The ten intraoperative adverse events included 
bleeding over 5000 milliliters in seven patients, bleeding of 17,000 milliliters in one, 
ventricular fibrillation in one and sciatic nerve injury in one. 
Abdominosacral resection (ASR) is the most advanced of the exenterative 
techniques, and associated with the highest morbidity. Only a few specialist centres 
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with the necessary surgical expertise and range of multidisciplinary support offer this 
procedure. In the 100 exenterations, 30 included ASR as part of multivisceral 
resection. Intraoperative blood loss, duration of surgery and length of hospital stay 
are shown in table 13. Six patients stayed in hospital for over 30 days and two for 
more than 60 days; the longest length of stay was 82 days. There were no deaths in 
hospital or within 30 days. 
High sacrectomy (S1/S2, 5 patients) had the highest rate of overall (80 per cent), 
intraoperative (20 per cent), major postoperative (60 per cent) and long-term (60 per 
cent) adverse events (table 14). There were two intraoperative adverse events, one 
sciatic nerve injury and one instance of major blood loss (17 000 ml). The major 30-
day/in-hospital adverse events included (accounting for multiple adverse events per 
patient): vacuum-assisted closure/refashioning of perineal flaps (5), ureteric leak 
requiring percutaneous drainage (2), relaparotomy for bleeding (2), secondary 
perineal flaps for pelvic sepsis (2), sacral debridement of osteomyelitis (2), stoma 
revision (1), laparotomy for enterocutaneous fistula (1) and wound dehiscence 
requiring resuture (1). The most frequently long-term complication was recurrent 
urinary tract infection (7). There were two new-onset long-term reductions in mobility, 
both in patients undergoing S1/2 sacrectomy.  
High sacrectomy was also associated with the greatest proportion of patients 
experiencing at least three adverse events (60 per cent) and the lowest proportion 
with no adverse events (20 per cent), compared with S3 sacrectomy (27 and 64 per 
cent respectively) and low sacrectomy (14 and 50 per cent respectively).
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Table 13: Technical details of abdominosacral resection as performed in 30 
consecutive patients. 
  Number of patients 
Level of sacrectomy   
S1/S2 5 
S3 11 
S4/S5 14 
Patient position for sacrectomy  
Prone 26 
Supine 4 
Cystectomy performed 12 
Perineal reconstruction   
Primary closure/no flap 8†  
Oblique rectus abdominis flap 16  
Vertical rectus abdominis flap 3 
Inferior gluteal artery pedicled flap  1 
Omentoplasty 1 
Biological mesh 1 
Blood loss (ml)* 1725 (1225–3275, 510–17 000) 
Duration of surgery (h)* 9.5 (8–12, 4–17) 
Length of hospital stay (days)* 15 (14–27, 10–82) 
 
*Values are median (interquartile range, range). †Two patients required secondary flaps owing to 
pelvic sepsis. 
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Table 14: Short-term outcomes and adverse events according to height of 
sacrectomy in 30 patients.  
 S1/S2 
(n = 5) 
S3 
(n = 11) 
S4/S5 
(n = 14) 
 
P 
Length of hospital stay (days)* 45 (14–66) 15 (14–52) 14 (14–18.75) 0.313 
Blood loss (ml)* 3200 (1500–
7000) 
2000 (1600–
3500) 
1450 (788–
1850) 
0.086 
Duration of surgery (h)* 12 (9–12.5) 11.5 (8.5–12) 8.75 (6.5–10) 0.049 
Patients with adverse events     
   Any  4 (80)  4 (36)   7 (50)   0.465 
   Intraoperative  1 (20)     1 (9)   0 (0)  0.684 
   Major, within 30 days or in hospital  3 (60)     3 (27)   4 (29)   0.302 
   Minor, within 30 days or in hospital 4 (80)     3 (27)   4 (29)  0.095 
   Long-term  3 (60)     4 (36)   2 (14)   0.049 
No. of adverse events per patient    0.157 
   0 1 (20)     7 (64) 7 (50)    
  1–2 1 (20)     1 (9)   5 (36)  
   ≥ 3 3 (60)    3 (27)   2 (14)    
 
Values in parentheses are percentages unless indicated otherwise; *values are median (interquartile range).  
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3.1.3.1 Survival  
Disease free survival 
Three year DFS after R0, R1 and R2 resection was 67%, 49% and 0% (p<0.001, 
Figure 14-17), and was 70% for LAP and 50% for RRC (p=0.188). For R0 resection 
only, 3 year DFS was 76% for LAP and 57% for RRC (p=0.212). On multivariable 
Cox regression analysis, only positive resection margin status (HR 4.04, 95% CI 
1.87-8.71, p<0.001) and positive lymph node staging (HR 2.43, 95% CI 1.14-5.18, 
p=0.022) were significant predictors of reduced DFS. 
Overall survival 
For all patients, three year OS for R0, R1 and R2 resections was 82%, 55% and 0% 
(p<0.001). This was 78% for LAP and 65% for RRC (p=0.461). Considering R0 
resection only, OS for LAP and RRC cancer was similar (85% versus 79% 
(p=0.766), HR 1.22 (95% CI 0.33-4.58, p=0.766). On multivariable Cox regression 
analysis, only positive resection margin status (HR 4.99, 95% CI 1.97-12.63, 
p=0.001) and positive lymph node stage (HR 2.86, 95% CI 1.12-7.33, p=0.028) were 
significant predictors of reduced OS. 
Local recurrence free survival 
Three year LRFS for R0 and R1 resection (n=93) was 85% and 46% (p=0.001). For 
LAP and RRC patients, it was 84% and 72% (p=0.214) and for R0 resection only it 
was 86% (LAP) and 84% (RRC) (p=0.817). On multivariable Cox regression 
analysis, only positive resection margin status (HR 5.48, 95% CI 1.83-16.39, 
p=0.002) was a significant predictor of reduced LRFS (table 15). 
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Table 15: Univariable and multivariable Cox proportional regression models for 
predictors of 3-year disease free and local recurrence free survival in 93 consecutive 
patients with primary or recurrent rectal cancer undergoing R0 or R1 exenterative 
resection. Results are shown as hazard ratios, 95% confidence interval and 
corresponding p-value. 
 Disease free survival  Local recurrence free survival  
 Univariable  Multivariable  Univariable  Multivariable  
variable HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
Gender         
   Male Ref     Ref     
   Female 1.09 (0.50-2.34) 0.835   0.90 (0.28-2.92) 0.857   
Age         
   <65 Ref    Ref     
   65+ 1.78 (0.85-3.64) 0.130   2.24 (0.75-6.68) 0.146   
Neoadjuvant 
therapy 
        
   No Ref     Ref     
   Yes 1.68 (0.58-4.82) 0.339   0.26 (0.04-2.39) 0.261   
Number of 
compartments 
affected 
        
   1 Ref     Ref     
   2 1.00 (0.43-3.32) 0.992   1.11 (0.32-3.80) 0.869   
   3-4 1.46 (0.52-4.12) 0.472   2.10 (0.21-6.31) 0.871   
Peri-operative 
adverse events 
        
   No Ref    Ref     
   Yes 1.73 (0.83-3.61) 0.142   2.24 (0.73-6.85) 0.159   
T-stage         
   0-2 Ref     Ref     
   3 2.24 (0.46-10.81) 0.316   2.85 (0.32-25.54) 0.350   
   4 3.44 (0.80-14.74) 0.096   2.94 (0.37-23.58) 0.309   
N-stage         
   0 Ref  Ref  Ref     
   1+ 2.02 (0.97-4.20) 0.061 2.43 (1.14-5.18) 0.022 1.17 (0.36-3.80) 0.796   
Tumour type         
   LAP Ref    Ref     
   RRC 1.64 (0.78-3.44) 0.192   2.01 (0.66-6.14) 0.223   
Resection 
margin 
        
   Negative Ref  Ref   Ref  Ref   
   Positive  3.50 (1.66-7.35) 0.001 4.04 (1.87-8.71) <0.001 5.48 (1.83-16.39) 0.002 5.48 (1.83-16.39) 0.002 
 
HR: hazard ratio; CI: confidence interval; LAP: locally advanced primary; RRC: recurrent rectal cancer. 
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Figure 14: Three-year disease free survival for R0, R1 and R2 resection (p<0.001) in 
100 consecutive patients undergoing pelvic exenteration.  
 
Patients at risk: 
Time (months) 0 12 24 36 
R0 78 45 28 19 
R1 15 6 5 3 
R2 7 2 1 0 
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Figure 15: Three-year disease free survival in 100 consecutive patients undergoing 
exenterative surgery for locally advanced primary (LAP) and recurrent rectal cancer 
(RRC) following R0 resection (p=0.212).  
 
Patients at risk: 
Time (months) 0 12 24 36 
LAP 50 29 15 9 
RRC 28 16 13 10 
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Figure 16: Three-year local recurrence free survival in 93 consecutive patients 
undergoing R0 and R1 resection following pelvic exenteration for locally advanced 
primary and recurrent cancer (p=0.001). 
 
Patients at risk: 
Time (months) 0 12 24 36 
R0 78 46 29 20 
R1 15 7 4 2 
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Figure 17: Three-year LRFS in 78 patients undergoing pelvic exenteration and R0 
resection for locally advanced primary and recurrent rectal cancer (p=0.780). 
 
Patients at risk: 
Time (months) 0 12 24 36 
LAP 50 29 15 9 
RRC 28 17 14 11 
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3.1.4 Description of patients undergoing non-exenterative surgery 
The Royal Marsden Hospital colorectal service started in 2006. From then until July 
2013, 309 non-exenterative rectal cancer resections have been performed in 
addition to the exenterations previously described. Details relating to gender, age, 
neoadjuvant status, laparoscopic surgery and pathological variables, split by height, 
are shown in table 16. Significantly more patients with low rectal cancer received 
neoadjuvant therapy (78%, 107/137) compared to those with high/middle cancer 
(41%, 71/172, p<0.001), although final pathological staging was similar. There were 
also significantly fewer laparoscopic operations, lower rates of EMVI and a lower 
proportion of stage IV patients (table 16). 
There were 273 (88%) restorative and 36 (12%) non-restorative procedures. 
Compared to restorative procedures, patients undergoing non-restorative resection 
were at no higher risk of advanced stage (stage III-IV 34% nonrestorative, 39% 
restorative, p=0.568) or EMVI positive status (23% versus 25%, p=0.798) but were 
significantly more likely to receive neoadjuvant therapy (53% versus 94%, p<0.001) 
and have adverse tumour differentiation (21% versus 36%, p=0.035). 
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Table 16: Patient and tumour demographics for 309 patients with non-advanced 
rectal cancer undergoing anterior resection or abdominoperineal resection, based 
upon height of rectal cancer. 
 
  Height of rectal cancer   
  Middle/High  Low   
  N % N % P-value 
Gender Male 111 64.5% 80 58.4% 
  Female 61 35.5% 57 41.6% 0.270 
Age (years) 18-64 107 62.2% 87 63.5% 
  65-74 43 25.0% 34 24.8%   75+ 22 12.8% 16 11.7% 0.952 
Neoadjuvant therapy No 101 58.7% 30 21.9% 
  Yes 71 41.3% 107 78.1% <0.001 
Operation type Restorative 172 100.0% 101 73.7% 
  Non-restorative 0 0.0% 36 26.3% NA 
Laparoscopic surgery No 98 57.0% 118 86.1% 
  Yes 74 43.0% 19 13.9% <0.001 
AJCC Stage 0-I 59 34.3% 70 51.1% 
  II 43 25.0% 30 21.9%   III 58 33.7% 33 24.1%   IV 12 7.0% 4 2.9% 0.016 
Resection margin Clear 169 98.3% 126 92.0% 
  Positive 3 1.7% 11 8.0% 0.008 
Tumour differentiation Well/ moderate 132 76.7% 108 78.8% 
  Poor/ mucinous/ signet 40 23.3% 29 21.2% 0.662 
EMVI Negative 123 71.5% 114 83.2% 
  Positive 49 28.5% 23 16.8% 0.016 
 
AJCC = American Joint Committee on Cancer; EMVI = Extramural vascular invasion  
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3.1.4.1 Circumferential resection margin status 
The overall positive CRM rate was 4.5% (n=14). This was significantly higher with 
low (8%, 11/137) versus middle/high cancer (1.7%, 3/169, p=0.008). Other factors 
relating to a positive CRM are shown in table 17, with significant factors including 
use of neoadjuvant therapy, advanced stage, EMVI positive status and adverse 
tumour differentiation. Overall, those undergoing non-restorative surgery had a 
borderline significantly higher positive CRM rate (11% versus 4%, p=0.066, table 
17). However, when considering only low rectal cancer, the CRM positive rate 
between restorative and non-restorative surgery was non-significant (7% [7/101] 
versus 11% [4/36] respectively, p=0.479). 
3.1.4.2 3-year survival outcome 
At Kaplan-Meier analysis, there were no significant differences between middle/high 
and low cancer for 3-year DFS (81% versus 85%, p=0.385) and OS (92% versus 
93% respectively, p=0.745). Considering only low cancer, there were no significant 
differences between restorative and non-restorative procedures (89% versus 76%, 
p=0.289). 
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Table 17: Factors associated with positive circumferential resection margin status in 
14 of 309 patients with non-advanced rectal cancer undergoing either anterior 
resection or abdominoperineal resection. 
 
  
Resection margin status 
   
  Negative  Positive  P-value 
  N % N %  
Gender Male 183 62.0% 8 57.1% 
  Female 112 38.0% 6 42.9% 0.713 
Age (years) 18-64 186 63.1% 8 57.1% 
  65-74 73 24.7% 4 28.6%   75+ 36 12.2% 2 14.3% 0.905 
Neoadjuvant therapy No 129 43.7% 2 14.3% 
  Yes 166 56.3% 12 85.7% 0.029 
Operation type Restorative 263 89.2% 10 71.4% 
  Non-restorative 32 10.8% 4 28.6% 0.043 
Laparoscopic surgery No 205 69.5% 11 78.6% 
  Yes 90 30.5% 3 21.4% 0.469 
AJCC Stage 0-I 129 43.7% 0 0.0% 
  II 70 23.7% 3 21.4%   III 81 27.5% 10 71.4%   IV 15 5.1% 1 7.1% 0.002 
Tumour differentiation Well/ moderate 233 79.0% 7 50.0% 
  Poor/ mucinous/ signet 62 21.0% 7 50.0% 0.011 
EMVI Negative 231 78.3% 6 42.9%  
 Positive 64 21.7% 8 57.1% 0.002 
Height Middle/High 169 57.3% 3 21.4% 
  Low 126 42.7% 11 78.6% 0.008 
 
AJCC = American Joint Committee on Cancer; EMVI = Extramural venous invasion  
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3.2 EMT biomarker studies 
3.2.1 Patient description 
From patients undergoing surgery for rectal cancer at the Royal Marsden Hospital, 
consecutive patients with available FFPE specimens were selected. This resulted in 
103 includable patients who were operated on between 2009 and 2011. These 
patients consisted of 83 with primary rectal cancer and 20 with recurrent rectal 
cancer.  
There were 48 pelvic exenterations (46.6%), 44 anterior resections (42.7%), eight 
extra-levator abdominoperineal excision of rectums (7.8%) and three trans-anal 
excisions (2.9%). Of these, 69 patients underwent neoadjuvant radiotherapy, with 34 
proceeding straight to surgery. Of the 69 undergoing neoadjuvant radiotherapy, 
34.8% (24) were responders and 65.2% (45) were non-responders. 
The final pathological stage was AJCC stage III in 33.0% of patients, stage II in 
42.7% of patients and 0-I in 24.3% of patients. Two patients underwent complete 
pathological response to neoadjuvant therapy (2.9%, 2/69). Other basic patient 
demographics and pathological characteristics, split by primary and recurrent tumour 
type, are shown in table 18. Patients with recurrent cancer were significantly more 
likely to have adverse tumour differentiation (poor, necrotic or mucinous, p=0.033), 
with a trend toward lower R0 rates (p=0.083).  
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Table 18: Clinical and pathological characteristics of 103 patients with available 
specimens who completed biomarker studies, split into primary and recurrent types 
receiving neoadjuvant therapy and controls. 
 
 Overall Primary Recurrence 
 
 
 N % N % N % P 
Total  103 
 
82 80.6% 20 19.4% 
 
Female gender  30 29.1% 24 28.9% 6 30.0% 0.924 
Age 65+ years  29 28.2% 24 28.9% 5 25.0% 0.727 
Differentiation Well/ moderate 84 81.6% 71 8.50% 13 65.0% 
 
 Poor/ mucinous/ necrotic  19 18.4% 12 14.5% 7 35.0% 0.033 
T-stage T0-2 30 29.1% 24 28.9% 6 30.0% 
 
 T3-4 73 70.9% 59 71.1% 14 70.0% 0.924 
N-stage 0 69 67.0% 55 66.3% 14 70.0% 
 
 1-2 34 33.0% 28 33.7% 6 30.0% 0.750 
EMVI present  30 29.1% 26 31.3% 4 20.0% 0.317 
Complete (R0) 
resection 
 93 90.3% 77 92.8% 16 80.0% 0.083 
AJCC Stage 0-I 25 24.3% 21 25.3% 4 20.0% 
 
 II 44 42.7% 34 41.0% 10 50.0% 
 
 III 34 33.0% 28 33.7% 6 30.0% 0.755 
Received nCRT  69 67.0% 54 65.1% 15 75.0% 0.396 
Response to nCRT Responder 24 23.3% 18 21.7% 6 30.0% 
 
 Non-responder 45 43.7% 36 43.4% 9 45.0% 
 
 Control (no nCRT) 34 33.0% 29 34.9% 5 25.0% 0.616 
 
EMVI=extramural vascular invasion; AJCC = American Joint Committee on Cancer; 
nCRT= neoadjuvant chemoradiotherapy 
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3.2.2 Slide preparation  
Representative FFPE tissue blocks were selected for each patient to include the 
deepest part of the tumour, in order to analyse the invasive front. Where the invasive 
front was wide, multiple blocks were selected. Figure 18 shows a representative 
block used. The yellow arrow represents the resection margin, inked in green, where 
no tumour was present. The red arrow represents the deepest tumour edge, where 
growth is at its most rapid; the invasive front. The red lines represent the bowel 
lumen and the muscular wall of the colon. Slides were prepared according to the 
previously mentioned protocol. 
Figure 18: Representative FFPE rectal cancer tissue block used for biomarker 
studies showing the invasive front (red arrow) and the resection margin (yellow 
arrow). 
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3.2.3 Biomarker examples 
Representative examples from each of the three biomarkers are shown in figure 19 – 
21, positive and negative controls in figure 22 and tumour budding in figure 23-24. 
Figure 19: Representative examples of E-cadherin normal and reduced expression. 
 
Normal expression (brown staining 
membranes) 
Reduced expression (reduced or 
absent membranous expression) 
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Figure 20: Representative examples of membranous and nucleic beta-catenin 
expression. 
 
Membranous expression (blue staining 
nuclei) 
Nucleic expression (brown staining nuclei) 
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Figure 21: Representative examples of microRNA-200c normal and reduced 
expression. 
 
Normal expression (purple staining 
cytoplasm) 
Reduced expression (reduced or absent 
cytoplasmic expression) 
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Figure 22: Positive and negative controls, using mouse bowel. 
E-cadherin Positive controls Negative controls 
 
  
Beta-
catenin 
Positive membranous expression Negative expression 
 
 
 
Mir-200c Positive expression  Negative expression 
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Figure 23: Example of tumour budding at the invasive front. Detection by beta-
catenin, as showed here, provides the reference for this study.  
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Figure 24: Tumour budding detected by biomarkers. 
E-cadherin 
 
Beta-catenin 
 
microRNA-200c 
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3.2.4 Predictors of final histopathological staging 
Following biomarker assessment, differences in biomarkers expression split by 
tumour type (primary versus recurrent, tumour depth (T-stage), lymph node 
involvement (N-stage) and presence of extra mural venous invasion (EMVI) were 
tested.  
The first analysis was performed in the whole cohort of 103 patients, the complete 
results for which are shown in table 19. The summary findings included: 
• T-stage – Higher T-stage was associated by reduced microRNA 200c 
expression (p=0.029). There was further association between tumour budding 
and higher T-stage (39.1% versus 60.7%), although this did not reach 
significance (p=0.077). E-cadherin expression and nucleic beta-catenin were 
not significant predictors. 
• N-stage – None of the biomarkers were associated with nodal status. 
• Extra-Mural Venous Invasion – reduced E-cadherin expression, nucleic 
beta-catenin expression and tumour budding were significantly associated 
with EMVI; mir200c expression was not. 
• None of the biomarkers differed significantly between primary and recurrent 
cancer types. 
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Table 19: Relation of EMT biomarkers to final pathological tumour variables. 
Numbers of patients reflect the specimens in which technical success of biomarker 
studies was achieved. 
Biomarker 
Total 
completed 
analysis 
Subgroups     P-value 
T-stage  T0-2  T3-4   
Reduced E-cadherin expression 97 11/29 37.9% 36/68 52.9% 0.176 
Nucleic beta-catenin expression  84 9/23 39.1% 35/61 57.4% 0.135 
microRNA 200c loss 79 22/38 57.9% 33/41 80.5% 0.029 
Tumour budding 84 9/23 39.1% 37/61 60.7% 0.077 
N-stage 
 
N0 
 
N1-2 
  
Reduced E-cadherin expression 97 29/64 45.3% 18/33 54.5% 0.389 
Nucleic beta-catenin expression  84 29/55 52.7% 15/29 51.7% 0.930 
microRNA 200c loss 79 12/38 31.6% 16/41 39.0% 0.489 
Tumour budding 84 29/55 52.7% 17/29 58.6% 0.606 
Extra-Mural Venous Invasion 
 
Absent 
 
Present 
  
Reduced E-cadherin expression 97 28/69 40.6% 19/28 67.9% 0.015 
Nucleic beta-catenin expression  84 25/59 42.4% 19/25 76.0% 0.005 
microRNA 200c loss 79 10/38 26.3% 15/41 36.6% 0.327 
Tumour budding 84 28/59 47.5% 18/25 72.0% 0.039 
Tumour type  Primary 
 
Recurrence 
  
Reduced E-cadherin expression 97 39/79 49.4% 8/18 44.4% 0.706 
Nucleic beta-catenin expression  84 39/70 55.7% 5/14 35.7% 0.171 
microRNA 200c loss 79 5/38 13.2% 8/41 19.5% 0.447 
Tumour budding 84 40/70 57.1% 6/14 42.9% 0.327 
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These relationships were tested again in only patients undergoing neoadjuvant 
therapy. Only the relationships between reduced E-cadherin, nucleic beta-catenin 
and tumour budding with relation to EMVI remained significant (table 20).  
 
Table 20: Relation of EMT biomarkers to final pathological tumour variables in only 
patients undergoing neoadjuvant therapy. Numbers of patients reflect the specimens 
in which technical success of biomarker studies was achieved. 
Biomarker 
Total 
samples 
available 
T0-2  T3-4  P-value 
T-stage       
Reduced E-cadherin expression 65 8/14 57.1% 26/51 51.0% 0.683 
Nucleic beta-catenin expression  57 5/12 41.7% 22/45 48.9% 0.656 
microRNA 200c loss 52 5/13 38.5% 25/39 64.1% 0.105 
Tumour budding 57 5/12 41.7% 25/45 55.6% 0.392 
N-stage  N0  N1-2   
Reduced E-cadherin expression 65 22/42 52.4% 12/23 52.2% 0.987 
Nucleic beta-catenin expression  57 16/35 45.7% 11/22 50.0% 0.752 
microRNA 200c loss 52 18/33 54.5% 12/19 63.2% 0.545 
Tumour budding 57 17/35 48.6% 13/22 59.1% 0.439 
EMVI  Absent  Present   
Reduced E-cadherin expression 65 21/47 44.7% 13/18 72.2% 0.047 
Nucleic beta-catenin expression  57 15/41 36.6% 12/16 75.0% 0.017 
microRNA 200c loss 52 20/37 54.1% 10/15 66.7% 0.404 
Tumour budding 57 18/41 43.9% 12/16 75.0% 0.043 
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3.2.5 Correlation between EMT biomarkers 
Biomarker correlation was tested between E-cadherin, beta-catenin and 
microRNA20c expression in all combinations. Each biomarker was used in turn as 
the reference, with the number of samples available for that biomarker as the 
denominator. Hence, when assessing which patients with E-cadherin loss also had 
nucleic beta-catenin, the denominator was different to assessing those with nucleic 
beta-catenin who had E-cadherin loss.  
Correlation between reduced E-cadherin and nucleic beta-catenin was moderate 
(Kappa 0.67), between reduced E-cadherin and mir200c loss was good (0.83), and 
between nucleic beta-catenin and mir200c was good (0.71). Reduced mir200c 
expression had good correlation with reduced E-cadherin expression (0.83, 82%). 
Overall correlation between all three biomarkers was good (alpha 0.79). 
Figure 25 shows the correlation of biomarkers for individual patients. Considering 
only patients with complete biomarker analysis, each row represents a single patient. 
This shows the pattern of positive findings (i.e. an abnormal biomarker) where all 
biomarker results are abnormal. This represents patients that have abnormal 
biomarker expression and a likely EMT phenotype.  
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Table 21: Correlation of E-cadherin, beta-catenin and microRNA 200c expression. 
Patients included were those in whom all biomarker studies were successfully 
completed. 
Reference biomarker Correlated biomarker Number  Kappa OR (95% CI) P-value 
Reduced E-cadherin 
expression 
Nuclear beta-catenin 
expression 
29/36 
(81%) 
0.67 9.88 (3.46-28.21) <0.001 
 Reduced mir200c 
expression 
32/36 
(89%) 
0.83 37.71 (10.06-141.35) <0.001 
Nuclear beta-catenin 
expression 
Reduced E-cadherin 
expression 
29/42 
(69%) 
0.67 3.13 (1.86-5.31) <0.001 
 Reduced mir200c 
expression 
31/41 
(76%) 
0.71 3.46 (2.00-5.98) <0.001 
Reduced mir200c 
expression 
Reduced E-cadherin 
expression 
32/39 
(82%) 
0.83 6.14 (3.17-11.89) <0.001 
 Nuclear beta-catenin 
expression 
31/38 
(82%) 
0.71 3.46 (2.00-5.98) <0.001 
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Figure 25: Correlation of patients with complete biomarker panel analysis. Each row 
represents a single patient; grey shading represents a positive (adverse) finding from 
biomarker analysis. A=mir200c, B=E-cadherin, C=beta-catenin; D=tumour budding 
(detected by beta-catenin staining). 
Type 
 
A B C D 
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Recurrence         
Primary         
Primary         
Recurrence         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Recurrence         
Primary         
Primary         
Recurrence         
Primary         
Primary         
Recurrence         
Primary         
Primary         
Primary         
Recurrence         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Recurrence         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Primary         
Recurrence         
Primary         
Primary         
Recurrence         
Primary         
Primary         
Primary         
Primary         
Recurrence         
Primary         
Primary         
Primary         
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3.2.6 Correlation of tumour budding detection 
Tumour budding detected by beta-catenin was taken as the main reference. When 
compared to E-cadherin detection, expression was moderate (kappa 0.61) but was 
good compared to mir200c detection (0.71). This association in both cases was 
strong (p<0.001, table 22). When the tumour budding predictive ability of E-cadherin 
and microRNA-200c were tested, there was strong prediction between E-cadherin 
loss and tumour budding (OR 33.00, 95% confidence interval 8.43-129.18, p<0.001) 
and also between reduced microRNA-200c and tumour budding (OR 26.44, 95% 
confidence interval 7.36-95.07, p<0.001). 
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Table 22: Correlation of E-cadherin, beta-catenin and microRNA 200c detected 
tumour budding in specimens where all biomarker studies were successfully 
completed. 
Reference biomarker Correlated biomarker Number  Kappa OR (95% CI) P-value 
Nuclear beta-catenin 
expression 
Reduced E-cadherin 
expression 
22/42 
(52%) 
0.61 4.96 (2.29-10.74) <0.001 
 Reduced mir200c 
expression 
26/43 
(61%) 
0.71 4.79 (2.20-10.43) <0.001 
 
Tumour budding detection was tested as detected by beta-catenin, E-cadherin and 
mir200c separately (figure 26). This allows a measure of the correlation between 
adverse biomarker expression (and thus an EMT phenotype) and the presence of 
tumour budding. In all three cases, adverse biomarker expression was significantly 
associated with tumour budding (figure 27).  
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Figure 26: Correlation of tumour budding detection by (A) mir200c, (B) E-cadherin 
and (C) beta-catenin. Each row represents a single patient; grey shading represents 
a positive (adverse) finding from biomarker analysis. 
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Figure 27: Tumour budding and adverse biomarker expression. 
Reduced E-cadherin P<0.001 
 
Nucleic Beta-catenin P<0.001 
 
Reduced mir200c P<0.001 
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3.2.8 Predictors of response to neoadjuvant radiotherapy 
From the cohort of 103 patients, 69 underwent neoadjuvant radiotherapy, with 34.8% 
(24) responders and 65.2% (45) non-responders. Table 23 shows only patients 
undergoing neoadjuvant therapy (n=69), split into responders and non-responders. 
These results are displayed by all patients and then by primary and recurrent cancer 
type. Responders were significantly more likely to have EMVI positive tumours (8.3% 
versus 35.6%, p=0.020). When split by tumour type, this only showed a borderline 
significance for primary cancer (11.1% versus 38.9%, p=0.057) and was not 
significant in recurrent cancer (0% versus 22.2%, p=0.486), although the percentage 
differences suggest that this may be due to low numbers. Adverse tumour 
differentiation was not associated with regression both overall and when split by 
tumour type.  
  
 178	  
Table 23: Clinical, pathological and biomarker variables associated with response 
versus non-response to neoadjuvant therapy. Numbers of patients are those in 
whom biomarker assessment was successfully completed.  
Patient group 
 
Completed 
analysis 
Responder Non-responder P 
All patients (n=69) 
       
Age 65+ years Yes (versus <65 years) 69 3/24 12.5% 14/45 31.1% 0.087 
Gender Female (versus male) 69 3/24 33.3% 11/45 24.4% 0.431 
Tumour type Recurrent (versus primary) 69 3/24 25.0% 9/45 20.0% 0.632 
Resection margin Positive (versus negative) 69 3/24 4.2% 6/45 13.3% 0.408 
EMVI Present (versus absent) 69 3/24 8.3% 16/45 35.6% 0.020 
Tumour differentiation Poor* (versus well/moderate) 69 3/24 16.7% 10/45 22.2% 0.756 
Reduced E-cadherin 
expression 
Yes (versus no) 65 3/24 17.4% 30/42 71.4% <0.001 
Nucleic beta-catenin 
expression  
Yes (versus no) 57 3/24 10.5% 25/38 65.8% <0.001 
microRNA 200c loss Yes (versus no) 52 3/24 12.5% 28/36 77.8% <0.001 
Tumour budding Yes (versus no) 57 3/24 10.5% 28/38 73.7% <0.001 
Primary cancer (n=54)  
 
      
Age 65+ Yes (versus <65 years) 54 2/18 11.1% 12/36 33.3% 0.073 
Gender Female (versus male) 54 6/18 33.3% 8/36 22.2% 0.380 
Resection margin Positive (versus negative) 54 1/18 5.6% 4/36 11.1% 0.655 
EMVI Present (versus absent) 54 2/18 11.1% 14/36 38.9% 0.057 
Tumour differentiation Poor* (versus well/moderate) 54 2/18 11.1% 6/36 16.7% 0.704 
Reduced E-cadherin 
expression 
Yes (versus no) 52 4/17 23.5% 24/35 68.6% 0.003 
Nucleic beta-catenin 
expression  
Yes (versus no) 45 1/14 7.1% 22/31 71.0% <0.001 
microRNA 200c loss Yes (versus no) 42 1/12 8.3% 22/30 73.3% <0.001 
Tumour budding Yes (versus no) 45 1/14 7.1% 24/31 77.4% <0.001 
Recurrent cancer (n=15) 
       
Age 65+ Yes (versus <65 years) 15 1/6 16.7% 2/9 22.2% 0.659 
Gender Female (versus male) 15 2/6 33.3% 3/9 33.3% 1.000 
Resection margin Positive (versus negative) 15 0/6 0.0% 2/9 22.2% 0.486 
EMVI Present (versus absent) 15 0/6 0.0% 2/9 22.2% 0.486 
Tumour differentiation Poor* (versus well/moderate) 15 2/6 33.3% 4/9 44.4% 1.000 
Reduced E-cadherin 
expression 
Yes (versus no) 13 0/6 0.0% 6/7 85.7% 0.005 
Nucleic beta-catenin 
expression  
Yes (versus no) 12 1/5 20.0% 3/7 42.9% 0.576 
microRNA 200c loss Yes (versus no) 10 1/4 25.0% 6/6 100.0% 0.033 
Tumour budding Yes (versus no) 12 1/5 20.0% 4/7 57.1% 0.293 
EMVI=extramural vascular invasion; * poor/ mucinous/ necrotic 
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In non-responders, E-cadherin loss was detected in 71.4% of patients versus 17.4% 
in responders (p<0.001). Corresponding figures for nucleic beta-catenin were 65.8% 
and 10.5% (p<0.001) and for microRNA 200c loss were 77.8% and 12.5% (p<0.001). 
The corresponding rates in control patients are shown in figure 28, where their rates 
are ranked in-between those for responders and non-responders.   
The association between tumour budding, detected by the three biomarkers in turn, 
and response to neoadjuvant therapy was also tested. These show significant 
relationships between responders and non-responders and the presence of tumour 
budding, with control groups as the middle ranked group (figure 29). 
Corresponding rates split by primary and recurrent cancer type are shown in figure 
30, where these significant patterns are repeated, except for beta-catenin expression 
in recurrence.  
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Figure 28: Biomarker expression between controls and those undergoing 
neoadjuvant therapy (split into responders and non-responders). 
Reduced E-cadherin P<0.001 
 
Nucleic Beta-catenin P<0.001 
 
Reduced mir200c P<0.001 
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Figure 29: Association between tumour budding (as detected by the three 
biomarkers) and response to neoadjuvant therapy. 
Reduced E-cadherin P<0.001 
 
Nucleic Beta-catenin P<0.001 
 
Reduced mir200c P=0.002 
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Figure 30: Biomarker expression between controls and those undergoing 
neoadjuvant therapy (split into responders and non-responders), split by primary and 
recurrent cancer types. 
Reduced E-cadherin Nucleic Beta-catenin Reduced mir200c 
Primary   
   
P=0.005 P<0.001 P<0.001 
Recurrent   
   
P=0.005 P=0.647 P=0.030 
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3.2.9 Multivariable predictors of response to neoadjuvant therapy  
Table 24 shows the univariable predictors of response to neoadjuvant therapy by 
logistic regression analysis, which included extramural vascular invasion, the EMT 
related biomarkers and beta-catenin detected tumour budding. At univariable 
analysis, EMVI, reduced E-cadherin expression, nucleic beta-catenin and 
microRNA200c loss were all significantly associated with non-response. At 
multivariable analysis, using a forward stepwise selection, tumour budding (odds 
ratio 10.42, p=0.014) and reduced mir200c expression (odds ratio 7.72, p=0.034) 
were included in the final model as association with response. It is notable that the 
95% confidence intervals associated with these were both wide (tumour budding 
1.61-67.58 and microRNA 200c 1.67-51.13). 
Table 24: Univariable and multivariable binary regression models for responder 
versus non-responders in only patients undergoing neoadjuvant therapy (n=69) 
 Univariable  Multivariable  
 HR 95% CI P HR 95% CI P 
Age 65+ years (versus <65) 3.16 0.81-12.37 0.098    
Female Gender (versus male) 0.65 0.22-1.92 0.433    
Recurrent cancer (versus primary) 0.75 0.32-2.44 0.632    
Positive resection margin (versus negative) 3.54 0.40-31.27 0.256    
Extra-mural venous invasion (versus none) 6.07 1.26-29.20 0.024    
Poor differentiation (versus good/moderate) 1.43 0.40-5.15 0.586    
Reduced E-cadherin expression 11.88 3.34-42.25 <0.001    
Nuclear beta-catenin expression 16.35 3.26-81.87 0.001    
Beta-catenin related tumour budding 23.80 4.65-121.89 <0.001 10.42 1.61-67.58 0.014 
Reduced mir200c expression 24.50 4.58-131.07 <0.001 7.72 1.67-51.13 0.034 
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3.2.10 Pathological predictors of survival  
Non-response to neoadjuvant therapy was associated with worse OS (p=0.017) and 
CSS (p=0.049). Overall, 90.3% of patients underwent complete macroscopic (i.e. R0 
resection), which was associated with improved DFS (p=0.007), CSS (p=0.021) and 
a trend towards improved OS (p=0.086). Advanced final pathological stage (i.e. 
stage II or III) was associated with significantly worse DFS (p=0.017) and CSS 
(p=0.036), but similar OS (p=0.495). Corresponding Kaplan-Meier survival curves 
are shown in figures 31-33.  The patients at risk for these survival curves are shown 
below. 
 
Table 25: Life tables showing the number of patients at risk entering each time 
period, considering response to neoadjuvant therapy.  
Time (months) 0 12 24 36 
Overall Survival      
Responder 24 16 11 8 
Non-responder 45 34 14 4 
Control 34 25 12 7 
Disease Free Survival      
Responder 24 15 9 5 
Non-responder 45 28 9 2 
Control 34 24 11 6 
Cancer Specific Survival      
Responder 24 15 9 5 
Non-responder 45 24 7 0 
Control 34 23 10 6 
 
 185	  
Figure 31: Survival outcomes assessed by Kaplan-Meier curves (with log-rank p-
values), related to response to neoadjuvant chemoradiotherapy. 
Overall survival, 0.017 
 
Disease free survival, 0.103 
 
Cancer specific survival, 0.049 
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Figure 32: Survival outcomes assessed by Kaplan-Meier curves (with log-rank p-
values), related to resection margin status. 
Overall survival, 0.086 
 
Disease free survival, 0.007 
 
Cancer specific survival, 0.021 
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Figure 33: Survival outcomes assessed by Kaplan-Meier curves (with log-rank p-
values), related to final pathological stage. 
Overall survival, 0.495 
 
Disease free survival, 0.017 
 
Cancer specific survival, 0.036 
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3.2.11 EMT biomarkers and predictors of survival  
Next, the relationship of EMT biomarkers and survival was correlated. Reduced E-
cadherin was associated with lower CSS (p=0.036). Changes in nucleic beta-catenin 
did not predict reduced survival. MicroRNA-200c loss was associated with reduced 
OS (p=0.010), reduced CSS (p=0.009) and a trend towards reduced DFS (p=0.069). 
Corresponding Kaplan-Meier survival curves are shown in figures 34-36. The 
patients at risk for these survival curves are shown below.
 
Table 26: Life tables showing the number of patients at risk entering each time 
period, for each biomarker related to overall survival. 
Time (months) 0 months 12 months 24 months 36 months 
E-cadherin       
Normal expression 50 38 17 10 
Reduced expression 47 33 18 8 
Beta-catenin      
Membranous 40 30 14 7 
Nucleic  44 29 11 3 
microRNA-200      
Normal expression 38 31 12 6 
Reduced expression 41 28 13 3 
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Figure 34: Survival outcomes assessed by Kaplan-Meier curves (with log-rank p-
values), related to E-cadherin expression. 
Overall survival, 0.184 
 
Disease free survival, 0.053 
 
Cancer specific survival, 0.036 
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Figure 35: Survival outcomes assessed by Kaplan-Meier curves (with log-rank p-
values), related to beta-catenin expression. 
Overall survival, 0.301 
 
Disease free survival, 0.904 
 
Cancer specific survival, 0.440 
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Figure 36: Survival outcomes assessed by Kaplan-Meier curves (with log-rank p-
values), related to microRNA 200c expression. 
Overall survival, 0.010 
 
Disease free survival, 0.069 
 
Cancer specific survival, 0.009 
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3.2.12 Tumour budding and survival  
Tumour budding is being established as an increasingly important prognostic factor, 
although more evidence is required to support this. Therefore, the relationship 
between tumour budding and survival was tested in depth. When using beta-catenin 
related detection, the strongest survival relationship detected was tumour budding 
with reduced cancer specific survival. Although a visual difference was detected in 
survival curves, this did not achieve statistical significance. 
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Figure 37: Survival outcomes assessed by Kaplan-Meier curves (with log-rank p-
values), relating beta-catenin detected tumour budding to survival. 
Overall survival, 0.112 
 
Disease free survival, 0.304 
 
Cancer specific survival, 0.155 
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3.2.13 E-cadherin gene expression 
Amplification curves for positive and negative controls are shown in the appendix. 
Complete gene expression studies were performed in 70 patients undergoing 
neoadjuvant therapy, which included 61.4% with poor response (n=43) and 38.6% 
with response (n=27). Average delta Ct results showed a normal distribution.  
Figure 38: Normal distribution of average delta-delta Ct values. 
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Figure 39: Representative Ct amplification plot. 
  
E-cadherin (purple) and endogenous 
control GAPDH (blue) amplifications plots 
E-cadherin (light green) and endogenous 
control GAPDH (dark green) 
amplifications plots 
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Patients who were responders and non-responders had similar levels of low relative 
quantitation of the gene for E-cadherin (70.4% and 69.8% respectively, p=0.507). 
This is further represented by similar average delta-delta Ct values between 
responders (2.98, 95% confidence interval -0.04 – 9.60) and non-responders (2.08, 
95% confidence interval -1.73 – 8.21, p=0.163). 
Figure 40: Box-plot of relative E-cadherin gene expression levels between 
responders and non-responders (p=0.163). 
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Proportions of low relative quantitation of the gene for E-cadherin were similar for E-
cadherin expression (74.1% and 73.1%) and microRNA-200c expression (70.0% and 
71.4%). Patients with normal beta-catenin expression had lower relative quantitation 
(85.7%) versus those with reduced expression (58.3%, p=0.033). 
 
Table 27: Relative expression of the gene for E-cadherin related to tumour 
regression and EMT biomarkers. Numbers of patients reflect the specimens in which 
technical success of biomarker studies was achieved. 
Relative quantitation Low  Normal/high   
 n % n % P-value 
Tumour regression      
No 19 70.4% 8 29.6%  
Yes 30 69.8% 13 30.2% 0.957 
E-cadherin        
Normal expression 20 74.1% 7 25.9%  
Reduced expression 19 73.1% 7 26.9% 0.934 
Beta-catenin      
Normal expression 24 85.7% 4 14.3%  
Nucleic expression 14 58.3% 10 41.7% 0.033 
Micro-RNA 200c      
Membranous expression 14 70.0% 6 30.0%  
Reduced expression 20 71.4% 8 28.6% 0.915 
Tumour budding      
Absent 19 76.0% 6 24.0%  
Present 19 70.4% 8 29.6% 0.647 
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4 Discussion  
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4.2 Summary of main findings 
This study has:  
• Associated adverse expression of EMT adhesional molecules E-cadherin and 
beta-catenin to non-response to neoadjuvant therapy. 
• Assigned causality by proving association between reduced microRNA-200c 
expression (the upstream master-regulator of EMT processes), and non-
response to neoadjuvant therapy. 
• Showed associations between EMT biomarkers and adverse pathological 
features, including advanced tumour invasive and extra-mural venous 
invasion. 
• In turn, showed that extra-mural venous invasion predicts non-response to 
neoadjuvant therapy. 
• Proved that tumour budding is strongly associated with adverse biomarker 
expression in rectal cancer, and may be a consequence of the EMT process. 
• Showed that tumour budding is associated with adverse pathological and 
survival outcome, and may readily act as a practical biomarker. 
• Showed that reduced E-cadherin and micro-RNA-200c expression was 
associated with worse cancer related survival. 
• Showed that relative E-cadherin gene expression was not related to tumour 
response. 
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Additionally, this study has validated important technical principles relating to 
analysis of human rectal cancer tissue and response to neoadjuvant radiotherapy: 
• FFPE tumour biobanks are cheap, stable and made for an excellent research 
resource with immediate clinical endpoints available. 
• Showed that in-situ hybridisation of rectal cancer FFPE was achievable to 
show positive results.  
• Further proven that microRNA stabilisation in FFPE was adequate for long 
periods at room temperature.  
Analysis of clinical data during this thesis has proven some valuable treatment 
principles in relation to patients with advanced rectal cancer: 
• Exenterative surgery for advanced rectal cancer resulted in good long-term 
survival. 
• Considering primary and recurrent rectal cancer together (as well as apart) 
was feasible due to their similar clinical outcome when treated with R0 
resection. 
• Resection margin status was more important than primary or recurrent cancer 
in predicting long-term outcome. 
• Extra-mural venous invasion was an important predictor of overall outcome. 
The main aim of this thesis was to test whether markers of EMT were associated 
with non-response to neoadjuvant therapy. This relationship has been shown in two 
co-functioning adhesional markers (membranous E-cadherin and nuclear beta-
catenin). It has also been shown that tumour budding, a consequence of EMT and a 
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marker of tumour aggression, was further associated with non-response. Finally, the 
positive relationship to reduced mir200c expression, which has been established as 
an upstream master-regulator of EMT processes,198 confirms this process. These 
relationships were shown in the overall cohort, in primary cancers only, and also in 
the smaller recurrence only group (for reduced E-cadherin and mir200c). The key 
secondary findings of this study were the association of EMT biomarkers to 
advanced tumour characteristics (in terms of stage and EMVI) and reduced survival, 
emphasising further the importance of EMT processes to these patients.  
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4.4 Membranous adhesion molecules 
4.4.1 Interpretation of findings for E-cadherin and beta-catenin 
The interplay of the E-cadherin-beta-catenin complex at the epithelial cellular 
membrane is essential for maintaining normal tissue architecture. There are 10 types 
of cadherin, which function to maintain adhesion, polarity and differentiation. E-
cadherin is critical, as shown through E-cadherin knock-out in mice, which induces 
lethality 204. Cadherin binding and communication to cytoplasmic molecules is 
mediated though catenins. Loss of cadherin-catenin complexes is recognised in the 
progression of cancer151. As differentiation decreases, immunohistochemical staining 
of cadherin-catenin reduces. This process may also be responsible for production of 
motile cancer cells, also termed stem cells. As these cells are capable of movement 
into blood and lymph capillaries, their potential to translocate to distant organs is a 
feasible molecular mechanism for metastases.  
Inactivation of cadherin-catenin complex is a key route to cancerous progression. 
There are, potentially, many routes to this inactivation, including loss of E-cadherin 
locus on the long arm of chromosome 16, and other genetic mutations of the gene 
for E-cadherin.  
With existing knowledge of the poor prognostic value of E-cadherin in breast, 
pancreatic and bladder cancers, there has been increasing interest in EMT as a 
biomarker for metastatic disease in breast, pancreatic and lung cancers.151 In 
addition, a further body of evidence now links EMT to chemoresistance in other 
cancer types, including ovarian cell lines,180 pancreatic cell lines,181 breast cancer 
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cell lines182 183 and human lung cancer resections.148 However its role in colorectal 
cancers is less well established. Alongside a limited number of existing colorectal 
cell line models,178 179 there are few studies relating EMT and non-response to 
neoadjuvant therapy in human specimens. 
This thesis has investigated the role of the epithelial-mesenchymal-transition, and its 
upstream pathways, as one route to loss of the cadherin-catenin complex.  It used E-
cadherin as key marker an EMT phenotype, associated its loss with local tumour 
aggressiveness, extra-mural venous invasion and tumour budding. It was not 
associated with tumour depth or lymph node stage. This may indicate that vascular 
invasion (i.e. EMVI) is the primary route of spread from the EMT phenotype and the 
source of its aggressive nature, rather than effects on the local tumour.  
4.4.2 Variable definitions of EMT biomarkers 
There is no established consensus on the pathological definition of EMT. E-cadherin 
is a key and frequently used biomarker of EMT, representing the final endpoint of the 
intra-cellular pathway before formation of tumour buds, followed by vimentin as part 
of a mesenchymal phenotype. Beta-catenin is released from the cellular membrane 
following down-regulation of E-cadherin, increasing its nuclear concentration with 
subsequent effect on EMT target genes. However the relationship of beta-catenin 
and cancer progression is complex and is affected by other co-existing pathways151. 
Further variation is added due to the lack of accepted reporting methods for tumour 
budding199. This thesis used a standard and commonly used set of biomarkers, 
which were selected following review of EMT literature, and colorectal specific EMT 
studies. In particular, loss of membranous E-cadherin is the most commonly used 
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hallmark finding of EMT184. Further research is needed to improve definitions of 
EMT. This will also assist multicentre research and validation studies. 
4.4.3 Source of Epithelial Mesenchymal Transition  
Cadherins are affected by multiple upstream pathways, including wnt, TGF-beta, 
adenomatous polyposis coli (APC) tumour suppressor gene, and also an array of 
microRNAs205. It is reasonable to assume that end-result of cadherin loss is affected 
by multiple upstream signaling pathways, of which only one of which is EMT 
This thesis included a control group of patients treated without neoadjuvant therapy. 
Analysis of biomarker levels for E-cadherin and microRNA-200c in this group 
showed that responders had highest expression, non-responders lowest expression 
and that non-radiotherapy controls had a middle value. There were also EMT 
phenotypes observed in control group, suggesting that in some patients EMT 
changes may be present before radiotherapy. In others, the application of 
radiotherapy may have split the middle control groups into groups with high and low 
phenotype expression, representing responders and non-responders179.  
The traumatic stimulus of radiotherapy may have induced an EMT phenotype. 
However, since some control patients exhibited EMT features (i.e. before 
radiotherapy), this is inadequate to explain all the changes observed. It is likely that 
there is overlap between the two hypotheses, and further research to elucidate these 
pathways is warranted. In a previous study, Shintani et al., showed that epithelial 
markers were present in pre-treatment specimens from 63 patients with non-small 
cell lung cancers and that after treatment, 20 of these patients displayed 
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mesenchymal markers148. They also found that only 2 out of 13 patients with 
complete responses displayed mesenchymal markers. Future research should be 
directed towards pre-treatment biopsies, in order to determine the feasibility of 
stratified treatment.  
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4.6 microRNA-200c  
4.6.1 microRNA-200c as a master regulator of EMT 
This thesis has showed a significant relationship between microRNA-200c loss and 
advanced tumour invasion, tumour budding and non-response to neoadjuvant 
therapy. In experimental colorectal cancer models, microRNA-200c has been 
previously proven as a master-regulator of the EMT process198. Although there are 
other established mechanisms leading to loss E-cadherin (including apoptotic and 
hypoxic signalling pathways), these findings suggest that EMT (as marked by 
microRNA-200c loss), is one such pathways in rectal cancer. 
This thesis supports the scanty existing evidence of the importance of the role of 
microRNAs in relation of EMT to and progression colorectal cancer, including 
metastasis. There is increasing evidence that the five members of the microRNA-200 
family play a key role in development of colorectal cancer metastases. The proposed 
mechanism is through mir200c related suppression of the E-cadherin transcriptional 
repressors zinc finger E-box-binding homeobox 1 and 2, leading to an EMT 
process.198  
In the most significant of recent publications, Hur et al., tested the associations and 
causes of microRNA-200c as a modulator of EMT in human colorectal cancer 
metastasis198. Their study originated from Japan, and tested two colorectal cancer 
cell lines and 54 FFPE primary colorectal cancer tissues with corresponding liver 
metastases. In-situ-hybridisation was used to detect microRNA-200c expression 
using the Exiqon kit, which was also used in this thesis. Additionally, the authors 
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used total RNA reverse transcriptase to cDNA and quantitative real-time polymerase 
chain reaction (qRT-PCR). They additionally tested TaqMan microRNA analysis, 
analysis of DNA methylation, and western blotting protein analysis of antibodies 
against E-cadherin. Finally, they used Boyden chambers to test cell migration. 
By showing low in-situ-hybridisation of microRNA-200c at the invasive front of the 
colorectal tumour and high mir200c in subsequent liver metastases, they showed the 
EMT and mesenchymal epithelial transition (MET, the reverse physiological process 
of EMT) required for proliferation of the metastases. They established the 
importance of hypomethylation of microRNA-200c an epigenetic regulator based on 
the colorectal cancer cell lines and the microRNA200c/141 cluster in liver 
metastases from primary colorectal cancer. Furthermore, they show the relationship 
of over-expressed mir200c with negative regulation of its gene targets (ZEB1, ETS1 
and FLT1) and their up-regulatory effect on E-cadherin, further proving mir200c as a 
regulator of EMT and MET. The authors conclude that epigenetic regulation of 
microRNA-200 family members plays a pivotal role in the metastatic behaviour of 
colorectal cancer, and that it represents a potential therapeutic and diagnostic 
biomarker. Although this thesis did not analyse the role of microRNA-200c to 
metastases, it did relate its loss to increased tumour aggression in terms of tumour 
penetration, tumour budding and non-response to neoadjuvant therapy. The similar 
experimental methodology and complimentary findings highlight the importance of 
EMT to patients with colorectal cancer. 
Another recent study assessed candidate biomarkers of response to radiotherapy in 
rectal cancer, drawn from those representing angiogenesis (thymidine 
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phosphorylase, thymidylate synthase, and vascular endothelial growth factor), 
apoptosis (bax, p53, nuclear factor-kappa B, and surviving), proliferation 
(cyclooxygenase [COX]-2, proliferating cell nuclear antigen), and cell adhesion 
(CD44, CD133, matrix metalloproteinase 2 and 9)206. This study included 123 
patients with pre-treatment biopsies prior to chemoradiation, the mRNA levels of 13 
candidate biomarkers were analysed by reverse transcriptase-polymerase chain 
reaction. There were no significant correlation for T-stage downstaging, N-stage 
downstaging or tumour-node-metastases downstaging. On multiple logistic 
regression, only CD44 expression was significant for tumour regression grade (odds 
ratio 4.69, 95% CI 1.15-17.74, p=0.030). Validation beyond this single centre study 
has not been confirmed. Positive CD44 expression is an additional marker of the 
EMT phenotype, and is associated with reduced E-cadherin expression across a 
range of cancers207. This shows the potential for overlapping cancer related 
pathways that may affect response to neoadjuvant therapy, and E-cadherin 
expression. This study highlights the importance of apoptotic and vascular 
proliferative mechanisms to radioresistance, which when taken with the findings of 
this thesis, show that EMT may co-exist with other pathways. This illustrates the 
future need for stratified care of patients undergoing radiotherapy.  
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4.7 Tumour budding and EMT 
4.7.1 Relating tumour budding to EMT and its prognostic significance 
Tumour budding has been previously associated with poor outcome from colorectal 
cancer,208 including the distinct morphological and prognostic significance of post-
irradiation budding in rectal cancer.200 This thesis further defines its important 
biological relationship to EMT, with the motile phenotype potentially leading to 
tumour budding, distinct from the main tumour mass. It has confirmed previous 
findings that tumour budding is an important marker of cancer aggression. It was 
significantly related to the presence of extra-mural venous invasion and to non-
response to neoadjuvant therapy. Although it was not statistically related to cancer 
specific survival, there was a trend for reduced survival in those with beta-catenin 
detected tumour budding. The lack of statistical significance could also be due to low 
numbers.  
Overall in this thesis, 55% of patients displayed evidence of tumour budding. In a 
study published in July 2013 (online), Rogers et al., analysed the role of intra-
tumoural budding as a risk factor for advanced pathology and non-response to 
neoadjuvant therapy209. Whilst tumour budding is generally considered to occur at 
the invasive front, intra-tumoural budding can occur which may be a useful 
prognostic marker in biopsies, although validation is needed. They detected budding 
at a rate of 20% (19/89) in pre-treatment biopsies. Intra-tumoural budding was 
associated with higher post-treatment T-stage (p=0.032). No patients with tumour 
budding achieved a complete pathological response, whilst 12 did in the no-budding 
group (17%). Finally, they related the presence of budding to reduced 5-year 
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disease free and cancer specific survival. They highlight a manner in which biopsies 
may be used to stratify neoadjuvant therapy, although with low numbers and a single 
centre status, validation is needed.  
In a study of 96 Chinese patients with rectal cancer, post-therapy post-surgery 
specimens showed that tumour budding was significantly associated with reduced 
long-term disease free survival, and that there was a distinct post-radiation 
morphology associated with fibrosis and large populations of infiltrating inflammatory 
cells200. This study highlights the potential of post-treatment tumour budding as a 
potential prognostic marker, in keeping with the findings from this thesis. 
4.7.2 Variability in detection of tumour budding 
Despite the increasing evidence of its importance in prognostication, including 
evidence from this thesis, tumour budding has yet to be incorporated into daily 
diagnostic practice. The reasons for this are that there is a lack of standard 
definition, no consensus on optimum means to identify it, and a high risk of inter-
observer variability.  
This thesis has showed that tumour budding is related to non-response to 
neoadjuvant therapy, which in turn is associated with poor response. Additionally, 
both reduced E-cadherin and microRNA-200c were predictive of tumour budding, 
which directly associates tumour budding to the EMT process. Additional studies 
have showed that budding is associated to both overall and cancer specific 
survival200 209. 
Tumour budding is readily detectable on normal immunohistochemistry, which is a 
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commonly used technique in laboratories across the world. Conversely, in-situ-
hybridisation is a technically more challenging technique that has not yet achieved 
high volume status. It is thus costly and lacks validity in terms of reproducibility. 
Tumour budding can be detected through a variety of stains, including haematoxylin 
and eosin stain, beta-catenin and E-cadherin. It thus represents a cheap and easily 
readable biomarker, and may be the most practical to arise from this thesis. 
However, consistency in identifying and defining tumour budding is variable and has 
limited its application to date. In one of the only multicentre comparative studies 
available, 10 pathology teams from different countries performed a multicentre, 
virtual assessment of 50 pT1-pT4 colorectal cancers. The reproducibility of various 
methods was tested, which included staining by haematoxylin and eosin, and 
pancytokeratin antibody (AE1-3 cytokeratin-immunostained), whole slide digital 
scans. Testing interobserver agreements, the study found that overall agreement 
was fair for all methods, and increased to moderate for pT1 cancers. Agreement was 
dependent on participant’s experience with tumour budding reporting and 
performance time. Haematoxylin and eosin was as good as other methods in terms 
of agreement levels. This study highlights the need for further research into the 
definition and detection of tumour budding. 
This thesis further analysed agreement between different modalities of detecting 
tumour budding. Compared to that detected by beta-catenin, there was good 
agreement with detection by microRNA-200c and moderate agreement from reduced 
E-cadherin detection. This shows that the method used is important and agrees with 
previous studies that variation is present. However, since haematoxylin and eosin is 
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universally used, is relatively easy to interpret and is comparatively cheap, it may 
represent the most universally applicable method. This would make tumour budding 
practical, cheap and potentially reproducible as a wide scale biomarker for both 
prognosis and likelihood of response to neoadjuvant therapy.  
4.7.3 Variability in definition of tumour budding 
The difficulty in standardising methods of detection is made harder by the differences 
in definition of tumour budding. Subjective methods involve determining the 
predominant pattern in terms of presence or absent, with further sub-classification of 
quantity possible (e.g. none, mild, moderate, severe210 211). Further quantitative 
assessment has been recently suggested, typically by initial visual definition of a 
high density area of tumour budding at the invasive front, followed by counting the 
number of buds within a set area of a field201.  However, consensus has not been 
achieved yet, and further international efforts are warranted. The methods used in 
this thesis represent a balance of methods in the current literature, by using semi-
quantitative assessment and a definition based on presence versus absence (rather 
than a range). 
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4.8 E-cadherin gene expression  
This thesis found no relationship between E-cadherin gene expression and response 
to neoadjuvant therapy. There was further no relationship to E-cadherin protein 
expression, microRNA-200c or tumour budding. There was, however, a significant 
finding related to beta-catenin expression, where membranous expression was 
associated with low quantitation and nucleic expression with high quantitation. Thus, 
whilst microRNA-200c was associated to changes in EMT and tumour regression, 
the genetic expression the E-cadherin gene was not. This negative finding has 
several possible explanations and implications. 
The precise stimulus for EMT is uncertain in patients with rectal and other types of 
cancer. It is likely to be from either a innate genetic predisposition, or from the 
traumatic stimulus of radiotherapy when applied to cancerous tissue. The results of 
this thesis have shown that in a control group of patients not undergoing neoadjuvant 
therapy, EMT processes still occur. Thus, it is likely to be a combination of genetic 
and traumatic stimuli, although whether one of these predominates, and thus can act 
as primary target, requires further research. 
That microRNA-200c expression was then associated with response suggests that 
radiotherapy affected downstream pathways, either through or by direct effect on 
microRNAs. Since microRNAs have been shown to play a key role in cellular 
signalling and cancer progression, it is feasible that gene expression was not 
affected, but microRNA-200c expression was. Radiotherapy may primarily affect 
post-transcriptional microRNAs, rather than the pre-transcriptional genes. 
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This is further reinforced by the significant findings with beta-catenin expression. 
Here, high expression of E-cadherin gene was associated with nucleic beta-catenin. 
This acts as a marker of EMT, since the unbound catenin-cadherin complexes in the 
cellular membrane allow translocation of beta-catenin to the nucleus; nucleic beta-
catenin is also increased by other cancer related signalling pathways184. 
Interpretation of this finding has important implications for this thesis. Normal or 
increased relative expression of the gene for E-cadherin may be in response to 
membranous loss of E-cadherin protein expression, explaining the association with 
nucleic beta-catenin. It is also feasible that it represents a separate, independent 
pathway. In either case, the alteration to cytoplasmic microRNA-200c expression 
that is significantly associated with the EMT phenotype highlights its potential as a 
potential independent therapeutic target.  
Disconnect between nucleic E-cadherin gene and cytoplasmic microRNA-200c 
expression as part of the EMT pathway relates to the timing of prognostic testing. 
Testing pre-treatment biopsies for markers of EMT may be ineffective, as absence of 
innate genetic changes may be absent and a traumatic radiotherapy stimulus has 
not yet been applied. At this stage, expression of both E-cadherin genes and 
membranous E-cadherin protein may be normal, or lack prognostic accuracy; more 
research on biopsy specimens is required. Testing after commencement of 
neoadjuvant treatment may prove practically and technically difficult, and may 
provide too late a therapeutic window.  
These findings support further research into accurate and novel prognostic 
biomarkers. Unless this research can determine accurate biomarkers through pre-
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treatment biopsy or serum usage, it may be that the whole cohort undergoing 
neoadjuvant therapy requires novel treatment. This could be delivered through a 
randomised controlled trial, allocating patients to a novel treatment (e.g. through 
microRNA-200c replacement therapy) with parallel prognostic marker development. 
This negative finding could represent a false negative, where the complex reverse 
transcriptase-polymerase chain reaction techniques did not identify true positive 
relationships. This could be explained through experimental technical aspects, 
although the resulting normal distribution of delta-delta Ct and positive finding in 
relation to beta-catenin make this unlikely.  
The negative finding could also be explained due to inclusion of whole slide 
specimens into the reverse transcriptase process. These are likely to have contained 
tumour and non-tumour tissue, with differing genetic expression representative of 
mosaicism. Furthermore, within each tumour, there is increased genetic 
heterogeneity due to competing factors at the invasive and non-invasive fronts. 
These situations may have masked differing levels of E-cadherin gene expression.  
The clinical application of this genetic change is as a prognostic marker in pre-
treatment biopsies, to identify patients at risk of reduced E-cadherin expression, at 
genomic level. Thus whole slide testing, rather than specific tissue, provides a more 
pragmatic approach. Future experiments should be designed to confirm this 
relationship. Laser microdissection of cancerous tissue with concurrent testing of 
adjacent mucosal and stromal tissues would provide an accurate description of 
specific tumour tissue and the microenvironment. 
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4.9 Other factors influencing tumour proliferation at the invasive 
front 
There has been limited investigation into other prognostic biomarkers of response to 
neoadjuvant therapy in rectal cancer. In one of the largest studies to date, Edden et 
al., form the Cleveland Clinic studied the expression of apoptosis protease-activating 
factor-1, cyclooxygenase-2 and vascular endothelial growth factor to response to 
neoadjuvant therapy in 152 patients with rectal cancer84. They selected these as 
markers of apoptotic pathways, as this programmed cell death is protective against 
cancerous development. They used standard immunohistochemistry on FFPE 
blocks, with tumour specimens obtained before and after neoadjuvant therapy 
(comprising long-course radiotherapy up to a maximum of 50.4 Gy). With this 
schedule, they achieved a very high pathological complete response rate of 24.5%, 
which means their patients represent a different group to those included in this 
thesis. They correlated expression of apoptosis-associated marker APAF-1 to be 
significantly associated with tumour regression grade (p<0.001), complete 
pathological response (p<0.031) and T-downstaging (p<0.001). In contrast, 
overexpression of Cox-2 and VEGF in pretreatment biopsies was related to less 
tumour regression (p<0.003) and less likelihood of T-downstaging (p<0.003). This 
means that suppression of apoptotic pathways may be a mechanism of 
radioresistance.  
This confirms previous epidermal and vascular growth factor receptor research and 
the potential ability to predict complete pathological response208 212. However, the 
study by Huh et al., correlated 13 biomarkers to response to radiotherapy in pre-
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treatment biopsies of 123 patients with rectal cancer. They were only able to 
correlate CD44 (a marker of cellular adhesion) with response206. VGEF and 
apoptosis markers were not associated with tumour or node regression, or with 
overall TNM downstaging. Further research into external validation is needed. 
In addition to EMT and apoptosis, hypoxia at the invasive front is likely to affect both 
E-cadherin and subsequent tumour budding. Hypoxia in patients with rectal cancer 
itself is multifactorial. The anti-angiogenesis properties of radiotherapy, leading to 
destruction of cellular components and down-regulation of blood vessels, can induce 
hypoxia at the deepest tumour margins and stimulate tumour budding. Research 
from the hypoxic environment of laparoscopy, caused by carbon dioxide insufflation, 
can be extrapolated to the situation of hypoxia following radiotherapy. In a study 
inducing hypoxia in colonic cancer cell lines, hypoxia was induced by exposure to 
the laparoscopic gases carbon dioxide and helium for four hours213. A cellular 
hypoxic insult was demonstrated by induction of hypoxia inducible factor 1-alpha and 
reduction of E-cadherin and CD44 expression. Of further interest to this thesis is that 
these effects were recoverable under re-oxygenation, which may be a route to 
reversal of EMT. Other studies have shown that hypoxia and acidity at the cancer-
stromal cell interaction at the invasive front are likely to promote aggressiveness and 
invasiveness214.  
Further research should be targeted towards testing the influence of EMT, hypoxia 
and apoptosis on response to radiotherapy. Candidate biomarkers for such a study 
include E-cadherin, beta-catenin, microRNA-200c, hypoxia inducible factor 1-alpha, 
VEGF and CD44. It is likely that these three domains function separately and in 
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combination to induce tumour budding and radioresistance. This exposes the need 
for a stratified approach to selecting patients who are best likely to benefit, and 
reliable methods of identification. 
In the modern era, colorectal cancer continues to represent an heterogeneous 
collection of anatomical, histological and genetic conditions. Within an individual 
colorectal cancer, it is being increasingly recognised that there are differences 
between the invasive and non-invasive edges. These differences may be driven by 
mosaicism, which is the presence of two or more populations of cells with different 
genotypes in one individual. Additionally, there is a dynamic interface of pro- and 
anti-tumour factors, both within the tumour and from the surrounding stroma. These 
lead to a variety of conditions that can promote tumour budding. Related to the EMT 
phenotype, moving from the tumour centre to the front is related to decreased E-
cadherin, Ki67, CD44, CD44v6, CD166, EpCAM, APAF-1, and increased MMP-2, 
tubulin, CD133, cytoplasmic podia, vimentin and tumour budding158. This thesis used 
the patient’s non-invasive edge as the primary control for IHC and ISH. The 
significant differences in expression of E-cadherin and microRNA-200c between 
these two interfaces suggests a degree of mosaicism must be present. This is 
important for external validation studies, which must use the correct sample site to 
test for biomarker alteration, especially microRNA-200c, to prevent false negative 
results; this is also a risk with relying solely on pre-treatment biopsies. The presence 
of mosaicism also has implications for novel drug delivery, which must be proven to 
penetrate to the patient’s tumour invasive margin. 
  
 219	  
4.10 Limitations  
4.10.1 Generalisability  
Patients in this study included those with advanced cancer, including those requiring 
pelvic exenteration to achieve cure. This is due to the referral base of the Colorectal 
Department at the Royal Marsden Hospital, which serves as a base for assessment 
of advanced colorectal cancer. Generalisability to other populations with rectal 
cancer needs to be established, both in the United Kingdom and beyond. There are 
likely to be similarities between these patients and those with non-locally advanced 
primary cancer, including the importance of negative resection margins and adverse 
tumour pathology. However, there are also likely to be differences, particularly in 
terms of tumour biology for recurrent rectal cancer. These also include clinical 
factors, such as lower rates of negative resection margins196, and there may be other 
biological and molecular differences, which are largely unexplored in the literature. 
Although this thesis takes some of these into account by stratifying analysis by 
primary versus recurrent type, relatively low numbers in some areas prevented 
further sub-group analyses.  
4.10.2 Variability in histopathological assessment of regression 
This thesis used the original pathology report to determine response to neoadjuvant 
therapy, by Mandard’s classification. Such an approach may produce bias, since 
different pathologists may interpret response and non-response in different ways. 
There is a body of published literature that has analysed this variability. The largest 
and most robust of these studies was published in 2012. It assessed inter-observer 
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variability between 17 gastrointestinal pathologists who encountered more than 20 
neoadjuvant rectal cancer resection specimens per year195. Scoring 10 
representative slides from 10 cases of rectal cancer treated with long-course 
neoadjuvant chemoradiotherapy, using the Mandard and Dworak systems, there was 
generally low agreement. Kappa coefficients were 0.28 for Mandard and 0.35 for 
Dworak, with one case of complete agreement. The authors concluded that a simple, 
reproducible regression grading system with clear criteria was required. However, 
other recent studies have also disagreed with this viewpoint. A review by two 
pathologists of 100 consecutive chemoradiated rectal cancer specimens found good 
agreement (weighted kappa 0.89)215. Others show low agreement216. 
Within this thesis, non-response was not reassessed for several reasons, whilst 
balancing the risk of bias through variation. Firstly, the reporting methodology of 
exenterative and non-exenterative is standardised and agreed between the two 
specialised gastrointestinal pathologists and the wider multi-disciplinary team at the 
Royal Marsden Hospital, minimising the potential variation. Secondly, there are 
medicolegal and clinical consequences of re-assessment of previous treatment 
pathways. These were beyond the scope of this thesis, and beyond the scope of the 
ethical approval gained. 
4.10.3 Incomplete biomarker studies 
Completion of biomarker studies in all patients was not achieved in this thesis. In 
some cases, the fragility of FFPE tissue specimens for in-situ hybridisation 
prevented completion of the hybridisation procedure. In these cases, and for similar 
scenarios during immunohistochemistry, experiments were repeated in triplicate to 
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obtain results. If these were still not achieved, further experiments were not repeated 
to preserve valuable FFPE for future research. 
4.10.4 Limitations of semi-quantitative methodology  
The methodology used to score IHC and ISH in this study may have introduced bias. 
However, methods were undertaken to limit the extent of this bias, including a 
training module, validation of interpretation by an experienced pathologist (with 
discussion of cases of disagreement until consensus was reached), and observer 
blinding to case name and clinical outcome. An attempt to use automated software 
analysis for this thesis proved impossible, since the range of tissues present over the 
invasive front meant image analysis based on intensity was unachievable. This 
technology may better be suited following tissue microarray or laser microdissection 
analysis. The methodology employed by this thesis has been used and validated in 
similar previous studies198 217, and represents a reasonable approach to 
interpretation of the complex invasive front. 
4.10.5 Limitations of real-time polymerase chain reaction 
These limitations have already been discussed in context of the results above. The 
main limitation of the methodology employed is the use of the whole tissue 
specimens from the slide to enter the reverse transcriptase process. This may have 
introduced mixed tissue with different levels of expression of the same gene. Future 
studies should be targeted towards defining this heterogeneity further, in terms of 
differences between tumour and stroma, and cancerous invasive and non-invasive 
front. External validation in other populations is also required. 
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4.11 Directed future research  
4.11.1 The role of biopsies 
This thesis did not use biopsies. A key aim was to identify the EMT process 
occurring in rectal cancer, which has not yet been widely proved in this group of 
patients. Since EMT occurs at the deepest parts of a tumour (i.e. the invasive front, 
where growth is at its most rapid and poorly controlled), superficial biopsies may 
miss these areas. Furthermore, EMT is dynamic and may occur at any point across 
this invasive front, further increasing the chance that biopsies will miss important 
areas that full slide analysis will not. Small, deep samples are also at risk of missing 
the dynamic EMT process across the invasive front; this is also a reason to avoid 
tissue microarray analysis. Whilst other studies have made use of these tissue 
microarrays, which increase speed and reduce costs, we judged that limited 
sampling may miss the dynamic nature of EMT at the invasive front158 and so used 
larger tissue blocks (often multiple) to ensure adequate representation.  
This thesis has now proved that EMT is a relevant process in advanced rectal 
cancer. To treat patients with stratified therapies, analysis of pre-treatment biopsies 
is needed. Future studies should concentrate on feasibility of pre-therapy biopsies to 
correlate EMT biomarkers to patterns of tumour regression; this will further assess 
suitability as a therapeutic marker.  
However, biomarker identification for response to neoadjuvant therapy in rectal 
cancer remains challenging. There are in fact few treatments for colorectal cancer 
that currently rely on pre-treatment biopsies alone, except for KRAS-mutation testing 
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for selective application of EGFR-targeted drugs77. Many treatments, including 
application of radiotherapy, are applied across whole populations, with acceptance 
that failure rates exist. Thus non-reliance on biopsies is not necessarily a limitation in 
itself. Application of treatments to a non-stratified patient group, followed by proof of 
efficacy, allows future research from these patients to identify biomarkers for future 
generations.  
4.11.2 Serum based application 
Serum biomarker tests are gaining increasing acceptance amongst clinicians and 
are already acceptable to patients due to their non-invasive nature. Serum 
carcinoembryonic antigen (CEA) is frequently used for predicting prognosis and 
detecting recurrence218. However, CEA has a significant false-positive and false-
negative rate that limits its widespread applicability17. In a study of Japanese patients 
with colorectal cancer, four microRNA-200c family members (microRNA-200b, -
200c, 141, -429) were associated with metastases in 12 patients with stage I and IV 
colorectal cancer217. From a candidate search in 446 colorectal specimens, they 
found that microRNA-200c was the best serum candidate associated with 
metastases. They further found that high serum microRNA-200c levels were 
associated with higher stage, lymph node metastases, distant metastases and 
recurrence. As their study did not look at response to radiotherapy and the findings 
of this thesis are positive, future research should be directed towards analysing 
serum microRNA-200c prediction of response to neoadjuvant therapy. 
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4.11.3 Moderation of the EMT process 
Establishing EMT as a predictive biomarker would allow either tailoring or avoidance 
of neoadjuvant therapies for rectal cancer when a poor response is expected. As a 
potential therapeutic target, blocking or reversing EMT would allow improved 
response to neoadjuvant therapy, and thus improved survival43. Metformin and COX-
2 inhibitors are potential existing candidates for this therapeutic modulation.  
4.11.3.1 Metformin as a modulator of EMT 
Metformin is the most widely used oral anti-hyperglycaemic agent used to treat type 
II diabetes mellitus. It has also been shown to improve survival in patients with 
diabetes and cancer in a dose response relationship, including endometrial, breast 
and colorectal cancers219 220. The biological action of metformin is largely through 
activation of 5-adenosine monophosphate (AMP) activated protein kinase (AMPK). 
Its action has also been shown to down-regulate the main transcription factors of 
EMT (TGFβ-1, ZEB, TWIST and SLUG) with up regulation of E-cadherin221. The use 
of metformin in breast cancer has been shown in retrospective studies to be 
associated with the highest rate of complete pathological response (24%), when 
compared to non-metformin diabetics (8%) and non-diabetics (16%)222. The wide 
usage and low toxicity profile of metformin would make it a particularly attractive 
option as a speculative modulator of EMT (through blockade or reversal) and 
subsequent improvement of response rates to neoadjuvant therapies.  
4.11.3.2 COX-2 inhibitors as modulators of EMT 
Cyclo-oxygenase (COX) inhibitors, which are key enzymatic convertor of arachidonic 
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acid to prostaglandins, have been shown to reduce the risk of development of 
cancers and also progression of cancers. COX-2 is highly expressed in a range of 
cancers, including colorectal and bladder cancers223. There has been particular 
interest in the effects of preventing the adenoma-carcinoma sequence in colorectal 
cancers224. This has stimulated its interest in prevention/ reversal of EMT, where it 
has been shown in cell line models to reduce vimentin expression and increase E-
cadherin microRNA and cell surface E-cadherin expression225. Furthermore, E-
cadherin negative and COX-2 receptor positive tumours may have a worse survival 
than the expression of each biomarker separately, suggesting possible interaction223. 
Selective COX-2 inhibitors have been shown to induce up-regulation of E-cadherin in 
human bladder cancer cells226. However, due to the potentially serious 
cardiovascular side-effects of selective COX inhibitors, the particular agent and 
doses would require optimisation224 225. 
4.11.3.3 Modulating microRNAs 
MicroRNAs are important post-transcriptional regulators of nearly every biological 
process in the cell, and play key roles across the full spectrum of human disease227. 
Since their discovery is relatively new and most knowledge has transpired in the last 
five years, there are relatively few drugs targeting them. There is scope for both 
microRNA antagonism and for replacement therapy.  
The most advanced of these novel therapeutic agents is miravirsen, which is a 
specific inhibitor of microRNA-122. It targets the liver-expressed microRNA-122 
using the locked nucleic acid modified antisense oligonucleotide miravirsen227. With 
a phase 2 study initiating in 2010, results from the safety and antiviral activity of this 
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drugs in patients with chronic hepatitis C are awaited. 
As this thesis has shown, microRNA-200c expression is reduced in cases of non-
response to neoadjuvant therapy and when E-cadherin expression is reduced. The 
hypothetical correct counter to this is microRNA replacement therapy.  This fits with 
the general principle that microRNAs have tumour supressing properties228. Since 
microRNA mimics will have the same sequence as naturally occurring microRNAs, 
they are unlikely to have off-target side-effects, and may limit dose-dependent 
effects. The first of these therapies is microRNA-34 replacement therapy229. 
MicroRNA-34 has strong tumour suppression therapies and is down-regulated in 
cancer progression, metastases and chemoresistance. Its combination with 
chemotherapeutic agents including 5-flourourcil for colorectal cancer may reduce 
non-response. In colorectal cancer cell lines, microRNA-34a has been identified as 
being down-regulated in 5-FU resistant cells230.  
There are virtually no microRNA-200c replacement therapies available. Future 
research needs to be targeted towards: 
1. Development of product with exact matching sequence 
2. Test of efficacy in cell models 
3. Test of reversal in animal models 
4. Human phase I-II trials. 
This should be a core aim of future work in this area. 
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4.11.4 Effective use of FFPE tissue 
This study used FFPE as the primary tissue source. Other studies use cellular 
tissue, animal models, fresh human tissue and frozen human tissue. Cellular and 
animal models, although allowing for accurate control of experimental conditions, are 
criticised as they are removed from the realities of human tissue. Fresh and fresh 
frozen tissues provide excellent experimental opportunity on human tissue, but are 
expensive to store and process, and can lack long-term clinical follow-up data for 
survival studies. FFPE bridges these gaps, as it is cheap to store at room 
temperature with no special conditions, it preserves human cancer tissue and it can 
easily be correlated to long-term clinical follow-up. There have been concerns that 
FFPE is limited due to degradation of RNA samples kept overtime. However, this 
thesis and other similar studies have shown that FFPE can readily preserve RNA for 
long periods of time in order to perform this type of analysis198.  
This thesis shows that FFPE is a feasible, cost-effective and reliable biobank for 
cancer research. In challenging economic times, they represent an ideal storage 
mechanism and can be readily transported for multicentre clinical studies. This thesis 
advocated their use for future studies, and the validity of in-situ hybridisation.  
To facilitate this, several important lessons should be applied to the future storage of 
FFPE samples, for maximum RNA yield and clinical relevance:  
1. Pre-operative consent - patients should be consented for future use of FFPE 
blocks beyond normal diagnosis. Extra blocks should be cut and stored 
separately where possible and where tissue allows. Storage separate to 
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normal histopathology specimens will allow for optimum handling and 
retrieval.  
2. Upstream tissue preparation and archiving - tissues should be fixed within 
one hour of surgical resection. Extensive RNA degradation occurs before 
fixation, and the ideal fixation time is 12-24 hours. Fixed tissues should be 
thoroughly dehydrated prior to the embedding. 
3. Tissue type - samples should be taken from the invasive front, the non-
invasive edge, and a normal tissue edge to facilitate future comparative 
research. Additionally, paired biopsies should be stored, ideally as an 
additional, pre-consented research protocol. 
4. Storage - storage of blocks without cut faces if preferable to prevents ongoing 
damage from exposure to atmospheric factors and contaminants (e.g. fungus 
and insects). 
5. Deparaffinisation - where possible excess paraffin should be trimmed away 
prior to xylene-ethanol based deparaffinisation. This can be facilitated by 
correct storage of adequate tissue within small blocks. 
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4.13 Clinical outcomes  
4.13.1 Importance of clinical outcomes described within this thesis 
This thesis described surgical management of patients with locally advanced and 
non-advanced rectal cancer in terms of treatment strategies and outcomes. This 
information is important in terms of identifying best practice techniques that will allow 
stratified radiotherapy to have maximum beneficial effect. 
4.13.1.1 Complete surgical resection 
The thesis has shown that pelvic exenteration can achieve long-term survival and 
local control for both locally advanced primary and recurrent rectal cancer. In 
particular, the main finding is that achieving R0 resection is a more important 
prognostic factor than the differentiation between locally advanced primary and 
recurrent cancer types. There have been few other prospective reports of pelvic 
exenteration specifically for advanced rectal cancer from single centers with high 
numbers102 110. With R0 resection for LAP and RRC, 3-year OS was similar (85% 
versus 79% respectively, p=0.766), as was 3 year LRFS (86% versus 84%, 
p=0.817). However, recurrent cancer was at significantly higher risk of margin 
positive resection, with a trend towards lower 3-year DFS (LAP 76% versus RRC 
57%, p=0.212). 
Complete (R0) surgical resection was associated with the best outcome in this study, 
which confirms the findings of other studies103. Smith et al., describe a large series of 
124 patients undergoing exenteration for locally advanced primary rectal cancer, 
finding that sphincter preserving surgery, absence of metastatic disease and R0 
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resection were the only factors predictive of overall survival at multivariable 
analysis20. Nielsen et al showed a 5 year OS of 42% for LAP cancer and 17% for 
RRC cancer, although this difference was not significant102. Resection margin status 
was the only independent predictor of LRFS for R0 and R1 resection in the present 
study, indicating the importance of microscopic as well as macroscopic clearance 
and confirming previous findings. The effect on survival between LAP and RRC was 
less important then good surgical technique, despite differences in tumour biology, 
tissue planes and anatomical resection. As follow-up increases, the survival 
differences between LAP and RRC may increase, although they are likely to remain 
less significant than the differences between margin negative and positive status. 
Lymph node status was also an independent predictor of reduced OS from the 
present study, representing the effects of local tumour spread. However this was not 
as strong a predictor as resection margin status. 
4.13.1.2 Surgical technique 
Pelvic exenteration includes a group of multivisceral resectional procedures that are 
performed on an individualised patient basis. The most common extra-rectal organ 
specific procedures in the study included sacrectomy, cystectomy and hysterectomy. 
Sacrectomy was of particular use in recurrent disease with 22 (73%) of 30 
sacrectomies being performed for RRC, a proportion in keeping with that reported by 
Nielson et al who found that 15/20 (75%) sacrectomies were for RRC. When taken 
with flap reconstruction of the perineum, these procedures were more important than 
tumour type in determining operating time, blood loss and length of stay. The 
number of affected compartments did not confer prognostic information. Of the 
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classification systems in existence for pelvic exenteration based on pelvic 
compartments, none currently has cross-center validation or universal use33 34 231. 
The rate of exenteration for locally advanced primary rectal cancer was high (20.2%, 
55/272), especially when compared to the series from the Memorial Sloan-Kettering 
group in New York (6.8%, 124/183120). The likely source of this difference is the 
national and international referral pattern seen at the Royal Marsden Hospital, 
specifically for pelvic exenteration of advanced rectal cancer.  
Decisions on the extent of multivisceral resection necessary to achieve tumour 
clearance remain controversial. A balance should be attained between increasing 
the complexity of surgery and thus morbidity, versus less extensive resection which 
maybe less likely to achieve oncological tumour clearance.  Surgical planning in this 
unit is based upon high resolution pelvic MRI, which provides a high level of 
accuracy (compartment specific sensitivity 89-100%, specificity 82-86%) and a low 
level of overstaging, even in the presence of neoadjuvant therapy232.  
R1 resection, whilst unplanned, resulted in improved survival outcome compared to 
R2 resection. Whilst R0 resection resulted in much improved LRFS, the difference in 
DFS was less pronounced, with a three year LRFS of 46%. It appears that R1 
resection has a role in improving survival and may provide good palliation, especially 
with adjuvant therapies including stereotactic body radiation therapy to the affected 
margin (which can be marked intra-operatively). 
4.13.1.3 Adverse event profiles 
The high rate of adverse events shown from patients undergoing exenterative 
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surgery, and in particular sacrectomy, is consistent with previous findings104 233. 
Adverse events were often multiple and affected several different body systems. 
High sacrectomy (at S1/2) was associated with more frequent, multiple and serious 
adverse events than mid-level and low sacrectomy. Increasing level of sacrectomy 
was only significantly associated with an increased rate of long-term adverse events; 
the other complication categories did not show statistical significance owing to small 
sample sizes, despite higher complication rates. The two instances of long-term 
mobility problems reported in this study both resulted from S1/2 sacrectomy. All 
patients should be counselled carefully regarding postoperative risks, with full 
cardiopulmonary assessment and optimisation before surgery. Careful consideration 
should be given to the maximum height of sacrectomy in order to minimise these 
risks. High sacrectomy should be carried out only in highly selected patients in 
centres where expertise is available to manage the patient’s expectations and 
postoperative rehabilitation. Further information on quality of life, including 
comparisons with non-surgically treated patients, is needed before its widespread 
acceptance.  
Perineal pedicled flaps were frequently used for reconstruction. They eliminate the 
dead space and close the pelvic outlet. The primary objective is to prevent deep 
pelvic sepsis which often leads to multiple organ dysfunction. Two patients whose 
wounds were closed primarily and suffered deep pelvic sepsis required secondary 
pedicled flaps to close the defect and to convert deep into superficial sepsis. The use 
of flaps must be balanced against the risk of flap-related complications, which 
include necrosis, dehiscence, fistulation, sinus formation and prolonged operation.  
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Intraoperative and sometimes postoperative bleeding can be challenging in patients 
undergoing ASR. One patient, whose internal iliac vessels were preserved in an 
attempt to use the inferior gluteal arteries for pedicled flap reconstruction, had the 
procedure complicated by an intraoperative blood loss of 17 000 ml. The same 
patient had two further returns to theatre to control secondary bleeding. Adjuncts to 
control haemostasis, including iliac artery embolisation and topical haemostatic 
agents, are all of use, but are not without complication themselves. One patient who 
underwent internal iliac artery embolisation developed total pelvic necrosis; this 
patient required 11 further returns to the operating theatre, but remained alive and 
disease-free at 5 years. Further data are required on methods to limit complications 
in these patients, including outcomes from different types of perineal wound closure, 
methods to control bleeding (including selective preoperative embolisation) and 
results from different types of bladder reconstruction.  
4.13.1.4 Post-operative quality of life 
Quality of life (QoL) is a fundamental issue for patients undergoing surgery for 
advanced pelvic malignancy, with uncertain differences in outcome between curative 
resection, non-curative surgery and best medical palliation. With 53 patients from 
100 undergoing exenteration experiencing at least one adverse event and 22 
experiencing long-term adverse events, complications may further reduce QoL even 
in the presence of R0 resection; this should be addressed routinely in pre-operative 
consent. Austin et al., have performed one of the largest studies regarding QoL 
following exenteration for rectal cancer120. They found that from 37 patients who 
completed a questionnaire, functional scores were comparable to patients 
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undergoing low anterior resection or abdominoperineal resection, and although the 
physical components were lower than those for the Australian population, mental 
health scores were similar. QoL data was not routinely collected on the cohort of 
patients in the present study. Further research is clearly needed in this area, with 
prospective QoL scoring (including a pre-operative assessment) and validation of 
tools specific to patients undergoing surgery for recurrence. Assessment between 
resection types and best medical therapy will further improve patient selection and 
prevent unnecessary surgery that may worsen QoL. 
This thesis also identified other differences (and similarities) between patients with 
locally advanced primary and recurrent rectal cancer. The two groups were similar in 
age of the patient, duration of surgery, length of stay, T-stage, N-stage, rates of 
cystectomy and perineal reconstruction. They were different in that RRC was 
associated with a higher positive resection margin rate, higher use of sacrectomy 
and a greater intra-operative blood loss. Higher intra-operative blood loss may be 
due to more difficult planes of dissection and the increased use of sacrectomy. The 
high morbidity rate from this type of resection is consistent with other series, which 
has ranged from 38 to 78%102 234. 
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4.15 EMT and other types of colorectal cancers 
4.15.1 Advanced colon cancer  
Radiotherapy is not included in the management of patients with colon cancer due 
the inability to target the moving bowel sections, and also the high risk of toxicity to 
overlying small bowel. Thus the mainstay of adjuvant therapy is based around 
adjuvant (post-operative) chemotherapy for patients with pathologically advanced 
tumours at time of examination of resection specimens.  
The Foxtrot trial is a randomised controlled trial comparing pre-operative 
chemotherapy and surgery, compared to surgery with post-operative chemotherapy. 
Patients were includable with radiologically staged T3 (>/= 5mm invasion beyond the 
muscularis propria) or T4 colon cancers from 35 UK centres. Pre-operative 
chemotherapy included three cycles of oxaliplatin, folinic acid and fluorouracil. The 
pilot stage of 150 patients was recently published, demonstrating the trial feasibility, 
safety and early efficacy. The key outcome findings were a reduced positive 
resection margin rate (4% versus 10%, p=0.002) and increased tumour regression 
grade (31% versus 2%, p=0.001) with pre-operative chemotherapy. The phase III 
trial is now continuing to recruit over 1000 patients. 
Foxtrot may lead to a key change in management for advanced colon cancer, with a 
shift to pre-operative chemotherapy. This will be accompanied by a rate of non-
response to this therapy. The Foxtrot trial showed that only 31% (29/94) of those 
receiving pre-operative therapy had moderate or greater regression. The two thirds 
of patients without response represent a group facing a treatment dilemma 
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equivalent to patients with a threatened CRM rectal cancer being treated with 
neoadjuvant radiotherapy. Biomarker experiments need to be performed to begin 
stratification of patients likely to respond. There may be a translational role of EMT in 
advanced colonic cancer, which should be explored in this novel group of patients.  
4.15.2 Early rectal cancer 
The management of early rectal cancer poses a dilemma for the colorectal surgeon 
and multidisciplinary team. The oncological benefits of major resection must be 
balanced against the risks of post-operative mortality. Local resection overcomes the 
peri-operative risks, although there may be an oncologic compromise. Endoscopic 
and endoluminal techniques allow for local resection of early colon and rectum 
lesions when the risk of lymph node involvement is low.  
In these early lesions, there may be a role for downstaging with neoadjuvant 
chemoradiotherapy. This strategy can lead to complete pathological response and 
long-term remission, as shown from the pioneering Brazilian group86. The UK 
Transanal Endoscopic Microsurgery (TEM) and Radiotherapy in Early Rectal Cancer 
(TREC) trial is randomising patients with T1-T2N0M0 cancer to either surgery or 
neoadjuvant radiotherapy and surgery. The results will give important information to 
refine selection criteria and future stratification of neoadjuvant therapy. Extrapolating 
findings from this thesis, it is feasible that a proportion of patients with early rectal 
cancer who do no response to pre-operative radiotherapy may exhibit evidence of 
EMT processes. Further research in this group to test biomarkers of EMT for 
prognosis and treatment efficacy is needed for patients with early rectal cancer. 
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4.16 Conclusion 
In conclusion, this thesis has provided human tissue evidence for the role of EMT in 
rectal cancer progression, specifically:  
(1) Establishing the relationship of E-cadherin and beta-catenin as adhesional 
markers of EMT in rectal cancer through association with mir200c reduction;  
(2) Relating EMT biomarkers and tumour budding to non-response to 
neoadjuvant therapy and reduced survival;  
(3) Establishing the importance of mir200c as an independent predictor of 
non-response to neoadjuvant therapy.  
Blocking or reversing EMT may improve the proportion of patients who respond to 
neoadjuvant therapy. 
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6.1 Ethical approval from NRES Committee London (Fulham) 
12/LO/0943 
 
A Research Ethics Committee established by the Health Research Authority 
 
 
 
National Research Ethics Service 
 
NRES Committee London - Fulham 
HRA NRES Centre Manchester 
Barlow House 
3rd Floor, 4 Minshull Street 
Manchester 
M1 3DZ 
 
 Telephone: 0161 625 7821  
Facsimile: 0161 625 7299 
02 July 2012 
 
Mr Aneel Bhangu 
PhD Student 
Imperial College London 
Exhibition Road 
London 
SW7 2AZ 
 
 
Dear Mr Bhangu 
 
Study title: 
 
 
IRAS Project Number: 
Epithelial mesenchymal transition and perineural 
invasion as adverse pathological prognostic factors for 
outcomes of rectal cancer resection 
108316 
REC reference: 12/LO/0943 
Protocol number: 1.4 
 
Thank  you  for  your  letter  of  27  June  2012,  responding  to  the  Committee’s  request  for  further  
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below). 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
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Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s  role  in  the  study  is  limited  to  identifying  and  referring  potential  
participants to research sites ("participant identification centre"), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date    
Covering Letter    24 May 2012  
Covering Letter    27 June 2012  
Evidence of insurance or indemnity    28 July 2011  
Investigator CV  Professor 
Robert D 
Goldin  
   
Other: CV - Aneel Bhangu       
Other: CV - Paris Tekkis       
Other: CV - Syed Mohammed Ali       
Participant Consent Form: RMH Standard tissue consent       
Protocol  1.4  15 May 2012  
REC application  3.4  25 May 2012  
Response to Request for Further Information    27 June 2012  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After  ethical  review  – guidance  for  researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
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 Progress and safety reports 
 Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views known 
please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review  
 
12/LO/0943 Please quote this number on all correspondence 
 
With  the  Committee’s  best  wishes  for  the  success  of  this  project 
 
Yours sincerely 
 
Signed on behalf of: 
Dr Charles Mackworth-Young 
Chair 
 
Email: shehnaz.ishaq@northwest.nhs.uk 
 
Enclosures: “After  ethical  review  – guidance for researchers”   
 
Copy to: Ms Lucy Parker – R&D Department, Imperial College London  
 
Ms Ann Gandolfi - R&D Department , The Royal Marsden NHS 
Foundation Trust  
 
Professor Robert Goldin  
Centre for Pathology  
Imperial  College  at  St  Mary’s  Hospital   
Praed Street  
London  
W2 1PG  
 
Mr S Mohammed Ali  
Centre for Pathology c/o Prof Goldin  
Imperial  College  at  St  Mary’s  Hospital   
Praed Street  
London  
W2 1PG  
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6.2 Ethical approval from Royal Marsden Hospital  
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6.3 Royal Marsden Hospital Standard Tissue Consent Form 
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6.4 Experimental protocols  
Weblinks for protocols were checked in October 2013 
• miRCURY LNA microRNA In-situ hybridisation Optimisation Kit: 
http://www.exiqon.com/ls/Documents/Scientific/miRCURY-LNA-microRNA-
ISH-Optimization-Kit-manual.pdf  
• RNeasy Total RNA isolation from FFPE: www.qiagen.com/goto/RNeasyFFPE 
• RNA to cDNA Conversion: 
http://tools.lifetechnologies.com/content/sfs/manuals/cms_047249.pdf 
• Real-time Polymerase Chain Reaction: 
http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/gen
eraldocuments/cms_042115.pdf  
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6.5 Positive and negative control RNA amplification plots 
Positive RNA control 
 
Negative control 
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